(54) Titre : GENES DE FUSION ASSOCIES A UN CANCER DE LA PROSTATE EVOLUTIF
(54) Title: FUSION GENES ASSOCIATED WITH PROGRESSIVE PROSTATE CANCER

(57) Abrégé/Abstract:
The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMTI 1-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of "progressive prostate cancer"), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMTI 1-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1 -FER fusion gene exhibits kinase activity.

(73) **Propriétaires(suite)/Owners(continued):**
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, US

(74) **Agent:** BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.

(12) **INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)**

(19) **World Intellectual Property Organization**
International Bureau

(43) **International Publication Date**
9 July 2015 (09.07.2015)

WIPO | PCT

(10) **International Publication Number**
WO 2015/103057 A1

(51) **International Patent Classification:**
C12Q 1/68 (2006.01)

(21) **International Application Number:**
PCT/US2014/072268

(22) **International Filing Date:**
23 December 2014 (23.12.2014)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
61/921,836   30 December 2013 (30.12.2013)   US
62/014,487   19 June 2014 (19.06.2014)   US
62/025,923   17 July 2014 (17.07.2014)   US

(71) **Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION** [US/US]; 200 Gardner Steel Conference Center, Pittsburgh, PA 15260 (US).

(72) **Inventors: LUO, Jianhua**; 431 McKean Dr, Wexford, PA 15090 (US). **YU, Yangping**; 431 McKean Dr, Wexford, PA 15090 (US). **NELSON, Joel, B.**; 148 Shady Lane, Pittsburg, PA 15215 (US). **MICHALOPOULOS, George**; 172 Lancaster Ave., Pittsburgh, PA 15228 (US). **TSENG, Chien-Cheng**; 181 Streamside Drive, Pittsburgh, PA 15237 (US). **DING, Ying**; 6335 Osler St., San Diego, CA 92111 (US).

(74) **Agent: KOLE, Lisa, B.**; Baker Botts L.L.P., 30 Rockefeller Plaza, New York, NY 10112-4498 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) **Title:** FUSION GENES ASSOCIATED WITH PROGRESSIVE PROSTATE CANCER

(57) **Abstract:** The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT1 1-GRIK2, SLC45A2-AMACR, MT-OR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of "progressive prostate cancer"), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT1 1-GRIK2 or MT-OR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1 -FER fusion gene exhibits kinase activity.

FUSION GENES ASSOCIATED WITH PROGRESSIVE PROSTATE CANCER

PRIORITY CLAIM

This application claims priority to U.S. Provisional Patent Application Serial No.
61/921,836, filed December 30, 2013, U.S. Provisional Patent Application Serial No.
62/014,487, filed June 19, 2014, and U.S. Provisional Patent Application Serial No.
62/025,923, filed July 17, 2014

GRANT INFORMATION

1. INTRODUCTION

The present invention relates to methods of determining which prostate cancer
patients are more likely to develop progressive disease based on the presence of specific
fusion genes, and methods of treating such patients.

2. BACKGROUND OF THE INVENTION

Despite a high incidence, only a fraction of men diagnosed with prostate cancer
develop metastases and even fewer die from the disease. The majority of prostate cancers
remain asymptomatic and clinically indolent. The precise mechanisms for the
development of progressive, clinically concerning prostate cancer remain elusive.
Furthermore, the inability to predict prostate cancer's potential aggressiveness has
resulted in significant overtreatment of the disease. The dichotomous nature of prostate
cancer-a subset of life-threatening malignancies in the larger background of histological
alterations lacking the clinical features implicit with that label-is a fundamental challenge
in disease management. Therefore, there is a need in the art for methods of determining
whether a subject is at an increased risk of developing progressive prostate cancer.

1

3. SUMMARY OF THE INVENTION

The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at increased risk of developing progressive disease, and methods of treating such subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of "progressive prostate cancer"), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.

In various non-limiting embodiments, the present invention provides for methods and compositions for identifying fusion genes in a subject, which are indicative that a subject is at increased or even high risk of manifesting progressive prostate cancer. Such fusion genes include TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67, KDM4B-AC011523.2, MAN2A1-FER, PTEN-NOLC1, CCNH-C5orf30, ZMPSTE24-ZMYM4, CLTC-ETV1, ACPP-SEC13, DOCK7-OLR1 and PCMTD1-SNTG1. Further, based on the presence of specific fusion genes, the present invention provides a means for identifying subjects at increased risk for relapse and/or rapid relapse. In certain non-limiting embodiments, the present invention further provides for methods of treating a subject at increased risk of manifesting progressive prostate cancer, relapse and/or rapid relapse.

4. BRIEF DESCRIPTION OF THE FIGURES

FIGURE 1. Unique fusion gene events. Left panel: Miniature diagrams of genome of the fusion genes, the transcription directions, the distances between the joining genes and directions of the fusions. Middle panel: Representative sequencing chromograms of fusion genes. The joining gene sequences were indicated (SEQ ID NOs: 45-52). Right panel: Diagrams of translation products of fusion genes. Medium grey-driver gene translation product; Dark grey-passenger gene translation product; Light grey-

2

novel translation products due to frameshift or translation products from a non-gene region.

FIGURE 2A-H. Fluorescence in situ hybridization suggests genome recombination in prostate cancer cells. (A) Schematic diagram of MAN2A1 and FER
5   genome recombination and FISH probe positions. Representative FISH images were shown for normal prostate epithelial cells and cancer cells positive for MAN2A1-FER fusion. (B) Schematic diagram of SLC45A2 and AMACR genome recombination and FISH probe positions. Representative FISH images were shown for normal prostate epithelial cells and cancer cells positive for SLC45A2-AMACR fusion. (C) Schematic
10   diagram of MTOR and TP53BP1 genome recombination and FISH probe positions. Representative FISH images were shown for normal prostate epithelial cells and cancer cells positive for MTOR-TP53BP1 fusion. (D) Schematic diagram of TRMT11 and GRIK2 genome recombination and FISH probe positions. Representative FISH images were shown for normal prostate epithelial cells and cancer cells positive for TRMT11-
15   GRIK2 fusion. (E) Schematic diagram of LRRC59 and FLJ60017 genome recombination and FISH probe positions. Representative FISH images were shown for normal prostate epithelial cells and cancer cells positive for LRRC59-FLJ60017 fusion. (F) Schematic diagram of TMEM135 and CCDC67 genome recombination and FISH probe positions. Representative FISH images were shown for normal prostate epithelial cells and cancer
20   cells positive for TMEM135-CCDC67 fusion. (G) Schematic diagram of CCNH and C5orf30 genome recombination and FISH probe positions. Representative FISH images were shown for normal prostate epithelial cells and cancer cells positive for CCNH-C5orf30 fusion. (H) Schematic diagram of KDM4B and AC011523.2 genome recombination and FISH probe positions. Representative FISH images were shown for
25   normal prostate epithelial cells and cancer cells positive for KDM4B-AC011523.2 fusion.

FIGURE 3A-D. Fusion genes in prostate cancer are associated with
30   **aggressive prostate cancers.** (A) Distribution of 8 prostate cancer samples positive for fusion genes. Samples from patients who experienced recurrence were indicated with grey (PSADT≥ 15 months) or dark grey (PSADT<4 months), samples from patients who have no recurrence at least 5 years in light grey, and samples from patients whose clinical

3

follow-up is ongoing but less than 5 years with white (undetermined). (B) Correlation of fusion gene events with prostate cancer recurrence. Percentage of prostate cancer relapse when fusion gene was positive in the prostate cancer samples was plotted for each fusion gene. Percentage of prostate cancer experiencing recurrence from samples positive for fusion transcripts was plotted for each fusion transcript. Left, University of Pittsburgh Medical Center cohort; Middle, Stanford University Medical Center cohort; Right, University of Wisconsin Madison Medical Center cohort. (C) ROC analyses of a panel of 8 fusion genes predicting prostate cancer recurrence (top) and short PSADT (bottom). (D) Kaplan-Meier analysis of patients who are positive for any of TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 versus those who are negative for these fusion events.

FIGURE 4A-C. Fusion genes predict recurrence of prostate cancer. (A) Schema of training and validation steps in building fusion gene prediction models for prostate cancer recurrence and short PSADT. The algorithm of fusion gene prediction of prostate cancer recurrence and PSADT<4 months was obtained from 90 random-assigned prostate cancer samples from University of Pittsburgh Medical Center (I). The algorithm was then applied to 89 samples from University of Pittsburgh Medical Center (II), 21 samples from Stanford University Medical center (III) and 33 samples from University of Wisconsin Madison Medical Center (IV). (B) Prediction rate of prostate cancer recurrence (top) and PSADT<4 months using prostate cancer samples cohorts from University of Pittsburgh Medical Center, Stanford Medical Center, and University of Wisconsin Madison Medical Center, based on algorithm obtained from the 90- training sample cohort. (C) Kaplan-Meier analysis of patients who were positive for any of TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 versus those who were negative for these fusion events. Top, Kaplan-Meier analysis of prostate cancer sample cohort from University of Pittsburgh; P-value is indicated for the significant difference in survival between the group that is positive for at least one fusion transcript and the group that is negative. Bottom, Kaplan-Meier analysis of prostate cancer sample cohort from Stanford University Medical Center; P-value is indicated for the significant difference in survival between the group that is positive for at least one fusion transcript and the group that is negative.

FIGURE 5A-B. Combining status of fusion transcript and clinical/pathological parameter to improve prediction of prostate cancer recurrence.

4

(A) Combining Gleason's grading and the status of 8 fusion transcripts in prostate cancer samples using LDA technique to predict the recurrence of prostate cancer. Left, ROC analysis of Gleason alone or Gleason plus the presence of fusion transcripts using LDA technique in the prediction of prostate cancer recurrence; *P* value (permutation test) is indicated for the significant difference between the ROC curve generated by Gleason alone and curve generated by Gleason plus the presence of fusion transcripts using LDA technique. Middle, Kaplan-Meier analysis of PSA free survival of prostate cancer patients with Gleason ≥8 versus <8 from combined UPMC testing, Wisconsin and Stanford data sets; *P*-value (Log-rank test) is indicated for the significant difference in survival between the group that has Gleason score at least 8 and the group that has score 7 or less. Right, Kaplan-Meier analysis of PSA free survival of prostate cancer patients with Gleason ≥8 or positive for any of the 8 fusion transcripts in the prostate cancer samples versus those <8 and negative for fusion transcripts using LDA from combined UPMC testing, Wisconsin and Stanford data sets. *P*-value (Log-rank test) is indicated for the significant difference in survival between the group that is positive for at least one fusion transcript or has Gleason ≥8 and the group that is negative for fusion transcript and has Gleason <8. (B) Combining nomogram and the status of 8 fusion transcripts in prostate cancer samples using LDA technique to predict the recurrence of prostate cancer. Left, ROC analysis of nomogram alone or nomogram plus the presence of fusion transcripts using LDA technique in the prediction of prostate cancer recurrence. *P*-value (permutation test) is indicated for the significant difference between the ROC curve generated by Nomogram alone and curve generated by Nomogram plus the presence of fusion transcripts using LDA technique. Middle, Kaplan-Meier analysis of PSA free survival of prostate cancer patients with probability >88 versus ≤88 from combined UPMC testing, Wisconsin and Stanford data sets; *P*-value (Log-rank test) is indicated for the significant difference in survival between the group that has probability >88 PSA free survival and the group that has ≤88 probability. Right, Kaplan-Meier analysis of PSA free survival of prostate cancer patients with Nomogram ≤88 or positive for any of the 8 fusion transcripts in the prostate cancer samples versus those >88 and negative for fusion transcripts using LDA from combined UPMC testing, Wisconsin and Stanford data sets. *P*-value (Log-rank test) is indicated for the significant difference in survival between the group that is negative for fusion transcript and has probability >88 PSA free survival and the group that is positive for fusion transcript or has ≤88 probability.

FIGURE 6. Circus plots of prostate cancer functional genome translocation.
Five prostate cancer functional translocations were based on RNA sequencing. Fourteen
of these functional translocations were supported by whole genome sequencing analysis.
Functional translocation is defined as at least one transcript identified in the translocation
5   process. Translocations in non-gene area were excluded.

FIGURE 7A-B. Identification of fusion genes in 174 prostate samples. (A) RT-
PCR of TMEM135-CCDC57, KDM4B-AC011523.2, MAN2A1-FER, TRMT11-GRIK2,
CCNH-C5orf30, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ6001, TMPRSS2-
ERG were performed on 213 prostate cancer samples. RT-PCR of β-actin was used as
10   quality control. The lane assignment is the following: 1-TP12-S0943T, 2-TP12-S0916T,
3-TP12-S0967T, 4-TP12-S1059T, 5-TP10-S093T, 6-JB770T, 7-TP08PPS0721T, 8-TP10-
S0638T, 9-TP12-S1032T, 10-TP12-S0624T, 11-TP12-S0981T, 12-TP10PPS0420T, 13-
TP12-S0966T, 14-TP12-S0988T, 15-TP12-S0704T, 16-PR053T, 17-IB110T, 18-TP12-
S0928T, 19-TP12-S0816T, 20-TP12-S0789T, 21-TP12-S0805T, 22-TP12-S0803T, 23-
15   TP12-S0765T, 24-TP12-S0770T, 25-TP12-S0799T, 26-TP12-S0795T, 27-TP12-S0786T,
28-PR534T, 29-TP12-S0790T, 30-TP12-S0740T, 31-TP12-S0723T, 32-PR536T, 33-
FB76, 34-IB378T, 35-IB180T, 36-HB303T, 37-GB368, 38-HB327T, 39-HB346T, 40-
PR227T, 41-HB322T, 42-HB658T, 43-IB289T, 44-HB492T, 45-IB111T, 46-TP12-
S0466T, 47-TP12-S0456T, 48-TP12-S0246T, 49-TP12-S0608T, 50-TP12-S0340T, 51-
20   TP12-S0337T, 52-TP12-S0048T, 53-TP12-S0191T, 54-TP12-S0194T, 55-TP12-S0049T,
56-HB340T, 57-TP12-S0102T, 58-PR530T, 59-1942T, 60-TP12-S1189T, 61-13745T,
62-5396T, 63-8432T, 64-HB261T, 65-FB183T, 66-HB591T, 67-HB568T, 68-HB526T,
69-TP08-S00542T, 70-IB298T, 71-TP09-S0420T, 72-PR303T, 73-GB400T, 74-PR018T,
75-HB603T, 76-PR310T, 77-JB197T, 78-PR300T, 79-PR236T, 80-JB154T, 81-PR434T,
25   82-7504T, 83-25313T, 84-8629T, 85-7270T, 86-2671T, 87-4308T, 88-28278T, 89-TP12-
S1224T, 90-TP12-S0918T, 91-TP12-S1197T, 92-TP12-S0915T, 93-16464T, 94-2644T,
95-1199T, 96-15922T, 97-15733T, 98-16947T, 99-19381T, 100-6837T, 101-9122T, 102-
6647T, 103-4336T, 104-29671T, 105-11462T, 106-8741T, 107-IB362T, 108-PR079T,
109-IB483T, 110-IB071T, 111-GB195T, 112-PR521T, 113-TP08-S00530T, 114-7221T,
30   115-JB426T, 116-34T, 117-HB951T, 118-FB94T, 119-IB273T, 120-DB237T, 121-
IB134T, 122-HB021T, 123-HB033T, 124-FB174 T, 125-KB170T, 126-FB120T, 127-
HB504T, 128-HB305T, 129-FB421T, 130-TP09-S0721T, 131-FB238T, 132-HB46T,
133-TP11PP-S0638T, 134-PR306T, 135-HB207T, 136-HB235T, 137-IB112T, 138-
IB136T, 139-PR375T, 140-2HB591T, 141-23HB021T, 142-TP09-S0006T, 143-2IB483T,

144-2HB568T, 145-M-11462T, 146-29825T, 147-3G989122T, 148-1AF8378T, 149-3Q-
10614T, 150-4L98-27086T, 151-3D994336T, 152-3K5772T, 153-2K98-8378T, 154-
14304T, 155-15463T, 156- 15875T, 157-98TA-83782T, 158-562T, 159-14878T, 160-
7943T, 161-995772T, 162-678T, 163-9927086T, 164-25265T, 165-HB705T, 166-
33PR053T, 167-TP12-S0954T, 168-19PR530T, 169-34PR227T, 170-56FB76T, 171-
TP09-S0704T, 172-78HB340T, 173-23FB120T, 174-23HB346T, 175-54IB289T, 176-
TP13-S0109T, 177-TP13-S0456T, 178-TP13-S0248T, 179-TP13-S0464T, 180-TP13-
S0043T, 181-TP13-S0314T, 182-8433T, 183-863176T, 184-R6TT, 185-84876T, 186-
994308T, 187-991199T, 188-9812033T, 189-855327T, 190-9814481T, 191-R3T, 192-
R13T, 193-R19T, 194-84375T, 195-832972T, 196-9210207T, 197-R57T, 198-828142T,
199-R26T, 200-23R19T, 201-8713205T, 202-9217293T, 203-R18T, 204-8712362T, 205-
9412443T, 206-R10T, 207-92SR293T, 208-R16T, 209-849731T, 210-67R13T, 211-
842620T, 212-R59T, 213-SR9R57T. (B) RT-PCR of TMEM135-CCDC67, KDM4B-
AC011523.2, MAN2A1-FER, TRMT11-GRIK2, CCNH-C5orf30, SLC45A2-AMACR,
MTOR-TP53BP1 and LRRC59-FLJ60017 on 10 organ donor prostate tissues.

**FIGURE 8. Identification of fusion genes in 30 prostate samples from
Stanford University Medical Center.** RT-PCR of TMEM135-CCDC67, KDM4B-
AC011523.2, MAN2A1-FER, TRMT11-GRIK2, CCNH-C5orf30, SLC45A2-AMACR,
MTOR-TP53BP1 and LRRC59-FJL60017 were performed on 30 indicated prostate
cancer samples. RT-PCR of β-actin was used as quality control.

**FIGURE 9. Identification of fusion genes in 36 prostate samples from
University of Wisconsin Madison Medical Center.** RT-PCR of TMEM135-CCDC67,
KDM4B-AC011523.2, MAN2A1-FER, TRMT11-GRIK2, CCNH-C5orf30, SLC45A2-
AMACR, MTOR-TP53BP1 and LRRC59-FJL60017 were performed on 36 indicated
prostate cancer samples. RT-PCR of β-actin was used as quality control.

**FIGURE 10. Inactivation of GRIK1 and TRMT11 RNA expression in
prostate cancer positive for TRMT11-GRIK2 fusion.** RT-PCR was performed on RNA
from TRMT11-GRIK2 fusion gene positive prostate cancer samples using primers
specific for GRIK2 and TRMT11. Products of RT-PCR using primers specific for β-actin
were used as template normalization control.

FIGURE 11. Genome breakpoint analysis of fusion genes. Top panel:
Miniature

diagrams of genome of the fusion genes, the transcription directions, the distances between the joining genes and directions of the chromosome joining. Middle panel: Miniature of fusion genome and transcription direction. Bottom: Representative sequencing chromograms encompassing the joining breakpoint of chromosomes (SEQ ID

5   NOs: 53-55).

FIGURE 12A-B. Prediction of prostate cancer recurrence and PSADT using a panel of 8 fusion genes. (A) ROC analyses of a panel of 8 fusion genes predicting prostate cancer recurrence using random assigned 90 prostate cancer samples from University of Pittsburgh Medical Center. Dotted line-random prediction; Solid line-fusion

10   prediction; Dot-optimal prediction. *P*-value (permutation test) is indicated for the significant difference between the ROC curve generated by fusion transcripts using LDA technique and the baseline control curve. (B) ROC analyses of a panel of 8 fusion genes predicting prostate cancer short PSADT (<4 months). Dotted line-random prediction; Solid line-fusion prediction; Dot-optimal prediction. *P*-value (permutation test) is

15   indicated for the significant difference between the ROC curve generated by fusion transcripts using LDA technique and the baseline control curve.

FIGURE 13A-C. PTEN-NOLC1 fusion gene in prostate cancer. (A) PTEN-NOLC1 fusion transcript. Top panel: Miniature diagrams of genome of the PTEN and NOLC1 genes, the transcription direction, the distance between the joining genes and

20   direction of the fusion. Middle panel: Representative sequencing chromogram of PTEN-NOLC1 transcript. The joining gene

sequences were indicated (SEQ ID NO: 56). Lower panel: Diagram of translation product of fusion transcript.

(B) Schematic diagram of PTEN and NOLC1 genome recombination and FISH probe

25   positions. Representative FISH images were shown for normal prostate epithelial cells and cancer cells positive for TENNOLC1 fusion. Asterisk * denotes probe 1 (RP11-124B18). Plus sign + denotes probe 2 (CTD-3082D22). Fusion joining signals are indicated by arrows. (C) PTEN-NOLC1 expression in prostate cancer samples. RT-PCRs were performed in 215 samples of prostate cancer using primers specific for

30   PTEN-NOLC1 (PN) fusion transcript. RT-PCRs using primers specific for β-actin (BAT) were performed as normalization controls.

FIGURE 14. Motif analysis of MAN2A1-FER. Diagram of functional domains of MAN2A1, FER and MAN2A1-FER fusion proteins.

8

FIGURE 15. Schematic diagram of Genome editing targeting at a fusion gene breakpoint in prostate cancer cells positive for CCNH-C5orf30 (SEQ ID NO: 57).

FIGURE 16. Schematic diagram of fusion genes. Left panel: Schematic diagram of genome of fusion partners. Genetic locus, distance between partners, transcription direction and fusion direction are indicated. Middle panel: Histogram of Sanger sequencing surrounding the fusion point of each fusion gene (SEQ ID NOs: 40-44). Right panel: Predicted protein products of fusion genes. Medium grey: Head gene protein; Light grey: frameshift translation; Dark grey: tail.

FIGURE 17. Schematic diagram of ZMPSTE24-ZMYM5 fusion formation. Functional domains are indicated.

FIGURE 18. Schematic diagram of CLTC-ETV1 fusion formation. Functional domains are indicated.

FIGURE 19. Schematic diagram of ACPP-SEC13 fusion formation. Functional domains are indicated.

FIGURE 20. Schematic diagram of DOCK7-OLR1 fusion formation. Functional domains are indicated.

FIGURE 21. Schematic diagram of PCMTD1-SNTG1 fusion formation. Functional domains are indicated.

FIGURE 22A-F. Pro-growth activity of MAN2A1-FER. (A) Expression of MAN2A1-FER in primary Prostate cancer Samples. Immunoblottings were performed using antibodies specific for MAN2A1 (upper panel) or FER (lower panel) on MAN2A1-FER RNA positive (JB770T, FB174T and FB421T) or MAN2A1-FER negative (IB071T, IB136T and HB504T) samples. (B) Expression of MAN2A1-FER-FLAG in RWPE-1 cells. RWPE-1 cells were transfected with pCDNA4-MAN2A1-FER-FLAG/pCDNA6 vectors. Two stable cell lines (RMF1 and RMF4) were selected to demonstrate tetracycline induced expression of MAN2A1-FER-FLAG using anti-FLAG antibodies. (C) Expression of MAN2A1-FER-FLAG accelerates entry to S phase of cell cycle. Cell cycle phases were quantified by flow cytometry analysis of BrdU incorporation and propidium iodine labeling. (D) Co-localization of MAN2A1-FER-FLAG and Golgi resident enzyme N-acetylgalactosaminyltransferase. MAN2A1-FER-FLAG was labeled with FITZ conjugated antibodies specific for FLAG, while N-acetylgalactosaminyltransferase was labeled with Rhodamine-conjugated antibodies

9

specific for N-acetylgalactosaminyltransferase. (E) Co-segregation of MAN2A1-FER-

FLAG and Nacetylgalactosaminyltranferase in sucrose gradient ultra-centrifugation. (F)

Expression of MAN2A1-FER-FLAG induced tyrosine phosphorylation of EGFR in the

absence of EGFR ligand. RMF1 and RMF4 cells were serum starved for 72 hrs, and were

5   subsequently induced with tetracycline (5 µg/ml) for 12 hrs. EGFR was

immunoprecipitated with anti-EGFR antibodies, and immunoblotted with anti-

phosphotyrosine or anti-pTyr1068 of EGFR or anti-EGFR antibodies.

FIGURE 23. Specific killing of MAN2A1-FER expressing cells by Crisotinib

and

10   **Canertinib.** Prostate cancer cell line PC3 was transformed with pCDNA4-MAN2A1-

FER-FLAG/pCDNA6. Expression of MAN2A1-FER was induced with 5µg/mL

tetracycline. Cells not treated with tetracycline nor any drug were used as background

controls. Upper panel: Crisotinib specifically kills cells expressing MAN2A1-FER. Lower

panel: Canertinib specifically kills cells expressing MAN2A1-FER.

15   **FIGURE 24. Schematic diagram of SLC45A2-AMACR chimera protein.**

Fusion between SLC45A2 and AMACR results in truncation of two-third of (MFS)

domain in SLC45A2, but largely retains CoA-transferase domain of AMACR.

        FIGURE 25A-I. Pro-growth activity of SLC45A2-AMACR. (A) Expression of

SLC45A2-AMACR in primary Prostate cancer samples. Immunoblottings were

20   performed using antibodies specific for AMACR (upper panel) or SLC45A2 (lower

panel) on SLC45A2-AMACR RNA positive (FB174T, HB207T, HB305T and FB238T)

or SLC45A2-AMACR negative (6637T, 6647T and 1199T) samples. (B) Expression of

SLC45A2-AMACR-FLAG in RWPE-1 cells. RWPE-1 cells were transfected with

pCDNA4-SLC45A2-AMACR-FLAG/pCDNA6 vectors. Two stable cell lines (RSLAM#2

25   and RSLAM#3) were selected to demonstrate tetracycline induced expression of

SLC45A2-AMACR-FLAG using anti-FLAG antibodies. (C) SLC45A2-AMACR is

primarily located in plasma membrane. Immunoblottings were performed on membranous

fraction (M) and non-membranous fraction (NM) of RSLAM#2 cells treated without

tetracycline (upper panel) or with tetracycline (lower panel), using antibodies specific for

30   AMACR (upper panel) and for FLAG (lower panel). (D) Immunofluorescence staining of

AMACR (upper panel) in RSLAM#2 cells treated without tetracycline using antibodies

specific for AMACR or of SLC45A2-AMACR-FLAG in RSLAM#2 cells treated with

tetracycline using antibodies specific for FLAG. (E) Expression of SLC45A2-AMACR increases cell growth in MTT assays. (F) Expression of SLC45A2-AMACR-FLAG accelerates entry to S phase of cell cycle. Cell cycle phases were quantified by flowcytometry analysis of BrdU incorporation and propidium iodine labeling. (G) Expression of SLC45A2-AMACR increases intracellular levels of PIP2(3,4). (H) Yeast Two-Hybrid validation of LC45A2-AMACR/SHIP2 interaction. (I) Co-immunoprecipitation of SHIP2 and SLC45A2-AMACR-FLAG in RSLAM#2 cells.

FIGURE 26. Ebselen specifically inhibits SLC45A2-AMACR expressing PC3 cells. Untransformed RWPE1, NIH3T3 cells and SLC45A2-AMACR transformed PC3 cells treated with (PC3/SLAM tet+) or without tetracycline (PC3/SLAM tet-) were applied with indicated concentration of Ebselen. Cell growths relative to unapplied controls were examined. IC50 for PC3/SLAM tet+ is 37μM, while for PC3/SLAM tet- is 173 μM. For NIH3T3 and RWPE1 cells, IC50s are >300 μM.

FIGURE 27A-D. PTEN-NOLC1 is localized in the nucleus and promotes cell growth. (A) Immunofluorescence staining of PTEN and PTEN-NOLC1- FLAG. NIH3T3 and PC3 cells were transformed with pCDNA4-Pten-NOLC1-FLAG/pCDNA6 and induced with tetracycline. Immunofluorescence staining were performed using antibodies specific for FLAG epitope. Uninduced NIH3T3 cells and PC3 cells transfected with pCMV-Pten immunostained with antibodies specific for Pten were controls. (B) Cell proliferation induced by Pten-NOLC1-FLAG. Cells (2000/ well) from (A) were grown for 4 days with tetracycline. Cell numbers were then quantified. Cells not treated with tetracycline were negative controls. (C) Cell cycle analysis of NIH3T3 and PC3 cells transformed with pCDNA4-Pten-NOLC1-FLAG/pCDNA6. (D) Colony formation analysis of NIH3T3 and PC3 cells transformed with pCDNA4-Pten-NOLC1-FLAG/pCDNA6.

FIGURE 28A-B. Genetic therapy targeting at TMEM135-CCDC67 genome breakpoint. (A) Transfection of PC3 cells containing TMEM135-CCDC67 breakpoint with pTMEM135-CCDC67-TK-GFP and pNicKase-RFP-gRNA-TMEM135-CCDC67-BrkPt resulted in integration and expression of TK-GFP. (B) Treatment of ganciclovir of PC3 cells and PC3/TMEM135-CCDC67-BrkPt transfected with pTMEM135-CCDC67-TK-GFP and pNicKase-RFP-gRNA-TMEM135-CCDC67-BrkPt resulted in specific killing of TMEM135-CCDC67 breakpoint containing PC3 cells.

5. DETAILED DESCRIPTION OF THE INVENTION

For clarity and not by way of limitation the detailed description of the invention is divided into the following subsections:

(i)   fusion genes;

(ii)   fusion gene detection;

(iii)   diagnostic methods and methods of treatment; and

(vi)   kits.

5.1 FUSION GENES

The term "fusion gene," as used herein, refers to a nucleic acid or protein sequence which combines elements of the recited genes or their RNA transcripts in a manner not found in the wild type/ normal nucleic acid or protein sequences. For example, but not by way of limitation, in a fusion gene in the form of genomic DNA, the relative positions of portions of the genomic sequences of the recited genes is altered relative to the wild type/ normal sequence (for example, as reflected in the NCBI chromosomal positions or sequences set forth herein). In a fusion gene in the form of mRNA, portions of RNA transcripts arising from both component genes are present (not necessarily in the same register as the wild-type transcript and possibly including portions normally not present in the normal mature transcript). In non-limiting embodiments, such a portion of genomic DNA or mRNA may comprise at least about 10 consecutive nucleotides, or at least about 20 consecutive nucleotides, or at least about 30 consecutive nucleotides, or at least 40 consecutive nucleotides. In a fusion gene in the form of a protein, portions of amino acid sequences arising from both component genes are present (not by way of limitation, at least about 5 consecutive amino acids or at least about 10 amino acids or at least about 20 amino acids or at least about 30 amino acids). In this paragraph, portions arising from both genes, transcripts or proteins do not refer to sequences which may happen to be identical in the wild type forms of both genes (that is to say, the portions are "unshared"). As such, a fusion gene represents, generally speaking, the splicing together or fusion of genomic elements not normally joined together.

The fusion gene TRMT11-GRIK2 is a fusion between the tRNA methyltransferase 11 homolog ("TRMT11") and glutamate receptor, ionotropic, kainate 2 ("GRIK2") genes. The human TRMT11 gene is typically located on chromosome 6q11.1 and the human GRIK2 gene is typically located on chromosome 6q16.3. In certain embodiments, the

TRMT11 gene is the human gene having NCBI Gene ID No: 60487, sequence chromosome 6; NC_000006.11 (126307576..126360422) and/or the GRIK2 gene is the human gene having NCBI Gene ID No:2898, sequence chromosome 6; NC_000006.11 (101841584..102517958).

The fusion gene SLC45A2-AMACR is a fusion between the solute carrier family 45, member 2 ("SLC45A2") and alpha-methylacyl-CoA racemase ("AMACR") genes. The human SLC45A2 gene is typically located on human chromosome 5p13.2 and the human AMACR gene is typically located on chromosome 5p13. In certain embodiments the SLC45A2 gene is the human gene having NCBI Gene ID No: 51151, sequence chromosome 5; NC_000005.9 (33944721..33984780, complement) and/or the AMACR gene is the human gene having NCBI Gene ID No:23600, sequence chromosome 5; NC_000005.9 (33987091..34008220, complement).

The fusion gene MTOR-TP53BP1 is a fusion between the mechanistic target of rapamycin ("MTOR") and tumor protein p53 binding protein 1 ("TP53BP1") genes. The human MTOR gene is typically located on chromosome 1p36.2 and the human TP53BP1 gene is typically located on chromosome 15q15 - q21. In certain embodiments, the MTOR gene is the human gene having NCBI Gene ID No:2475, sequence chromosome 1 NC_000001.10 (11166588..11322614, complement) and/or the TP53BP1 gene is the human gene having NCBI Gene ID No: 7158, sequence chromosome 15; NC_000015.9 (43695262..43802707, complement).

The fusion gene LRRC59-FLJ60017 is a fusion between the leucine rich repeat containing 59 ("LRRC59") gene and the "FLJ60017" nucleic acid. The human LRRC59 gene is typically located on chromosome 17q21.33 and nucleic acid encoding human FLJ60017 is typically located on chromosome 11q12.3. In certain embodiments, the LRRC59 gene is the human gene having NCBI Gene ID No:55379, sequence chromosome 17; NC_000017.10 (48458594..48474914, complement) and/or FLJ60017 has a nucleic acid sequence as set forth in GeneBank AK_296299.

The fusion gene TMEM135-CCDC67 is a fusion between the transmembrane protein 135 ("TMEM135") and coiled-coil domain containing 67 ("CCDC67") genes. The human TMEM135 gene is typically located on chromosome 11q14.2 and the human CCDC67 gene is typically located on chromosome 11q21. In certain embodiments the TMEM135 gene is the human gene having NCBI Gene ID No: 65084, sequence chromosome 11; NC_000011.9 (86748886..87039876) and/or the CCDC67 gene is the

human gene having NCBI Gene ID No: 159989, sequence chromosome 11; NC_000011.9 (93063156..93171636).

The fusion gene CCNH-C5orf30 is a fusion between the cyclin H ("CCNH") and chromosome 5 open reading frame 30 ("C5orf30") genes. The human CCNH gene is

5   typically located on chromosome 5q13.3-q14 and the human C5orf30gene is typically located on chromosome 5q21.1. In certain embodiments, the CCNH gene is the human gene having NCBI Gene ID No: 902, sequence chromosome 5; NC_000005.9 (86687310..86708850, complement) and/or the C5orf30gene is the human gene having NCBI Gene ID No: 90355, sequence chromosome 5; NC_000005.9

10   (102594442..102614361).

The fusion gene KDM4B-AC011523.2 is a fusion between lysine (K)-specific demethylase 4B ("KDM4B") and chromosomal region "AC011523.2". The human KDM4B gene is typically located on chromosome 19p13.3 and the human AC011523.2 region is typically located on chromosome 19q13.4. In certain embodiments the KDM4B

15   gene is the human gene having NCBI Gene ID NO: 23030, sequence chromosome 19; NC_000019.9 (4969123..5153609); and/or the AC011523.2 region comprises a sequence as shown in Figure 1.

The fusion gene MAN2A1-FER is a fusion between mannosidase, alpha, class 2A, member 1 ("MAN2A1") and (fps/fes related) tyrosine kinase ("FER"). The human

20   MAN2A1 gene is typically located on chromosome 5q21.3 and the human FER gene is typically located on chromosome 5q21. In certain embodiments, the MAN2A1gene is the human gene having NCBI Gene ID NO: 4124, sequence chromosome 5; NC_000005.9 (109025156..109203429) or NC_000005.9 (109034137..109035578); and/or the FER gene is the human gene having NCBI Gene ID NO: 2241, sequence chromosome 5:

25   NC_000005.9 (108083523..108523373).

The fusion gene PTEN-NOLC1 is a fusion between the phosphatase and tensin homolog ("PTEN") and nucleolar and coiled-body phosphoprotein 1 ("NOLC1"). The human PTEN gene is typically located on chromosome 10q23.3 and the human NOLC1 gene is typically located on chromosome 10q24.32. In certain embodiments, the PTEN

30   gene is the human gene having NCBI Gene ID NO: 5728, sequence chromosome 10; NC_000010.11 (87863438..87970345) and/or the NOLC1 gene is the human gene having NCBI Gene ID NO: 9221, sequence chromosome 10; NC_000010.11 (102152176..102163871).

The fusion gene ZMPSTE24-ZMYM4 is a fusion between zinc metallopeptidase STE24 ("ZMPSTE24") and zinc finger, MYM-type 4 ("ZMYM4"). The human ZMPSTE24 is typically located on chromosome 1p34 and the human ZMYM4 gene is typically located on chromosome 1p32-p34. In certain embodiments, the ZMPSTE24

5   gene is the human gene having NCBI Gene ID NO: 10269, sequence chromosome 1; NC_000001.11 (40258050..40294184) and/or the ZMYM4 gene is the human gene having NCBI Gene ID NO: 9202, sequence chromosome 1; NC_000001.11 (35268850..35421944).

The fusion gene CLTC-ETV1 is a fusion between clathrin, heavy chain (Hc)

10   ("CLTC") and ets variant 1 ("ETV1"). The human CLTC is typically located on chromosome 17q23.1 and the human ETV1 gene is typically located on chromosome 7p21.3. In certain embodiments, the CLTC gene is the human gene having NCBI Gene ID NO: 1213, sequence chromosome 17; NC_000017.11 (59619689..59696956) and/or the ETV1 gene is the human gene having NCBI Gene ID NO: 2115, sequence

15   chromosome 7; NC_000007.14 (13891229..13991425, complement).

The fusion gene ACPP-SEC13 is a fusion between acid phosphatase, prostate ("ACPP") and SEC13 homolog ("SEC13"). The human ACPP is typically located on chromosome 3q22.1 and the human SEC13 gene is typically located on chromosome 3p25-p24. In certain embodiments, the ACPP gene is the human gene having NCBI Gene

20   ID NO: 55, sequence chromosome 3; NC_000003.12 (132317367..132368302) and/or the SEC13 gene is the human gene having NCBI Gene ID NO: 6396, sequence chromosome 3; NC_000003.12 (10300929..10321188, complement).

The fusion gene DOCK7-OLR1 is a fusion between dedicator of cytokinesis 7 ("DOCK7") and oxidized low density lipoprotein (lectin-like) receptor 1 ("OLR1"). The

25   human DOCK7 is typically located on chromosome 1p31.3 and the human OLR1 gene is typically located on chromosome 12p13.2-p12.3. In certain embodiments, the DOCK7 gene is the human gene having NCBI Gene ID NO: 85440, sequence chromosome 1; NC_000001.11 (62454726..62688368, complement) and/or the OLR1 gene is the human gene having NCBI Gene ID NO: 4973, sequence chromosome 12; NC_000012.12

30   (10158300..10172191, complement).

The fusion gene PCMTD1-SNTG1 is a fusion between protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 ("PCMTD1") and syntrophin, gamma 1 ("SNTG1"). The human PCMTD1 is typically located on chromosome 8q11.23

and the human SNTG1 gene is typically located on chromosome 8q11.21. In certain embodiments, the PCMTD1 gene is the human gene having NCBI Gene ID NO: 115294, sequence chromosome 8; NC_000008.11 (51817575..51899186, complement) and/or the SNTG1gene is the human gene having NCBI Gene ID NO: 54212, sequence chromosome

5   8; NC_000008.11 (49909789..50794118).

5.2 FUSION GENE DETECTION

Any of the foregoing fusion genes described above in section 5.1 may be identified by methods known in the art. The fusion genes may be detected by detecting

10   the gene fusion manifested in DNA, RNA or protein. For example, and not by way of limitation, the presence of a fusion gene may be detected by determining the presence of the protein encoded by the fusion gene.

The fusion gene may be detected in a sample of a subject. A "patient" or "subject," as used interchangeably herein, refers to a human or a non-human subject.

15   Non-limiting examples of non-human subjects include non-human primates, dogs, cats, mice, etc.

The subject may or may not be previously diagnosed as having prostate cancer.

In certain non-limiting embodiments, a sample includes, but is not limited to, cells in culture, cell supernatants, cell lysates, serum, blood plasma, biological fluid (*e.g.*,

20   blood, plasma, serum, stool, urine, lymphatic fluid, ascites, ductal lavage, saliva and cerebrospinal fluid) and tissue samples. The source of the sample may be solid tissue (*e.g.*, from a fresh, frozen, and/or preserved organ, tissue sample, biopsy, or aspirate), blood or any blood constituents, bodily fluids (such as, *e.g.*, urine, lymph, cerebral spinal fluid, amniotic fluid, peritoneal fluid or interstitial fluid), or cells from the individual,

25   including circulating cancer cells. In certain non-limiting embodiments, the sample is obtained from a cancer. In certain embodiments, the sample may be a "biopsy sample" or "clinical sample," which are samples derived from a subject. In certain embodiments, the sample includes one or more prostate cancer cells from a subject. In certain embodiments, the one or more fusion genes can be detected in one or more samples

30   obtained from a subject.

In certain non-limiting embodiments, the fusion gene is detected by nucleic acid hybridization analysis.

In certain non-limiting embodiments, the fusion gene is detected by fluorescent in situ hybridization (FISH) analysis.

In certain non-limiting embodiments, the fusion gene is detected by DNA hybridization, such as, but not limited to, Southern blot analysis.

In certain non-limiting embodiments, the fusion gene is detected by RNA hybridization, such as, but not limited to, Northern blot analysis.

5   In certain non-limiting embodiments, the fusion gene is detected by nucleic acid sequencing analysis.

In certain non-limiting embodiments, the fusion gene is detected by probes present on a DNA array, chip or a microarray.

In certain non-limiting embodiments, the fusion gene is detected by a method

10   comprising Reverse Transcription Polymerase Chain Reaction ("RT-PCR"). In certain embodiments, the fusion gene is detected by a method comprising RT-PCR using the one or more pairs of primers disclosed herein (see Table 3).

In certain non-limiting embodiments, the fusion gene is detected by antibody binding analysis such as, but not limited to, Western Blot analysis and

15   immunohistochemistry.

In certain non-limiting embodiments, where a fusion gene combines genes not typically present on the same chromosome, FISH analysis may demonstrate probes binding to the same chromosome. For example, analysis may focus on the chromosome where one gene normally resides and then hybridization analysis may be performed to

20   determine whether the other gene is present on that chromosome as well.

5.3 DIAGNOSTIC METHODS AND METHODS OF TREATMENT

The present invention provides methods for assessing whether a subject having prostate cancer is at increased risk of developing progressive disease, at an increased risk

25   of relapse and/or at an increased risk of rapid relapse. The present invention further provides methods of treating subjects at an increased risk of developing progressive disease, at an increased risk of relapse and/or at an increased risk of rapid relapse.

"Increased risk," as used herein, means at higher risk than subjects lacking one or more of the disclosed fusion genes; in certain non-limiting embodiments, the risk is

30   increased such that progressive prostate cancer occurs in more than 50%, more than 60% or more than 70% of individuals bearing said fusion gene in one or more cells of their prostate cancer.

5.3.1 DIAGNOSTIC METHODS FOR ASSESSING THE RISK OF PROGRESSIVE CANCER

The present invention provides for methods of determining whether a subject is at increased risk of manifesting progressive prostate cancer.

5   In certain non-limiting embodiments, the method of determining whether a subject is at increased risk of manifesting progressive prostate cancer comprises determining whether a sample of the subject contains one or more fusion genes selected from the group consisting of TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67, KDM4B-AC011523.2, MAN2A1-FER, PTEN-NOLC1,

10   CCNH-C5orf30, ZMPSTE24-ZMYM4, CLTC-ETV1, ACPP-SEC13, DOCK7-OLR1, PCMTD1-SNTG1 or a combination thereof, where the presence of one or more fusion genes in the sample is indicative that the subject is at increased risk of manifesting progressive prostate cancer.

In certain embodiments, the method of determining whether a subject is at

15   increased risk of manifesting progressive prostate cancer comprises determining the presence and/or absence of one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more of the fusion genes disclosed herein in a sample of a subject. In certain embodiments, the sample can include one or

20   more prostate cancer cells of a subject.

In certain non-limiting embodiments, the method of determining whether a subject is at increased risk of manifesting progressive prostate cancer comprises determining whether a sample of the subject contains one or more fusion genes selected from the group consisting of TRMT11-GRIK2, SLC45A2-AMACR, PTEN-NOLC1 or MTOR-

25   TP53BP1, where the presence of one or more fusion genes in the sample is indicative that the subject is at increased risk of manifesting progressive prostate cancer.

5.3.2 DIAGNOSTIC METHODS FOR ASSESSING THE RISK OF RELAPSE

30   OF PROSTATE CANCER

The present invention provides for methods for determining whether a subject is at risk for relapse or rapid relapse of prostate cancer.

In certain non-limiting embodiments, a method of determining whether a subject is at risk for rapid relapse of prostate cancer (as reflected, for example, in a doubling of

serum prostate specific antigen (PSA) in less than 4 months), comprises determining the
sum of:

{[the vector of whether the fusion gene TMEM135-CCDC67 is present in a tumor
cell of the subject] times 0.4127877};

5   plus

{[the vector of whether the fusion gene KDM4B -AC011523.2 is present in a
tumor cell of the subject] times 0.4091903};

plus

{[the vector of whether the fusion gene MAN2A1 -FER is present in a tumor cell

10   of the subject] times 0.3879886};

plus

{[the vector of whether the fusion gene CCNH-C5orf30 is present in a tumor cell
of the subject] times (-2.0193237)};

plus

15   {[the vector of whether the fusion gene TRMT11-GRIK2 is present in a tumor cell
of the subject] times (-2.3301892)};

plus

{[the vector of whether the fusion gene SLC45A2-AMACR is present in a tumor
cell of the subject] times (-2.1499750)};

20   plus

{[the vector of whether the fusion gene MTOR-TP53BP1 is present in a tumor cell
of the subject] times (-2.1140216)};

plus

{[the vector of whether the fusion gene LRRC59-FLJ60017 is present in a tumor

25   cell of the subject] times (-0.8611482)};

where if the sum of the above is less than 0.0716, then the subject is at increased
risk for exhibiting rapid relapse of prostate cancer. In the above, where the particular
fusion gene is present, the value of the vector is [+1] and where the particular fusion gene
is absent, the value of the vector is [0].

30   In certain non-limiting embodiments, a method of determining whether a subject
is at risk for relapse of prostate cancer comprises determining the sum of:

{[the vector of whether the fusion gene TMEM135-CCDC67 is present in a tumor
cell of the subject] times (-0.01752496)};

plus

{[the vector of whether the fusion gene KDM4B-AC011523.2 is present in a tumor cell of the subject] times (-0.16638222)};

plus

{[the vector of whether the fusion gene MAN2A1-FER is present in a tumor cell of the subject] times 0.67180725};

plus

{[the vector of whether the fusion gene CCNH-C5orf30 is present in a tumor cell of the subject] times (-0.62367777)};

plus

{[the vector of whether the fusion gene TRMT11-GRIK2 is present in a tumor cell of the subject] times (-2.44068688)};

plus

{[the vector of whether the fusion gene SLC45A2-AMACR is present in a tumor cell of the subject] times (-2.18012958)};

plus

{ [the vector of whether the fusion gene MTOR-TP53BP1 is present in a tumor cell of the subject] times (-1.79668048)};

plus

{[the vector of whether the fusion gene LRRC59-FLJ60017 is present in a tumor cell of the subject] times (-1.75487809)};

where if the sum of the above is less than 0.056, then the subject is at increased risk for exhibiting relapse of prostate cancer. In the above, where the particular fusion gene is present, the value of the vector is [+1] and where the particular fusion gene is absent, the value of the vector is [0].

In certain non-limiting embodiments, the method of determining whether a subject is at increased risk of relapse of prostate cancer comprises determining whether a sample of the subject contains one or more fusion genes selected from the group consisting of TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67, KDM4B-AC011523.2, MAN2A1-FER, PTEN-NOLC1, CCNH-C5orf30, ZMPSTE24-ZMYM4, CLTC-ETV1, ACPP-SEC13, DOCK7-OLR1, PCMTD1-SNTG1 or a combination thereof, where the presence of one or more fusion genes in the sample is indicative that the subject is at increased risk of relapse, using the following formula:

$$Z=-0.0325*X + 1.6219*Y \hspace{3cm} \text{[Formula 1]}$$

where X% is the Nomogram score of the five-year progression free probability after surgery (X can be between 0 and 100) and Y is the presence of any of the fusion genes (where Y = 0 if no fusion genes are present, and Y = +1 if one or more fusion genes are present). In the above, when Z>=-1.9, then the patient is at risk for exhibiting relapse of prostate cancer and when Z<-1.9, then the patient is not at risk for exhibiting relapse of prostate cancer.

5.3.3   METHODS OF TREATMENT

The invention further provides methods for treating a subject having an increased risk for progressive prostate cancer, prostate cancer relapse or prostate cancer rapid relapse.

In certain embodiments, the method of treating a subject comprises determining if the subject is at an increased risk for progressive prostate cancer by determining the presence of one or more fusion genes selected from the group consisting of TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67, KDM4B-AC011523.2, MAN2A1-FER, PTEN-NOLC1, CCNH-C5orf30, ZMPSTE24-ZMYM4, CLTC-ETV1, ACPP-SEC13, DOCK7-OLR1, PCMTD1-SNTG1 or a combination thereof in a sample of the subject, where if one or more fusion genes are present in the sample so that the subject is at risk then treating the subject to produce an anti-cancer effect. In certain embodiments, the method can include determining the presence or absence of one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more or all nine of the fusion genes disclosed herein.

An "anti-cancer effect" refers to one or more of a reduction in aggregate cancer cell mass, a reduction in cancer cell growth rate, a reduction in cancer progression, a reduction in cancer cell proliferation, a reduction in tumor mass, a reduction in tumor volume, a reduction in tumor cell proliferation, a reduction in tumor growth rate and/or a reduction in tumor metastasis. In certain embodiments, an anti-cancer effect can refer to a complete response, a partial response, a stable disease (without progression or relapse), a response with a later relapse or progression-free survival in a patient diagnosed with cancer.

In certain embodiments, the method of treating a subject comprises determining if the subject is at an increased risk for progressive prostate cancer by determining the presence of one or more fusion genes selected from the group consisting TRMT11-

21

GRIK2, SLC45A2-AMACR, PTEN-NOLC1 or MTOR-TP53BP1or a combination
thereof in a sample of the subject, where if one or more fusion genes are detected in the
sample so that the subject is at risk then treating the subject to produce an anti-cancer
effect.

5   In certain embodiments, the method of treating a subject comprises determining if
a patient is at an increased risk for prostate cancer relapse or rapid relapse as described
above in section 5.3, where if the subject is at increased risk for prostate cancer rapid
relapse then treating the subject to produce an anti-cancer effect in the subject.

           In certain embodiments, the method of treating a subject comprises determining if
10   the subject is at an increased risk for progressive prostate cancer, prostate cancer relapse
or rapid relapse as described above, where if the subject is at increased risk for
progressive prostate cancer, prostate cancer relapse or rapid relapse, then administering to
the subject a therapeutically effective amount of an inhibitor. In certain embodiments, the
inhibitor can be administered to produce an anti-cancer effect in a subject.

15   A "therapeutically effective amount" refers to an amount that is able to achieve
one or more of the following: an anti-cancer effect, prolongation of survival and/or
prolongation of period until relapse.

           In certain embodiments, the method of treating a subject is directed to inhibiting
the fusion gene and/or inhibiting the fusion gene product, e.g., the protein and/or RNA
20   encoded by the fusion gene.

           Examples of inhibitors include, but are not limited to, compounds, molecules,
chemicals, polypeptides and proteins that inhibit and/or reduce the expression and/or
activity of the protein encoded by a fusion gene. Alternatively or additionally, the
inhibitor can include compounds, molecules, chemicals, polypeptides and proteins that
25   inhibit and/or reduce the expression and/or activity of one or more downstream targets of
the fusion gene.

           Additional non-limiting examples of inhibitors include ribozymes, antisense
oligonucleotides, shRNA molecules and siRNA molecules that specifically inhibit or
reduce the expression and/or activity of the fusion gene and/or inhibit or reduce the
30   expression and/or activity of one or more downstream targets of the fusion gene. One
non-limiting example of an inhibitor comprises an antisense, shRNA or siRNA nucleic
acid sequence homologous to at least a portion of the fusion gene sequence, wherein the
homology of the portion relative to the fusion gene sequence is at least about 75 or at least
about 80 or at least about 85 or at least about 90 or at least about 95 or at least about 98

percent, where percent homology can be determined by, for example, BLAST or FASTA software. In certain embodiments, the antisense, the shRNA or siRNA nucleic acid sequence can be homologous to the sequence at the "junction fragment" that encompasses the boundary between the spliced genes of the fusion gene. Non-limiting examples of

5   siRNAs homologous to the junction fragment sequences of the disclosed fusion genes are shown in Table 1.

In certain non-limiting embodiments, the complementary portion may constitute at least 10 nucleotides or at least 15 nucleotides or at least 20 nucleotides or at least 25 nucleotides or at least 30 nucleotides and the antisense nucleic acid, shRNA or siRNA

10   molecules may be up to 15 or up to 20 or up to 25 or up to 30 or up to 35 or up to 40 or up to 45 or up to 50 or up to 75 or up to 100 nucleotides in length. Antisense, shRNA or siRNA molecules may comprise DNA or atypical or non-naturally occurring residues, for example, but not limited to, phosphorothioate residues and locked nucleic acids.

In certain embodiments, an inhibitor can include an antibody, or a derivative

15   thereof, that specifically binds to and inhibits and/or reduces the expression and/or activity of the protein that is encoded by the fusion gene, e.g., an antagonistic antibody. Alternatively or additionally, an inhibitor can include an antibody, or derivative thereof, that specifically binds to and inhibits and/or reduces the expression and/or activity of one or more downstream targets of the fusion gene. The phrase "specifically binds" refers to

20   binding of, for example, an antibody to an epitope or antigen or antigenic determinant in such a manner that binding can be displaced or competed with a second preparation of identical or similar epitope, antigen or antigenic determinant. Non-limiting examples of antibodies, and derivatives thereof, that can be used in the disclosed methods include polyclonal or monoclonal antibodies, chimeric, human, humanized, primatized (CDR-

25   grafted), veneered or single-chain antibodies, phase produced antibodies (e.g., from phage display libraries), as well as functional binding fragments of antibodies. Antibody binding fragments, or portions thereof, include, but are not limited to, Fv, Fab, Fab' and F(ab')$_2$. Such fragments can be produced by enzymatic cleavage or by recombinant techniques.

30   In certain embodiments, where the protein encoded by the fusion gene detected in the sample of the subject exhibits kinase activity, the method of treating a subject can include administering a therapeutically effective amount of an inhibitor to the subject that inhibits and/or reduces the kinase activity of the protein encoded by the fusion gene, i.e., a kinase inhibitor. Non-limiting examples of kinase inhibitors include afatinib, alectinib,

axitinib, bevacizumab, bosutinib, cetuximab, crizotinib, dasatinib, erlotinib, fostamatinib, gefitinib, GSK1838705A, ibrutinib, imatinib, lapatinib, lenvatinib, mubritinib, nilotinib, panitumumab, pazopanib, pegaptanib, ranibizumab, ruxolitinib, sorafenib, sunitinib, su6656, trastuzumab, tofacitinib, vandetanib and vemurafenib. For example, and not by
5   way of limitation, if the protein encoded by the fusion gene detected in a sample of the subject exhibits tyrosine kinase activity, a therapeutically effective amount of a tyrosine kinase inhibitor can be administered to the subject.

In certain embodiments, a method of treating a subject can comprise determining if the subject is at an increased risk for progressive prostate cancer by determining the
10   presence of MAN2A1-FER in a sample of the subject, where if the MAN2A1-FER fusion gene is present in the sample, then treating the subject with a therapeutically effective amount of a FER inhibitor. Non-limiting examples of FER inhibitors include crisotinib, TAE684, WZ-4-49-8 and WZ-4-49-10. In particular non-limiting embodiments, the FER inhibitor can be derived from diaminopyrimidine or pyrazologyrididine compounds.
15   Further non-limiting examples of FER inhibitors are disclosed in PCT Application No. WO 2009/019708.

In certain embodiments, the FER inhibitor can include tyrosine kinase inhibitors and ALK inhibitors as FER exhibits high sequence similarity to ALK. In certain embodiments, the FER inhibitor is an antibody that reduces and/or inhibits the expression
20   and/or activity of the MAN2A1-FER protein. In certain embodiments, the FER inhibitor comprises an siRNA targeting the MAN2A1-FER fusion gene or the juncture sequence of the MAN2A1-FER fusion gene. A non-limiting example of an siRNA sequence targeting the MAN2A1-FER fusion gene is shown in Table 1.

Alternatively or additionally, the method of treating a subject expressing the
25   MAN2A1-FER fusion gene can comprise administering to the subject a compound that reduces and/or inhibits the activity and/or expression of one or more downstream targets of the MAN2A1-FER fusion gene. For example, and not by way of limitation, the method can include the inhibition of the EGFR-RAS-BRAF-MEK signaling pathway. Non-limiting examples of compounds that inhibit EGFR activity include erlotinib,
30   cetuximab, gefitinib, bevacizumab, panitumumab and bortezomib. A non-limiting example of a compound that inhibits BRAP activity includes RAF265. Non-limiting examples of compounds that inhibits MEK activity includes binimetinib, vemurafenib, PD-325901, selumetinib and trametinib. Additional non-limiting examples of compounds that inhibit the EGFR-RAS-BRAF-MEK signaling pathway include TAK-733, Honokiol,

24

AZD8330, PD318088, BIX 02188, pimasertib, SL-327, BIX 02189, PD98059, MEK162, PD184352 and U0126-EtOH.

In certain embodiments, a method of treating a subject can comprise determining if the subject is at an increased risk for progressive prostate cancer by determining the presence of SLC45A2-AMACR in a sample of the subject, where if the SLC45A2-AMACR fusion gene is present in the sample, then treating the subject with a therapeutically effective amount of a racemase inhibitor and/or an AMACR inhibitor. A non-limiting example of a racemase and/or AMACR inhibitors includes ebselen, 2-(2,5-dihydroxy-4-methylphenyl)-5-methyl benzene-1.4-diol (DMPMB), 2-methylsulfanyl-7,9-dihydro-3H-purine-6,8-dithione (MSDTP), 2,5-di(pyrazol-1-yl)benzene-1,4-diol (DPZBD), Rose Bengal, Congo Red, 3,5-di(pyridin-4-yl)-1,2,4-thiadiazole (DPTD), ebselen oxide and 3,7,12-trihydroxycholestanoyl Coenzyme A (THCA-CoA). In particular non-limiting embodiments, the racemase inhibitor can be a N-methylthiocarbamate. Further non-limiting examples of AMACR inhibitors are disclosed in Wilson et al., Mol. Cancer Ther. (2011), 10(5): 825–838, the content of which is hereby incorporated by reference in its entirety.

In certain embodiments, the method of treating a subject comprises determining if the subject is at an increased risk for progressive prostate cancer, prostate cancer relapse or rapid relapse as described above, where if the subject is at increased risk for progressive prostate cancer, prostate cancer relapse or rapid relapse, then administering a therapeutically effective amount of an anti-cancer agent. An anti-cancer agent can be any molecule, compound chemical or composition that has an anti-cancer effect. Anti-cancer agents include, but are not limited to, chemotherapeutic agents, radiotherapeutic agents, cytokines, anti-angiogenic agents, apoptosis-inducing agents or anti-cancer immunotoxins. In certain non-limiting embodiments, an inhibitor can be administered in combination with one or more anti-cancer agents. "In combination with," as used herein, means that the inhibitor and the one or more anti-cancer agents are administered to a subject as part of a treatment regimen or plan. This term does not require that the inhibitor and/or kinase inhibitor and one or more anti-cancer agents are physically combined prior to administration nor that they be administered over the same time frame. Non-limiting examples of anti-cancer agents include Abiraterone Acetate, Bicalutamide, Cabazitaxel, Casodex™ (Bicalutamide), Degarelix, Docetaxel, Enzalutamide, Goserelin Acetate, Jevtana™ (Cabazitaxel), Leuprolide Acetate, Lupron™ (Leuprolide Acetate), Lupron Depot (Leuprolide Acetate), Lupron Depot-3 Month (Leuprolide Acetate),

25

Lupron Depot-4 Month (Leuprolide Acetate), Lupron Depot-Ped (Leuprolide Acetate), Mitoxantrone Hydrochloride, Prednisone, Provenge™ (Sipuleucel-T), Radium 223 Dichloride, Sipuleucel-T, Taxotere™ (Docetaxel), Viadur™ (Leuprolide Acetate), Xofigo™ (Radium 223 Dichloride), Xtandi™ (Enzalutamide), Zoladex™ (Goserelin Acetate) and Zytiga™ (Abiraterone Acetate).

In certain embodiments, the method of treating a subject comprises determining if the subject is at an increased risk for progressive prostate cancer, prostate cancer relapse or rapid relapse as described above, where if the subject is at increased risk for progressive prostate cancer, prostate cancer relapse or rapid relapse, then performing one or more of cryotherapy, radiation therapy, chemotherapy, hormone therapy, biologic therapy, bisphosphonate therapy, high-intensity focused ultrasound, frequent monitoring, frequent prostate-specific antigen (PSA) checks and radical prostatectomy. A non-limiting example of a biologic therapeutic is Sipuleucel-T. Bisphosphonate therapy includes, but is not limited to, clodronate or zoledronate. In certain embodiments, these methods can be used to produce an anti-cancer effect in a subject.

Hormone therapy can include one or more of orchiectomy and the administration of luteinizing hormone-releasing hormone (LHRH) analogs and/or agonists, LHRH antagonists, anti-androgens or androgen-suppressing drugs. Non-limiting examples of LHRH analogs and/or agonists include leuprolide, goserelin and buserelin. Non-limiting examples of LHRH antagonists include abarelix, cetrorelix, ganirelix and degarelix. Anti-androgen drugs include, but are not limited to, flutamide, bicalutamide, enzalutamide and nilutamide. Non-limiting examples of androgen-suppressing drugs include estrogens, ketoconazole and aminoglutethimide. Frequent monitoring can include PSA blood tests, digital rectal exams, ultrasounds and/or transrectal ultrasound-guided prostate biopsies at regular intervals, *e.g.*, at about 3 to about 6 month intervals, to monitor the status of the prostate cancer. Radical prostatectomy is a surgical procedure that involves the removal of the entire prostate gland and some surrounding tissue. Prostatectomies can be performed by open surgery or it may be performed by laparoscopic surgery.

In certain embodiments, the method of treating a subject comprises determining if a subject is at an increased risk for progressive prostate cancer by determining the presence of one or more fusion genes selected from the group consisting of TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67, KDM4B-AC011523.2, MAN2A1-FER, PTEN-NOLC1, CCNH-C5orf30

26

ZMPSTE24-ZMYM4, CLTC-ETV1, ACPP-SEC13, DOCK7-OLR1, PCMTD1-SNTG1
or a combination thereof in a sample of the subject, where if one or more fusion genes are

26B

detected in the sample then performing a targeted genome editing technique on one or more prostate cancer cells within the subject.

In certain embodiments, the method of treating a subject comprises determining if a patient is at an increased risk for prostate cancer relapse or rapid relapse as described

5   above in section 5.3, where if the subject is at increased risk for prostate cancer relapse or rapid relapse then performing a targeted genome editing technique on one or more prostate cancer cells within the subject.

Genome editing is a method in which endogenous chromosomal sequences present in one or more cells within a subject, can be edited, e.g., modified, using targeted

10   endonucleases and single-stranded nucleic acids. The genome editing method can result in the insertion of a nucleic acid sequence at a specific region within the genome, the excision of a specific sequence from the genome and/or the replacement of a specific genomic sequence with a new nucleic acid sequence. For example, and not by way of limitation, the genome editing method can include the use of a guide RNA (gRNA),

15   including protospacer adjacent motifs (PAMs), complementary to a specific sequence within a genome, e.g., a chromosomal breakpoint associated with a fusion gene, to guide a nuclease, e.g., an endonuclease, to the specific genomic sequence. A non-limiting example of an endonuclease includes CRISPR associated protein 9 (Cas9). The endonuclease can result in the cleavage of the targeted genome sequence and allow

20   modification of the genome at the cleavage site through nonhomologous end joining (NHEJ) or homologous recombination. A non-limiting example of genome editing method is disclosed in PCT Application No. WO 2014/093701.

In certain embodiments, the genome editing method can be used to target specific

25   chromosomal breakpoints of a fusion gene present in prostate cancer cells. As normal, non-cancerous, prostate cells do not contain the fusion gene, and therefore do not contain the chromosomal breakpoint associated with the fusion gene, prostate cancer cells can be specifically targeted using this genome editing method. For example, and not by way of limitation, genome editing can be used to promote homologous recombination at a

30   chromosomal breakpoint of a fusion gene in one or more cells of a subject to insert a nucleic acid sequence encoding the Herpes Simplex Virus 1 (HSV-1) thymidine kinase at the chromosomal breakpoint. In certain non-limiting embodiments, the HSV-1 thymidine kinase nucleic acid sequence lacks a promoter and requires integration into the genome for expression. In certain embodiments, a therapeutically effective amount of the guanine

27

derivative, ganciclovir, or its oral homolog, valganciclovir, can be administered to a subject expressing HSV-1 thymidine kinase. HSV-1 thymidine kinase can phosphorylate and convert ganciclovir and/or valganciclovir into the triphosphate forms of ganciclovir and/or valganciclovir in the one or more cells of a subject. The triphosphate form of

5   ganciclovir and/or valganciclovir is as competitive inhibitor of deoxyguanosine triphosphate (dGTP) and is a poor substrate of DNA elongation, and can result in the inhibition of DNA synthesis. The inhibition of DNA synthesis, in turn, can result in the reduction and/or inhibition of growth and/or survival of prostate cancer cells that contain the targeted chromosomal breakpoint and the integrated Herpes Simplex Virus 1 (HSV-1)

10 thymidine kinase nucleic acid sequence. This genome editing method can be used to produce an anti-cancer effect in a subject that has been determined to have an increased risk for progressive prostate cancer, prostate cancer relapse or rapid relapse.

Table 1. siRNA sequences.

MAN2A1-FER
MAN2A1   FER GCAAATACTATTTCAGAAACAGCCTATGAGGGAAATTTTGGTGAAGTATATAAGGG CACA (SEQ ID NO: 1) siRNA sequence for MAN2A1-FER: Sense Strand: 5' RCrArGrCrCrUrArUrGrArGrGrGrArArArUrUrUrUrGrGrUGA (SEQ ID NO: 2) Antisense Strand: 5' RUrCrArCrCrArArArArUrUrUrCrCrCrUrCrArUrArGrGrCrUrGrUrU (SEQ ID NO: 3)
SLC45A2-AMACR
SLC45A2   AMACR TCCACTACCATGCCCTCTTCACAGGTGTCATGGAGAAACTCCAGCTGGGCCCAGAG A (SEQ ID NO: 4) siRNA sequence for SLC45A2-AMACR: Sense Strand: 5' RUrGrCrCrCrUrCrUrUrCrArCrArGrGrUrGrUrCrArUrGrGAG (SEQ ID

NO: 5)

Antisense Strand: 5' RCrUrCrCrArUrGrArCrArCrCrUrGrUrGrArArGrArGrGrGrCrArUrG (SEQ ID NO: 6)

MTOR-TP53BP1

                         MTOR   TP53BP1

TGTCAGAATCCAAGTCAAGTCAGGATTCCTTGTTCTGGGAATGTCAGTGGAATCTG
CTCCTGC (SEQ ID NO: 7)

siRNA sequence for MTOR-TP53BP1:

Sense Strand: 5' RGrUrCrArGrGrArUrUrCrCrUrUrGrUrUrCrUrGrGrGrArATG (SEQ ID NO: 8)

Antisense Strand: 5' RCrArUrUrCrCrCrArGrArArArCrArArArGrGrArArUrCrCrUrGrArCrUrU (SEQ ID NO: 9)

TMEM135-CCDC67

                       TMEM135   CCDC67

TTTTAAGACTCACCAAGGGCAAATAAGAAGCCAACTCCAACAGGTGGAAGAGTAC
CA (SEQ ID NO: 10)

siRNA sequence for TMEM135-CCDC67:

Sense Strand: 5' RGrArCrUrCrArCrCrArArGrGrGrCrArArArArUrArArGrArAGC (SEQ ID NO: 11)

Antisense Strand: 5' RGrCrUrUrCrUrUrArUrUrUrGrCrCrCrUrUrGrGrUrGrArGrUrCrUrU (SEQ ID NO: 12)

CCNH-C5orf30

                       CCNH   C5ORF30

TGTCACAGTTACTAGATATAATGAAAATACCTGGAGTAGAACAGAAAAATTATTAT
GTCT (SEQ ID NO: 13)

siRNA sequence for CCNH-C5orf30:

Sense Strand:	5' RArUrGrArArArArUrArCrCrUrGrGrArGrUrArGrArArCrAGA (SEQ ID NO: 14)
Antisense Strand:	5' RUrCrUrGrUrUrCrUrArCrUrCrCrArGrGrUrArUrUrUrUrCrArUrUrA (SEQ ID NO: 15)

KDM4B-AC011523.2

KDM4B	AC011523.2

AACTACCTGCACTTTGGGGGAGCCTAAGTCCTGGACAGTAAGCAAGCCTGGATCTGA
GAGA (SEQ ID NO: 16)

siRNA sequence for KDM4-AC011523.2:

Sense Strand:	5' RGrArGrCrCrUrArArGrUrCrCrUrGrGrArCrArGrUrArArGCA (SEQ ID NO: 17)
Antisense Strand:	5' RUrGrCrUrUrArCrUrGrUrCrCrArGrGrArCrUrUrArGrGrCrUrCrCrC (SEQ ID NO: 18)

TRMT11-GRIK2

TRMT11	GRIK2

AGCATCTGGAGTTCCGCCTGCCGGTGGTATTTTTGAATATGTGGAATCTGGCCCAA
TGGGAGCTG (SEQ ID NO: 19)

siRNA sequence for TRMT11-GRIK2:

Sense Strand:	5' RCrCrGrCrCrUrGrCrCrGrGrUrGrGrUrArUrUrUrUrUrGrAAT (SEQ ID NO: 20)
Antisense Strand:	5' RArUrUrCrArArArArArArUrArCrCrArCrCrGrGrCrArGrGrCrGrGrArA (SEQ ID NO: 21)

LRRC59-FLJ60017

LRRC69	FLJ60017

CTGCTTGGATGAGAAGCAGTGTAAGCAGTGTGCAAACAAGGTGACTGGAAGCAC
CTGCTCAATGGCTG (SEQ ID NO: 22)

siRNA sequence for LRRC59-FLJ60017:

Sense Strand:	5' RArCrArArGrGrUrGrArCrUrGrGrArArGrCrArCrCrUrGrCTC (SEQ ID

NO: 23)
Antisense Strand: 5' RGrArGrCrArGrGrUrGrCrUrUrCrCrArGrUrCrArCrCrUrUrGrUrUrU (SEQ ID NO: 24)

PTEN-NOLC1
PTEN   NOLC1 AAGCCAACCGATACTTTTCTCCAAATTTTAAGACACAGCAGGATGCCAATGCCTCTTCCCTC TTAGAC (SEQ ID NO: 25)
siRNA sequence for PTEN-NOLC1:
Sense Strand: 5' RCrUrCrCrArArArUrUrUrUrArArGrArCrArCrArGrCrArGGA (SEQ ID NO: 26)
Antisense Strand: 5' RUrCrCrUrGrCrUrGrUrGrUrCrUrUrArArArArUrUrUrGrGrAr GrArA (SEQ ID NO: 27)

Head gene is in highlighted in green and tail gene in yellow. Targeted sequences are underlined and bolded.

5.4 KITS

5   The present invention further provides kits for detecting one or more fusion genes disclosed herein and/or for carrying any one of the above-listed detection and therapeutic methods.

      Types of kits include, but are not limited to, packaged fusion gene-specific probe and primer sets (e.g., TaqMan™ probe/primer sets), arrays/microarrays, antibodies, which

10   further contain one or more probes, primers, or other reagents for detecting one or more fusion genes of the present invention.

      In certain non-limiting embodiments, a kit is provided comprising one or more nucleic acid primers or probes and/or antibody probes for use in carrying out any of the above-listed methods. Said probes may be detectably labeled, for example with a biotin,

15   colorimetric, fluorescent or radioactive marker. A nucleic acid primer may be provided as part of a pair, for example for use in polymerase chain reaction. In certain non-limiting embodiments, a nucleic acid primer may be at least about 10 nucleotides or at least about 15 nucleotides or at least about 20 nucleotides in length and/or up to about 200

31

nucleotides or up to about 150 nucleotides or up to about 100 nucleotides or up to about

75 nucleotides or up to about 50 nucleotides in length. An nucleic acid probe may be an

oligonucleotide probe and/or a probe suitable for FISH analysis. In specific non-limiting

embodiments, the kit comprises primers and/or probes for analysis of at least two, at least

5   three, at least four, at least five, six, seven, eight, nine, ten, eleven, twelve, thirteen,

fourteen of TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-

FLJ60017, TMEM135-CCDC67, KDM4B-AC011523.2, MAN2A1-FER, PTEN-NOLC1,

CCNH-C5orf30, ZMPSTE24-ZMYM4, CLTC-ETV1, ACPP-SEC13, DOCK7-OLR1 and

PCMTD1-SNTG1.

10   In certain non-limiting embodiments, the nucleic acid primers and/or probes may

be immobilized on a solid surface, substrate or support, for example, on a nucleic acid

microarray, wherein the position of each primer and/or probe bound to the solid surface or

support is known and identifiable. The nucleic acid primers and/or probes can be affixed

to a substrate, such as glass, plastic, paper, nylon or other type of membrane, filter, chip,

15   bead, or any other suitable solid support. The nucleic acid primers and/or probes can be

synthesized directly on the substrate, or synthesized separate from the substrate and then

affixed to the substrate. The arrays can be prepared using known methods.

         In non-limiting embodiments, a kit provides nucleic acid probes for FISH analysis

of one or more fusion gene selected from the group consisting of: TRMT11-GRIK2,

20   SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67,

CCNH-C5orf30, TRMT11-GRIK2, SLC45A2-AMACR, KDM4B-AC011523.2,

MAN2A1-FER, PTEN-NOLC1, MTOR-TP53BP1, ZMPSTE24-ZMYM4, CLTC-ETV1,

ACPP-SEC13, DOCK7-OLR1 or PCMTD1-SNTG1. In non-limiting embodiments, a kit

provides nucleic acid probes for FISH analysis of one or more fusion gene selected from

25   the group consisting of: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1,

LRRC59-FLJ60017, TMEM135-CCDC67, PTEN-NOLC1 and CCNH-C5orf30, and

TRMT11-GRIK2, SLC45A2-AMACR, KDM4B-AC011523.2, MAN2A1-FER, MTOR-

TP53BP1, ZMPSTE24-ZMYM4, CLTC-ETV1, ACPP-SEC13, DOCK7-OLR1 or

PCMTD1-SNTG1. In specific non-limiting embodiments, probes to detect a fusion gene

30   may be provided such that separate probes each bind to the two components of the fusion

gene or a probe may bind to a "junction fragment" that encompasses the boundary

between the spliced genes. In specific non-limiting embodiments, the kit comprises said

probes for analysis of at least two, at least three, at least four, at least five, six, seven,

eight or all nine of TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-
FLJ60017, TMEM135-CCDC67, KDM4B-AC011523.2, MAN2A1-FER, PTEN-NOLC1,
CCNH-C5orf30, ZMPSTE24-ZMYM4, CLTC-ETV1, ACPP-SEC13, DOCK7-OLR1 or
PCMTD1-SNTG1. An example of FISH analysis used to identify a fusion gene is

5   provided in Example 1 below.

In non-limiting embodiments, a kit provides nucleic acid primers for PCR analysis
of one or more fusion gene selected from the group consisting of: TRMT11-GRIK2,
SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67,
PTEN-NOLC1, CCNH-C5orf30, TRMT11-GRIK2, SLC45A2-AMACR, KDM4B-

10   AC011523.2, MAN2A1-FER, MTOR-TP53BP1, ZMPSTE24-ZMYM4, CLTC-ETV1,
ACPP-SEC13, DOCK7-OLR1 or PCMTD1-SNTG1. In non-limiting embodiments, a kit
provides nucleic acid primers for PCR analysis of one or more fusion gene selected from
the group consisting of: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1,
LRRC59-FLJ60017, TMEM135-CCDC67, PTEN-NOLC1 and CCNH-C5orf30, and

15   TRMT11-GRIK2, SLC45A2-AMACR, KDM4B-AC011523.2, MAN2A1-FER, MTOR-
TP53BP1, ZMPSTE24-ZMYM4, CLTC-ETV1, ACPP-SEC13, DOCK7-OLR1or
PCMTD1-SNTG1. In specific non-limiting embodiments, the kit comprises said primers
for analysis of at least two, at least three, at least four, at least five, six, seven, eight, nine,
ten, eleven, twelve, thirteen, fourteen of TRMT11-GRIK2, SLC45A2-AMACR, MTOR-

20   TP53BP1, LRRC59-FLJ60017, TMEM135 –CCDC67, KDM4B-AC011523.2,
MAN2A1-FER, PTEN-NOLC1, CCNH-C5orf30, ZMPSTE24-ZMYM4, CLTC-ETV1,
ACPP-SEC13, DOCK7-OLR1 and PCMTD1-SNTG1.

The following Examples are offered to more fully illustrate the disclosure, but are
25   not to be construed as limiting the scope thereof.

6.   **EXAMPLE 1: TRANSLOCATION AND FUSION GENE EVENTS
IN PROGRESSIVE PROSTATE CANCER.**

6.1   ABSTRACT

30   *Importance:* Prediction of prostate cancer clinical outcome remains a major
challenge after the diagnosis. An accurate and reproducible test predicting the behavior of
prostate cancer is urgently needed.

33

Objective: To identify biomarkers that are predictive of prostate cancer recurrence or prostate cancer related death.

Design: Genome DNA and/or total RNA from Nineteen specimens of prostate cancer (T), matched adjacent benign prostate tissues (AT), matched bloods (B) and organ
5   donor prostates (OD) were sequenced. Eight novel fusion genes were discovered and validated. These 8 novel fusion genes were then analyzed on 174 prostate samples, including 164 prostate cancer and 10 healthy prostate organ donor samples. Up to 15 years of clinical follow-ups on prostate cancer patients were conducted.

Setting: University of Pittsburgh Medical Center, Presbyterian and Shadyside
10   Campus.

Participants: One hundred sixty-four prostate cancer patients underwent radical prostatectomy from 1998-2012 were selected for fusion gene expression analysis. 80.5% (132/164) patients had been followed-up for at least 5 years.

Main measure: To identify the presence of any of the following fusion genes in
15   prostate cancer samples: TMEM135-CCDC67, KDM4B-AC011523.2, MAN2A1-FER, TRMT11-GRIK2, CCNH-C5orf30, SLC45A2-AMACR, MTOR-TP53BP1 and LRRC59-FLJ60017.

Results: Approximately 90% of men carrying at least one of six of these fusion genes (TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017,
20   TMEM135-CCDC67 and CCNH-C5orf30) experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy, while these outcomes occurred in only 36% of men not carrying those fusion genes. Four fusion genes occurred exclusively in prostate cancer samples from patients who experienced recurrence or prostate cancer related death. The formation of these fusion genes is the
25   result of genome recombination events.

Conclusion and relevance: These findings suggest that the formation of these fusion genes are associated with prostate cancer recurrence and may drive the progression.

6.2.   INTRODUCTION

30   Despite a high incidence[1, 2], only a fraction of men diagnosed with prostate cancer develop metastases and even fewer die from the disease. The majority of prostate cancers remain asymptomatic and clinically indolent. The precise mechanisms for the development of progressive, clinically concerning prostate cancer remain elusive. Furthermore, the inability to predict prostate cancer's potential aggressiveness has

resulted in significant overtreatment of the disease. The dichotomous nature of prostate cancer—a subset of life-threatening malignancies in the larger background of histological alterations lacking the clinical features implicit with that label—is a fundamental challenge in disease management.

5   To identify genome markers for prostate cancer, whole genome sequencing was performed on 14 prostate tissue samples from 5 prostate cancer patients: five prostate cancers (T) from patients who experienced poor clinical outcomes (reoccurrence with fast rise of prostate cancer antigen doubling time (PSADT <4 months)), five matched blood (B) samples and four matched benign prostate tissues from the prostate cancer patients

10   (AT) (Table 2). In one patient, normal adjacent prostate tissue was not available. An average of 200 GB was sequenced per sample to achieve 33 fold coverage of the entire genome. Total RNA from all T and AT samples was sequenced to achieve >1333 (average 400 million reads/sample) fold coverage per gene. Total RNA from four age-matched, entirely histologically benign prostate tissues harvested from healthy organ

15   donors was similarly sequenced as a tissue control. The sequencing data were aligned to human reference genome HG19[3]. Fusion genes were then identified and validated. We hypothesize that these fusion genes from cancer samples that prove metastatic are associated poor clinical outcome for prostate cancer patients. A prediction model for prostate cancer recurrence and short post-operative prostate specific antigen doubling

20   time (PSADT) was built. This model was then applied to 89 additional prostate cancer samples from University of Pittsburgh Medical Center, 30 samples from Stanford University Medical Center, and 36 samples from University of Wisconsin Madison Medical Center with follow-up ranging from 1 to 15 years. One hundred twenty-seven of these samples are from patients who experienced prostate cancer recurrence after radical

25   prostatectomy, and 106 are from patients with no evidence of recurrence for at least 5 years after the surgery. The remaining 46 samples are from patients who had less than 5 years of follow-up and had not yet experienced biochemical recurrence.

        The newly validated fusion genes were then analyzed on 164 prostate cancer samples with clinical follow-up ranging from 2 to 15 years. Seventy-eight of these

30   samples are from patients who experienced prostate cancer recurrence after radical prostatectomy, while 54 are from patients had no recurrence for at least 5 years after the surgery. The remainder samples are from patients who had radical prostatectomy less than 5 years ago. Association of fusion gene expression with prostate cancer recurrence was analyzed.

6.3   METHODS

Tissue samples. Nineteen specimens of prostate cancer (T), matched adjacent benign prostate tissues (AT), matched bloods (B) and organ donor prostates (OD) were obtained from University of Pittsburgh Tissue Bank in compliance with institutional regulatory guidelines (Table 2). To ensure high purity ($\geq 80\%$) of tumor cells, needle-microdissection was performed by pathologists to isolate the tumor cells from adjacent normal tissues (≥ 3 mm distance from the tumor). For AT and OD samples, similar needle-microdissections were performed to achieve 80% epithelial purity. Genomic DNA of these tissues was extracted using a commercially available tissue and blood DNA extraction kit (Qiagen, Hilden, Germany). The protocols of tissue procurement and procedure were approved by Institution Board of Review of University of Pittsburgh.

Whole genome and transcriptome sequencing library preparation. To prepare the genomic DNA libraries, 50 ng DNA was subjected to the tagmentation reactions using the NEXTERA™ DNA sample prep kit (Madison, WI) for 5 min at 55°C. The DNA was then amplified with adaptor and sequencing primers for 9 cycles of the following procedure: 95°C for 10s, 62°C for 30s and 72°C for 3 min. The PCR products were purified with Ampure beads. The quality of genomic DNA libraries was then analyzed with qPCR using Illumina sequencing primers and quantified with Agilent 2000 bioanalyzer. For transcriptome sequencing, total RNA was extracted from prostate samples using Trizol™, and treated with DNAse1. Ribosomal RNA was then removed from the samples using RIBO-ZERO™ Magnetic kit (Epicentre, Madison, WI). The RNA was reverse-transcribed to cDNA and amplified using TRUSEQ™ RNA Sample Prep Kit v2 from Illumina, Inc (San Diego, CA). The library preparation process such as adenylation, ligation and amplification was performed following the manual provided by the manufacturer. The quantity and quality of the libraries were assessed as those described in genome DNA library preparation.

Whole genome and transcriptome sequencing. The Illumina whole genome sequencing system was applied to the analysis. The operation procedures strictly followed the manufacturer's instructions. Briefly, DNA libraries were hybridized to flowcells and subjected to primer extension and bridge amplification in an automatic cBot process for 4 h to generate clusters of DNA sequencing templates. These clustered flowcells were then subjected to the sequencing analysis in the Illumina HiSeq2000 system. All samples were sequenced with paired-end runs for 200 cycles.

36

Read alignment. Whole genome DNA-seq reads from 5 Ts, 4 ATs and 5 Bs were aligned by BWA[3] version 1.4.1 against the UCSC hg19 human reference genome allowing maximal 2 base mismatches per (100 nucleotide) read. After alignment, the average coverage of whole genome is above 30X for all 14 samples. Picard tool

5 (http://picard.sourceforge.net) was applied to remove duplicate reads after the alignment. RNA-seq reads (from 5 T, 4 matched AT and 4 OD samples) were at an average of 1333X coverage. Whole transcriptome RNA-seq reads were aligned with the UCSC hg19 reference genome using Tophat[4-6] version 1.4.1. Maximal 2 mismatches per read were allowed.

10   *Fusion gene detection.* To identify fusion gene events, we applied a Fusioncatcher (v0.97) algorithm[7] on RNA sequencing samples. The analysis results by the software had been validated with high precision rate in breast cancer cell lines. Both BOWTIE and BLAT alignment were applied in the analysis and were plotted with circossoftware[8]. The preliminary list of candidate fusion transcripts are filtered in

15 Fusioncatcher based on the existing biological knowledge of the literature including: (1) If the genes are known to be the other's paralog in Ensembl; (2) If one of the fusion transcripts are the partner's pseudogene; (3) If one of the fusion transcripts are micro/transfer/small-nuclear RNA; (4) If the fusion transcript is known to be a false positive event (*e.g.*, Conjoin gene database[21]); (5) If it has been found in healthy samples

20 (Illumina Body Map 2.0[http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-513/]); (6) If the head and tail genes are overlapping with each other on the same strand. Fusion genes were visualized with CIRCOS software[8] as shown in Figure 6.

Table 2.

Case	TNM	Margin	Relapse	Relapse fast	Relapse simple	Gleason	Age	Gender	Race	PSA pre-operative	Time to progression (Months)	PSADT	Radiology follow-up	Time interval of follow-up (Months)	Length of follow-up (Months)	Additional treatment
Case 1	T3bN1MX	Negative	fast	f	y	7	50s	M	W	14.6	1.41	3.7	NEGATIVE	2.76	29.09	ADT
Case 2	T3aN0MX	Negative	slow	nf	y	7	60s	M	W	4.1	43.75	39.96	NO	2.56	133.3	RT
Case 3	T2cN0MX	Negative	fast	f	y	8	60s	M	W	2.38	33.76	2.99	NEGATIVE	3.42	33.93	RT
Case 4	T3bN1MX	Negative	fast	f	y	10	50s	M	W	29.3	1.35	0.93	POSITIVE FOR BONE METASTASIS	1.02	15.48	ADT, CHEMO
Case 5	T3bN1MX	Negative	fast	f	y	10	50s	M	W	9.17	1.35	1.83	POSITIVE FOR BONE METASTASIS	2.4	149.6	ADT

Machine learning classifier to predict relapse status. 8 fusion genes from 5 tumor samples validated by RT-PCR, Sanger sequencing and Fluorescence In-situ Hybridization (FISH) analyses were used as features to predict the relapse status (fast vs non-fast and relapse vs non-relapse) in a large validation cohort (PSADT<4 months vs

5   PSADT>15 months or non-recurrent). The presence for each fusion pair was coded either as 1 or 0 to represent whether the fusion gene exist in the sample. Linear discriminant analysis (LDA) was used to build a classifier. In light of relatively rare occurrence of the fusion transcripts (4.4%-9.0%) in our 90-sample Pittsburgh training cohort, we also applied a simple prediction rule based on the presence in any subset of the eight fusion

10   genes (*i.e.*, a patient is predicted as recurrence if any fusion transcript in a designated subset exists). Leave-one-out cross validation (LOOCV) was applied to construct the model and evaluate the prediction performance. ROC curves were constructed by varying the parameters in the LDA classifier construction and the optimal prediction model was selected with the best Youden index (=sensitivity+specificity-1)[22], and was then evaluated

15   in a 89-sample Pittsburgh test cohort, a 21-sample Stanford test cohort and a 30-sample Wisconsin test cohort. To compare the statistical significance of AUC difference between two models, a bootstrap test is used to generate p-values[23]. To compare accuracy of two models, a test for equal proportions using "prop.test" in R is applied.

To demonstrate the potential translational predictive value of these fusion

20   transcripts, information of Nomogram estimated five-year PSA free survival probability and Gleason scores of the patients was incorporated into our prediction models. The following models were generated: (I) 8 fusion transcripts alone, (II) Gleason scores alone, (III) Nomogram values alone, (IV) Gleason scores + 8 fusion transcripts, (V) Nomogram values + 8 fusion transcripts. Complete information of prediction accuracy, sensitivity,

25   specificity and Youden index for these eight models is available in Tables 7-16.

RT-PCR. To verify fusion genes detected by transcriptome and whole genome sequencing, total RNA was reverse-transcribed with random hexamer. Double strand cDNA was synthesized as described previously[9, 10]. PCRs were performed using primers indicated in Table 3 using the following condition: 94°C for 5 min, followed by 30 cycles

30   of 94°C for 30 seconds, 61°C for 1 min and 72°C for 2 min.

Table 3. Primer sequences for RT-PCR.

Fusion genes	Sequences
TMEM135-CCDC67	5'-TTGGCATGATAGACCAGTCCC-3'/5'-CAGCACCAAGGGAATGTGTAG-3' (SEQ ID NO: 58/SEQ ID NO: 59)
Mtor-TP53BP1	5'-TTGGCATGATAGACCAGTCCC-3'/5'-CAGCACCAAGGGAATGTGTAG-5' (SEQ ID NO: 60/SEQ ID NO: 61)
TRMT11-GRIK2	5'-GCGCTGTCGTGTACCCTTAAC-3'/5'-GGTAAGGGTAGTATTGGGTAGC-3' (SEQ ID NO: 62/SEQ ID NO: 63)
CCNH-C5orf30	5'-CCAGGGCTGGAATTACTATGG-3'/5'-AAGCACCAGTCTGCACAATCC-3' (SEQ ID NO: 64/SEQ ID NO: 65)
SLC45A2-AMACR	5'-TTGATGTCTGCTCCCATCAGG-3'/5'-TGATATCGTGGCCAGCTAACC-3' (SEQ ID NO: 66/SEQ ID NO: 67)
KDM4B- AC011523.2	5'-AACACGCCCTACCTGTACTTC-3'/5'-CTGAGCAAAGACAGCAACACC-3' (SEQ ID NO: 68/SEQ ID NO: 69)
MAN2A1-FER	5'-TGGAAGTTCAAGTCAGCGCAG-3'/5'-GCTGTCTTTGTGTGCAAACTCC-3' (SEQ ID NO: 70/SEQ ID NO: 71)
LRRC59-FLJ60017	5'-GTGACTGCTTGGATGAGAAGC-3'/5'-CCAGCATGCAGCTTTTCTGAG-3' (SEQ ID NO: 72/SEQ ID NO: 73)
TMPRSS2-ERG	5'-AGTAGGCGCGAGCTAAGCAGG-3'/5'-GGGACAGTCTGAATCATGTCC-3' (SEQ ID NO: 74/SEQ ID NO: 75)
β-actin	5'-TCAAGATCATTGCTCCTCCTGAGC-3'/5'-TGCTGTCACCTTCACCGTTCCAGT-3' (SEQ ID NO: 76/SEQ ID NO: 77)

Fluorescence In-situ Hybridization. Formalin-fixed and paraffin-embedded tissue slides (5 microns) were placed in 2XSSC at 37°C for 30 min. Slides were then removed and dehydrated in 70% and 85% ethanol for 2 min each at room temperature, and air dried. The DNA from the selected clones (Table 4) was extracted using Nucleobond Ax kit (Macherey-Nagel, Easton, PA). The biotin-labeled probes were prepared using standard nick-translation procedure and hybridized to sample slides as described previously[11, 12].

Table 4. Bacterial artificial chromosome clone for FISH.

Fusion genes	Probe 1	Probe 2
TMEM135-CCDC67	RP11-80F20	RP11-1034E22
Mtor-TP53BP1	RP4-647M16	RP11-114F23
TRMT11-GRIK2	RP11-92N18	RP11-70I17
CCNH-C5orf30	RP11-111M24	RP11-244M13
SLC45A2-AMACR	RP11-179D3	RP11-1072I21
KDM4B- AC011523.2	RP11-241K5	RP11-655K24
MAN2A1-FER	RP11-452L20	RP11-328A14
LRRC59-SLC35B3	RP11-269I10	RP11-360D22
LRRC59-FLJ60017	RP11-269I10	CTD-2116N11

6.4. RESULTS

Fusion genes discovered by RNA and whole genome sequencing. A total of 76 RNA fusion events were identified in prostate cancer samples by the Fusioncatcher[7] program. Thirteen of these fusion events were suggested by genome sequencing. To control for tissue-based fusion gene events, fusion genes present in any of the four age-

matched organ donor prostate tissues were eliminated (Table 5). Further, fusion genes with less than 20 kb between each element and read in the cis direction were also eliminated. As a result of this filtering, 28 of 76 fusion gene events were identified as prostate cancer specific (Table 6 and Figure 6). Among these fusion events, TMPRSS2-

5   ERG, the most common prostate cancer fusion gene[13-15], was found in two prostate cancer samples. Majority of the fusion events identified are novel and not reported in the literature. None of the 29 fusion genes were identified in the matched AT transcriptome analysis. To validate these fusion genes, RT-PCR was performed using primers specific for fusion gene regions encompassing the fusion breakpoints and the PCR products were

10 sequenced. Eight of these fusion gene events were validated through sequencing (Figure 1).

Five of the eight fusion events resulted in truncation of a driver gene and frameshift in translation of a passenger gene. One of the fusion genes produced a truncated cyclin H and an independent open reading frame of a novel protein whose

15 function is not known. Two fusion events, however, produced chimera proteins that possibly retain at least partial function of both genes. One of these fusion products is N-terminus 703 amino acids of α-Mannosidase 2A (MAN2A1) fusing to the C-terminus 250 amino acids of FER, a Feline tyrosine kinase. The fusion protein retains the glycoside hydrolase domain but has its manosidase domain replaced with a tyrosine kinase domain

20 from FER. Another fusion protein product produces a chimera of membrane-associated transporter protein (SLC45A20) and alpha-methylacyl-CoA racemase (AMACR). The chimera protein has 5 of its 10 transmembrane domains deleted from SLC45A2 and replaced with methyl-acyl CoA transferase domain from AMACR. Interestingly, both MAN2A1-FER and SLC45A2-AMACR fusions are in the trans-direction, eliminating the

25 possibility of a fusion event from simple chromosome deletion or collapse of extremely large RNA transcript.

Fluorescence in situ hybridization suggests genome recombination underlying fusion gene formation. To investigate the mechanism of these fusion events, fluorescence in situ hybridization (FISH) was performed on prostate cancer tissues where

30 the fusion gene was present. Using the probes surrounding MAN2A1 breakpoint, a physical separation of signals between 5' and 3' MAN2A1 in cancer cells containing the fusion gene was observed, in contrast to the overlapping nature of these signals in the wild type alleles in normal prostate epithelial cells (Figure 2). Similar "break-apart" hybridization occurred in SLC45A2-AMACR positive prostate cancer samples (Figure

2B). These findings indicate that MAN2A1-FER and SLC45A2-AMACR fusions are the result of chromosome recombination. Interestingly, in prostate cancer cells containing "break-apart" signals of MAN2A1, only 31% of the cells retained the 3' end signal, suggesting that the recombination of genome DNA in most prostate cancer cells results in
5   truncation of the C-terminus of MAN2A1. A similar "collateral loss" of the N-terminus of AMACR was found in prostate cancer cells expressing SLC45A2-AMACR fusion (29% retaining the N-terminus signal of AMACR). Other FISH analyses confirm that genome translocations occur in cancer cells expressing TRMT11-GRIK2, MTOR-TP53BP1, LRRC59- FLJ60017, TMEM137- CCDC67, CCNH-C5orf30 and KDM4B- AC011523.2
10   fusion genes (Figures 2C-G). These fusion genes are either separated by a large segment of genome DNA (TRMT11-GRIK2, TMEM135-CCDC67, CCNH-C5orf30 and KDM4B-AC011523.2) or located in separate chromosomes (MTOR-TP53BP1 and LRRC59-FLJ60017). The joining signals of hybridizations in prostate cancer cells suggest that these fusion genes were relocated to juxtapose to their fusion partners. Finally, genomic
15   breakpoints were identified in 3 fusion pair through Sanger sequencing of the cancer genomic DNA (CCNH-C5orf30, TMEM135-CCDC67 and LRRC59-FLJ60017) (Figure 11).

Fusion genes association with prostate cancer recurrence. A genomic alteration in prostate cancer without clinical consequence is of limited significance. Therefore, the
20   association of these fusion genes with prostate cancer progression was investigated in prostate cancer specimens obtained from 213 men and from entirely benign prostate tissues obtained from 10 organ donors free of urological disease aged 20 to 70. The prostate cancer samples were linked to the clinical outcomes after radical prostatectomy: those with no detectable prostate specific antigen (PSA) recurrence after a minimum of
25   five years of observation, those whose clinical outcomes remain unknown and those who had an observed PSA recurrence within five years. For 179 of the 223 prostate cancer samples, clinical outcome data after radical prostatectomy were available, and 81 had no detectable prostate specific antigen (PSA) recurrence after a minimum of five years of follow-up, while 98 developed biochemical recurrence (defined as a measurable PSA ≥ 0.2
30   ng/ml). Only 7.4% (6/81) primary prostate cancers expressed one of the fusion genes in non-recurrent patients. In contrast, 52% (51/98) primary prostate cancers expressed at least one fusion in patients who developed recurrence (Figure 3 and Figure 7A). No fusion genes were detected in benign prostate tissues obtained from healthy organ donors (Figure 7B). Three fusion events were observed exclusively in recurrent prostate cancer

42

after radical prostatectomy (TRMT11-GRIK2, MTOR-TP53BP1 and LRRC59-
FLJ60017; Figure 3A and B).

Fisher's exact test showed a significant difference in recurrent status between
patients with at least one of the 8 fusion transcripts and those without (p=6.8 x10^{-16}). In

5   the combined UPMC, Stanford and Wisconsin data sets, 91% (69/76) of patients positive
for one of the fusion transcripts experienced prostate cancer recurrence in 5 years after
prostate resection. Based on the hypothesis that the presence of at least one of the 8 fusion
transcripts would indicate a recurrence for a prostate cancer patient, a prostate cancer
prediction model was built and tested, using 90 randomly selected prostate cancer

10   samples from University of Pittsburgh Medical Center (training set). This training cohort
yielded an accuracy of prostate cancer recurrence prediction of 71% with 89% specificity
and 58% sensitivity (p<0.005) (Figure 12A, Table 10). When this model was applied to a
separate cohort of 89 samples (test set), the model correctly predicted recurrence in 70%
of patients. To further validate this model, we tested its performance in a 30-patient (21

15   with qualified clinical follow-up) cohort from Stanford University Medical Center and a
36-patient (30 with qualified clinical follow-up) cohort from University of Wisconsin
Madison Medical Center (Figure 3, Figure 8 and Figure 9). Once again, the model
correctly predicted recurrence with 76.2% accuracy and with 89% specificity and 67%
sensitivity on the prostate cancer cohort from Stanford, and 80% accuracy and with 100%

20   specificity and 63% sensitivity on the cohort from Wisconsin (Table 11).

Similar to the dichotomous nature of prostate cancer in general, recurrent prostate
cancer can progress in an indolent or aggressive manner. A PSA doubling time (PSADT)
less than four months after radical prostatectomy is strongly associated with the early
development of metastatic disease and prostate cancer-specific death, whereas these

25   events are rare and remote in men with a PSADT of greater than 15 months [16, 17]. Strong
association was found between the fusion genes (e.g., TRMT11-GRIK2, SLC45A2-
AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-
C5orf30) with prostate cancer recurrence (p=4.2 x 10^{-9}) and a PSADT less than four
months (p=6 X 10^{-9}). To examine whether these fusion gene events have prognostic

30   value for prostate cancer clinical outcome, receiver operator curve (ROC) analyses with
varying weights of fusion genes were performed. As shown in Figure 3C, the panel of
eight fusion genes correctly predicted 74.4% for PSA doubling time less than four months
in the 90-sample training cohort, and 67% for prostate cancer recurrence. To optimize the
prediction model, six fusion genes were selected for an improved association with

disease-free survival after radical prostatectomy. When the same algorithm was applied to a separate 89-sample test set from University of Pittsburgh Medical Center and 21-sample cohort from Stanford University Medical Center, the prediction rate for PSADT<4months was found to be 78% and 71%, respectively (Figure 4B). As shown in

5   Figure 3D, 89.5% of patients had an observed disease recurrence within five years of radical prostatectomy if they carried any of the six fusion genes. In addition, and as shown in Figure 4C, 84.2% of patients had an observed disease recurrence within five years of radical prostatectomy if they carried any of the eight fusion genes. No patient survived five years without recurrence if their primary prostate cancer contained a

10   TRMT11-GRIK2 or MTOR-TP53BP1 gene fusion. In contrast, 68% patients were free of disease recurrence if any of the novel fusion genes were not detected in their primary prostate cancer. Similar findings were also identified in the Stanford cohort: 88.9% patients experienced recurrence of prostate cancer if they carried any fusion transcript, while 66.7% patients were free of the disease recurrence if they are negative.

15

20

25

30

Table 5

Fusion gene 1	Fusion_gene2	read pairs	Validation Status
SORBS1	RP11-476E15.3	25	
AHCY	RP11-292F22.3	25	
DCUN1D3	ERI2	12	
MACF1	KIAA0754	11	
C10orf68	CCDC7	11	RT-PCR and sequencing
RP11-166D19.1	BLID	7	
ASS1	ASS1P9	6	
BACH1	BACH1-IT1	6	RT-PCR
MPDZ	RP11-272P10.2	5	
LIG3	RP5-837J1.2	4	
ACAD8	GLB1L3	4	RT-PCR
IGSF9B	RP11-259P6.1	3	
EYA1	RP11-1102P16.1	3	
TTC33	PRKAA1	3	RT-PCR
DNAH1	GLYCTK	3	
PSPC1	ZMYM5	3	
HSP90AB3P	RP11-759L5.2	3	
LSAMP	RP11-384F7.2	3	
RNF4	FAM193A	81	RT-PCR
AHCY	RP11-292F22.3	9	
LSAMP	RP11-384F7.2	8	
CBLL1	AC002467.7	4	
FNBP4	Y_RNA	4	
TBCE	RP11-293G6__A.2	4	
TRIM58	RP11-63487.4	4	
DCUN1D3	ERI2	4	
PHPT1	MAMDC4	3	
TRIP6	SLC12A9	3	
NAT14	ZNF628	3	
TLL2	RP11-35J23.5	3	
UFSP2	Y_RNA	3	
TSPAN33	Y_RNA	3	
CADM3	DARC	3	
KIF27	RP11-213G2.3	3	
RABL6	KIAA1984	3	
ZNF615	ZNF350	3	
ZYG11A	RP4-631H13.2	3	
RP11-522L3.6	MTND4P32	3	
MTND3P10	AC012363.10	3	
RP11-464F9.1	BMS1P4	3	
RNF4	FAM193A	14	RT-PCR
GBP3	Y_RNA	3	
NACA	PRIM1	1	
AHCY	RP11-292F22.3	3	
GBP3	Y_RNA	3	

5

Table 5 (continued)

Fusion gene 1	Fusion_gene2	read pairs	Validation Status
HARS2	ZMAT2	2	RT-PCR and sequencing
EED	C11orf73	1	RT-PCR
CNPY3	RP3-475N16.1	1	RT-PCR
RN7SL2	Metazoa_SRP	1	
SLC16A8	BAIAP2L2	2	RT-PCR
KLK4	KLKP1	2	RT-PCR and sequencing
ZNF137P	ZNF701	1	RT-PCR
AZGP1	GJC3	1	RT-PCR
USP7	RP11-252I13.1	1	
TRRAP	AC004893.11	1	
C6orf47	BAG6	1	RT-PCR
TTTY15	USP9Y	9	
AC005077.12	LINC00174	2	
ADCK4	NUMBL	2	
ZNF606	C18orf18	2	
SLC45A3	ELK4	3	RT-PCR and sequencing

The most frequent fusion events in prostate cancer are TRMT11-GRIK2 (7.9%, or 22/279) and SLC45A2-AMACR (7.2%, or 20/279) (Figures 3A, 7-9). TRMT11-GRIK2 fusion represents a giant truncation of TRMT11, a tRNA methyltransferase, and elimination of GRIK2, a glutamate receptor but reported to possess tumor suppressor activity [18]. Indeed, GRIK2 was not expressed in prostate cancer samples that contain TRMT11-GRIK2 fusions, while it was detected in organ donor prostate samples (Figure 10). Only 4 of 14 samples with TRMT11-GRIK2 expressed full length non-fusion TRMT11. Thus, the fusion event of TRMT11-GRIK2 represents a loss of function instead of a gain.

Combining detection of fusion transcripts and clinical/pathological parameters improved the prediction rate of prostate cancer recurrence. Prostate cancer samples with at least one fusion transcript correlate with more advanced stage of prostate cancer (p=0.004), Lymph node involvement status (P=0.005) and lower nomogram scores (p=0.0003) (Table 12). Gleason grading alone produced a prostate cancer recurrence prediction rate of 61.1%, with 85.7% specificity and 39.6% sensitivity in the 90-sample UPMC training cohort, when Gleason≥8 was used as cutoff to predict prostate cancer recurrence. The Gleason model yielded prediction accuracy ranging from 57-60% in 3 separate testing cohorts (Tables 13 and 14). However, when fusion transcript status was combined with Gleason Grade>8, improvement of prediction was found for all 4 cohorts: 72% for the UPMC training cohort, 74% for the UPMC test cohort, 76% for the Stanford cohort and 90% for the Wisconsin cohort. ROC showed a significant larger AUC (area

under the curve) (0.84 versus 0.67, P=6.6 x 10-7) and higher testing accuracy (77.7%
versus 59.7%, P=0.0019) (Figure 5A) when Gleason score was combined with detection
of any of 8 fusion transcripts. Similarly, Nomogram prediction of prostate cancer
recurrence has the best accuracy of 76% with 68.8% sensitivity and 83.3% specificity in
5   the analysis of 90-sample UPMC training cohort (Table 15). When this model was
applied to UPMC testing, Stanford and Wisconsin cohorts independently, the results
showed that the prediction accuracy ranged from 60% to 75% among the 3 cohorts (Table
16). When Nomogram was combined with the status of 8 fusion transcripts using LDA
technique to build a classifier, the accuracy of prediction improves to 81-83% among the
10   testing cohorts (Table 16). ROC showed an increase of AUC from 0.76 to 0.87
(P=0.0001) and an improvement of accuracy from 69% to 81% (P=0.026, Figure 5B). As
a result, we concluded that classifier combining Nomogram and the 8 fusion gene panel
generated the best prediction accuracy that outperforms each diagnostic tool alone.

6.5.   DISCUSSION

15   Transcriptome and whole genome sequencings revealed numerous fusion RNA
transcripts occurring not just in prostate cancer but also in healthy organ donor prostate
samples (Table 17). Some of these fusion events are verifiable by sequencing on the
cDNA products. The functions of these new transcripts are not known. Since most of
these chimeric RNA transcripts in healthy individuals are the splicing products of two
20   adjacent genes, they are likely the new isoforms of the existing genes. These previously
defined independent "genes" in the transcript could be one of the preferred spliced
isoforms of the existing larger genes.

25

30

Table 6. Putative fusion transcripts from 5 prostate cancer samples

1T						
Fusion gene 1	Fusion gene2	Gene 1 breakpoint	Gene2 breakpoint	Reads	In DNAseq	Distance
TMPRSS2	ERG	21:42870046:-	21:39817544:-	8	2	3052502
FZD4	RP11-736K20.5	11:86665843:-	11:86633140:-	7	0	32703
ZNF720	RP11-488L18.4	16:31734674:+	1:247363495:-	3	0	Inf
RP11-35609.1	TTC6	14:38033571:+	14:38075868:+	12	0	42297
IGLV2-8	IGLL5	22:23165779:+	22:23235961:+	5	0	70182
RP11-381K20.2	KLHL3	5:137150022:-	5:137056273:-	3	0	93749
ADAP2	RNF135	17:29286022:+	17:29311635:+	3	0	25613
LRRC59	FLJ60017	17:48469759:-	11:63129852:+	3	7	Inf
RIPK1	SERPINB9	6:3064293:+	6:2900855:-	5	24	163438
2T						
Fusion gene 1	Fusion gene2	Gene 1 breakpoint	Gene2 breakpoint	Read pairs	in DNAseq	Distance
MTOR	TP53BP1	1:11290982:-	15:43773220:-	12	2	Inf
3T						
Fusion gene 1	Fusion gene2	Gene 1 breakpoint	Gene2 breakpoint	Read pairs	in DNAseq	Distance
MAN2A1	FER	5:109153139:+	5:108380381:+	7	4	772758
KDM4B	AC011523.2	19:5047680:+	19:51354167:+	7	0	46306487
TRMT11	GRIK2	6:126307768:+	6:102069824:+	11	0	24237944
NAP1L1	CCDC88C	12:76444311:-	14:91850880:-	3	2	Inf
RP11-386M24.4	H2AFV	15:93277091:-	7:44874151:-	6	0	Inf
CCNH	C5orf30	5:86697519:-	5:102601609:+	3	8	15904090
UBA52	CTA-242H14.1	19:18685741:+	7:25729331:-	3	3	Inf
C1orf196	KAZN	1:14507087:+	1:14925479:+	3	0	418392
MTIF2	AL592494.3	2:55473480:-	1:121244615:+	6	0	Inf
RP11-	PPP2R5C	3:52408726:+	14:102368056:	3	2	Inf

5

Table 6 (continued)

168J18.6			+			
RPL38	AC007283.4	17:72205448:+	2:202027232:-	3	0	Inf
ACSS1	APMAP	20:24988402:-	20:24964655:-	3	0	23747
4T						
Fusion gene 1	Fusion gene2	Gene 1 breakpoint	Gene2 breakpoint	Read pairs	in DNAseq	Distance
RP11-443D10.3	ACACB	12:109551220:+	12:109577202:+	4	0	25982
SLC45A2	AMACR	5:33982341:-	5:34006004:-	3	0	23663
RP11-550F7.1	CAP1	3:76483671:+	1:40529899:+	7	9	Inf
TMC5	CCP110	16:19508485:+	16:19539189:+	6	0	30704
TLK2	RP11-274B21.1	17:60631098:+	7:128248237:+	6	126	Inf
TMEM135	CCDC67	11:87030419:+	11:93127625:+	7	26	6097206
5T						
Fusion gene 1	Fusion gene2	Gene 1 breakpoint	Gene2 breakpoint	Spanning_pairs	in DNAseq	Distance
TMPRSS2	ERG	21:42870046:-	21:39947671:-	12	2	2922375

This analysis reveals significant number of cancer specific fusion gene events. These fusions are not detectable in either organ donor prostate or benign prostate tissues from prostate cancer patients. Most of these fusion transcripts appear to express in low abundance, with only an average 6.6 reads of these fusion transcripts detected in >1333x sequencing. Indeed, when the coverage was reduced to 600x in simulation studies, only MTOR-TP53BP1 was detected consistently. The characteristics of these fusion genes are that they either have a large distance between the joining genes or have trans-direction of fusion that could only occur when chromosome recombination happens. In either scenario, DNA alteration in genome level must be the underlying mechanism.

Although the association between the eight novel fusion transcripts and prostate cancer recurrence is striking, the biological roles of these fusion transcripts are not yet elucidated. Given the known function of the genes contributing to the fusion transcripts, their formation may have impact on several cell pathways such as RNA stability[24] (TRMT11-GRIK2), protein glycosylation[25] (MAN2A1-FER), cell cycle progression[26,27,28] (CCNH-C5orf50 and MTORTP53BP1), fibroblast growth factor nuclear import[29] (LRRC59-FLJ60017), histone demethylation[30] (KDM4B-AC011523.2), and fatty acid

metabolism[31] (SLC45A2-AMACR). Many of these pathways appear to be fundamental to cell growth and survival.

Two of the fusion genes are of particular interest: MAN2A1-FER and SLC45A2-AMACR. First, MAN2A1 is a mannosidase critical in glycosylation of proteins[19]. It is

5 usually located in Golgi apparatus. The truncation in MAN2A1-FER replaces the mannosidase domain with a tyrosine kinase domain from FER[20], while leaves the glycosyl transferase domain intact. The chimera protein likely loses the mannosidase function. The new kinase domain in MAN2A1-FER may confer the chimera protein a tyrosine kinase activity. Thus, the impact of this fusion gene could be profound:

10 abnormal glycosylation and phosphorylation in hundreds of secreted or plasma membrane proteins. It may impact on cell-cell interactions and signal transduction, and generate a new immune response to the cancer cells. Second, AMACR is a racemase that catalyzes 2R stereoisomers of phytanic and pristanic acid to their S counterparts. AMACR is essential for β-oxidation of branch fatty acid in mitochondria. SLC45A2 is a

15 transmembrane solute carrier known for its protective role in melanoma. SLC45A2-AMACR chimeric protein has 5 transmembrane domains of SLC45A2 truncated and replaced with a largely intact racemase. SLC45A2-AMACR also loses the mitochondria target site in AMACR. Presumably, the fusion protein would be located in the plasma membrane. It is of interest that all prostate cancer samples with SLC45A2-AMACR

20 fusion proved highly aggressive. Identification of the signaling pathways of this chimeric protein may gain critical insight into the behavior of prostate cancer.

Even though the prevalence of each fusion transcript in prostate cancer samples is low (ranging from 2.9% to 7.9%), up to 60% of prostate cancers that later recurred and had short PSADT were positive for at least one of these fusion transcripts. The specificity

25 of these fusion transcripts in predicting prostate cancer recurrence appears remarkably high, ranging from 89-100% among 4 separate prediction cohorts. There were no long term recurrence-free survivors if the primary tumor contained either TRMT11-GRIK2, MTOR-TP53BP1 or LRRC59-FLJ60017 fusion transcripts.

To our knowledge, this is the first report showing that a set of fusion genes is

30 strongly associated with poor prognosis of prostate cancer. This discovery may have salient impact on clinical practice in light of the limit of serum PSA and Gleason's grading from biopsy samples in predicting prostate cancer clinical outcome. Detection of one of these prostate cancer recurrence association fusion genes in prostate cancer sample may warrant a more aggressive treatment regimen. The fusion RNA and chimera proteins

validated in this study may lay down the foundation for future molecular targeting therapy for prostate cancer patients carrying these genes.

5

Table 7. Clinical and pathological characteristics of 213 cases of prostate cancer from UPMC cohort

Sample	Type	TNM	Margin	Recurrence	Recurrence tsp	Recurrence simple	Gleason	Age	Sex	Race	PSA pre-operative	Time to progression (Months)	PSADT (months)	Radiology follow-up	Length of follow-up (Months)	Additional treatment
11462T	T	T3bN0MX	Negative	none	nr	n	7.0	50s	M	W	25.0	N/A	N/A	NEGATIVE	153.0	None
1199T	T	T3bN0MX	Negative	slow	nr	y	8.0	50s	M	W	40.0	13.0	33.7	NEGATIVE	150.0	NK
13743T	T	T2cN0MX	Negative	none	nr	n	7.0	60s	M	W	6.8	N/A	N/A	NO	151.0	None
14304T	T	T2bN0MX	Negative	none	nr	n	6.0	50s	M	W	7.8	N/A	N/A	NO	156.0	None
14878T	T	T2bN0MX	Negative	none	nr	n	8.0	60s	M	W	6.2	N/A	N/A	NO	151.5	None
15463T	T	T2bN0MX	Negative	none	nr	n	7.0	60s	M	W	7.8	N/A	N/A	NO	149.0	None
15733T	T	T2bN0MX	Negative	none	nr	n	7.0	50s	M	W	6.4	N/A	N/A	NO	152.0	None
15877T	T	T3bN0MX	Negative	none	nr	n	7.0	40s	M	W	5.6	N/A	N/A	NO	154.0	None
15922T	T	T3bN0MX	Negative	none	nr	n	7.0	60s	M	W	16.0	N/A	N/A	NO	154.0	None
16464T	T	T3cN0MX	Negative	slow	nr	y	7.0	60s	M	W	8.9	88.5	24.6	NEGATIVE	149.0	NK
16944T	T	T3bN1MX	Negative	slow	nr	y	8.0	70s	M	W	6.1	31.0	15.6	NEGATIVE	148.0	NK
19381T	T	T2bN0MX	Negative	none	nr	n	8.0	50s	M	AA	2.2	N/A	N/A	NO	124.0	None
1942T	T	T3bN0MX	Positive	fast	?	y	9.0	60s	M	W	7.5	80.1	14.8	NEGATIVE	157.0	NK
19PR53GT	T	T2cN0MX	Negative	NO	NO	NO	7.0	60s	M	W	4.4	N/A	N/A	not done	210	None
1AF8B7BT	T	T3bN0MX	Negative	none	nr	n	6.0	60s	M	W	12.9	N/A	N/A	NO	133.0	None
23FB120T	T	T3bN0MX	Negative	none	nr	n	7.0	60s	M	W	11.4	N/A	N/A	NEGATIVE	104.0	None
23HB021T	T	T2bN0MX	Negative	fast	?	y	7.0	50s	M	W	6.4	23.0	3.0	NEGATIVE	78.0	ADT, RT
23R13T	T	T2bN0MX	Negative	none	nr	n	7.0	50s	M	W	7.2	N/A	N/A	NO	151.0	None
23HB346T	T	T2cN0MX	Negative	NO	NO	NO	6.0	60s	M	W	7.3	N/A	N/A	NO	34.0	None
3526ST	T	T3bN0MX	Negative	none	nr	n	7.0	60s	M	W	3.4	N/A	N/A	NO	126.0	None
3531ST	T	T3bN0MX	Negative	none	nr	n	8.0	50s	M	W	9.5	N/A	N/A	NO	126.0	None
3644T	T	T3bN0MX	Negative	slow	nr	y	9.0	50s	M	W	11.2	3.9	31.1	NEGATIVE	164.0	NK
3671Y	T	T2cN0MX	Positive	slow	nr	n	7.0	60s	M	W	8.9	17.0	17.0	NEGATIVE	164.0	NK
3827BT	T	T3AN0MX	Negative	none	nr	n	7.0	50s	M	U	4.0	N/A	N/A	NO	157.0	None
3967TaT	T	T3AN0MX	Negative	slow	nr	y	7.0	60s	M	W	8.9	17.4	15.4	NEGATIVE	155.0	NK
38525T	T	T3bN0MX	Negative	none	nr	n	7.0	50s	M	W	12.0	N/A	N/A	NEGATIVE	159.0	None
2-HB56BT	T	T3bN0MX	Negative	fast	?	y	7.0	60s	M	W	3.7	24.1	3.9	NEGATIVE	70.3	ADT, RT
2-82937	T	T3bN1MX	Negative	fast	?	y	7.0	60s	M	W	19.3	1.9	3.9	POSITIVE FOR BONE AND HEPATIC METASTASIS	47.0	ADT, CHEMO

CA 02935216 2016-06-27

2 E4435T	T	T2BNOMX	Negative	none	nf	n	7.0	70%	M	W	8.6	N/A	N/A	N/A	NO	98.0	ADJ. CHEMO
2|X92-8379T	T	T3ANOMX	Positive	none	nf	n	7.0	60%	M	W	21.0	1.0	0.4	NO	152.0	None
35PRO5 3T	T	T3BN1MX	Negative	fast	nf	y	5.0	60%	M	W	21.0	1.0	0.4	Bone metastasis	16.0	CHEMO
34FR227T	T	T3BNOMX	Negative	none	nf	n	7.0	60%	M	W	11.6	N/A	N/A	NO	123.0	None
34T	T	T2CN3MX	Positive	none	nf	n	7.0	50%	M	D	3.6	N/A	N/A	NO	139.0	None
3D5B4336T	T	T2DNOMR	Negative	none	nf	n	6.0	60%	M	W	6.6	N/A	N/A	NEGATIVE	164.0	None
3G9B912 2T	T	T2BNOMX	Negative	none	nf	n	7.0	50%	M	W	9.0	N/A	N/A	NO	184.0	None
3K3772T	T	T3BNOMX	Negative	none	nf	n	7.0	60%	M	D	6.7	N/A	N/A	NO	160.0	None
3M-1146T	T	T3BNOMX	Negative	none	nf	n	7.0	50%	M	W	22.0	N/A	N/A	NEGATIVE	198.0	None
3Q-1061 4T	T	T3BNOMX	Negative	none	nf	n	7.0	70%	M	W	12.9	N/A	N/A	NO	77.0	None
4306T	T	T1CN3MX	Negative	none	nf	n	6.0	65%	M	W	12.4	N/A	N/A	NO	153.0	None
4336T	T	T1CN9MX	Positive	slow	nf	y	6.0	60%	M	W	2.9	22.7	22.0	NEGATIVE	165.0	NE
4L98-27086T	T	T3BNOMX	Negative	none	nf	n	7.0	65%	M	W	12.2	N/A	N/A	NO	72.0	None
53B9T	T	T2BN1MX	Negative	none	nf	n	9.0	60%	M	W	8.9	N/A	N/A	NO	196.0	None
54TB2239T	T	T2b NO MX	Negative	none	nf	n	6.0	50%	M	W	9.6	N/A	N/A	not Done	89.0	None
562T	T	T2BNOMX	Positive	none	nf	n	6.0	60%	M	W	11.3	N/A	N/A	NO	157.0	NE
56F878T	T	T3b NO MX	Negative	none	nf	n	6.0	60%	M	W	6.6	N/A	N/A	not done	137.0	None
66J-T	T	T3ANOMX	Negative	slow	nf	y	7.0	40%	M	AA	6.1	93.6	43.3	NEGATIVE	130.0	NE
67BT	T	T2BNOMX	Negative	none	nf	n	7.0	60%	M	W	5.3	N/A	N/A	NO	152.0	None
67R13T	T	T1DNOMX	Negative	none	nf	n	6.0	60%	M	W	10.8	N/A	N/A	NO	145.0	None
66337T	T	T3BNOMX	Negative	slow	nf	y	6.0	70%	M	W	10.4	87.4	12.4	NEGATIVE	159.0	NE
7221T	T	T3BNOMX	Negative	fast	nf	y	7.0	50%	M	W	13.5	16.6	2.4	POSITIVE FOR BONE METASTASIS	124.0	ADJ. CHEMO, RT
727 9T	T	T3BN1MX	Negative	none	nf	n	9.0	70%	M	W	11.9	N/A	N/A	NO	98.0	None
75047	T	T3BNOMX	Positive	none	nf	n	9.0	70%	M	D	10.3	N/A	N/A	NO	143.0	None
75MB3A0T	T	T3BNOMX	Negative	ND	ND	ND	7.0	60%	M	W	9.6	N/A	N/A	Not Done	14.0	None
7943T	T	T3ANOMX	Positive	none	nf	n	7.0	60%	M	W	9.6	N/A	N/A	NO	137.0	None
6151413T	T	T2DNOMX	Negative	none	nf	n	9.0	60%	M	W	7.4	N/A	N/A	NO	160.0	None
83297 3T	T	T2DNOMX	Negative	none	nf	n	10.0	60%	M	W	7.5	N/A	N/A	NO	160.0	None
54282 0T	T	T2DNOMX	Negative	none	nf	n	7.0	60%	M	W	7.7	N/A	N/A	NO	159.0	None
8432T	T	T3BNOMX	Positive	none	nf	n	7.0	50%	M	W	6.6	N/A	N/A	NO	166.0	None
8437 5T	T	T2DNOMX	Negative	none	nf	n	6.0	60%	M	W	6.8	N/A	N/A	NO	161.0	None
848787	T	T2DNOMX	Negative	none	nf	n	7.0	60%	M	W	8.9	N/A	N/A	NO	160.0	None
8497313T	T	T2DNOMX	Negative	none	nf	n	7.0	50%	M	W	6.1	N/A	N/A	NO	153.0	None

ID	T	TNM						Age	M						Bone metastasis		ADT/CHEMO
HB3353T	T	T3bN1MX	Negative	slow	nf	y	9.0	60s	M	W	4.6	4.3	2.3	20.8	POSITIVE FOR BONE METASTASIS	10.7	ADT, CHEMO
HB3261T	T	T3bN0MX	Negative	none	nf	n	7.0	50s	M	W	5.4	N/A	N/A	N/A	NO	74.0	None
HB3103T	T	T2cN0MX	Negative	none	nf	n	7.0	60s	M	W	31.3	N/A	N/A	N/A	not done	102.0	None
HB3105T	T	T3bN0MX	Negative	fast	t	y	6.0	60s	M	W	10.1	1.4	3.9	3.9	NO	68.8	ADT, CHEMO
HB3123T	T	T2cN0MX	Negative	none	nf	n	7.0	60s	M	W	4.9	N/A	N/A	N/A	not done	102.0	None
HB3127T	T	T2cN0MX	Negative	none	nf	n	8.0	50s	M	W	9.3	N/A	N/A	N/A	not done	102.0	None
HB3340T	T	T2cN0MX	Negative	NO	NO	NO	7.0	60s	M	W	9.6	N/A	N/A	N/A	not done	32.0	None
HB3346T	T	T2bN0MX	Negative	none	nf	n	7.0	60s	M	W	17.2	N/A	N/A	N/A	not done	102.0	None
HB3461T	T	T3bN0MX	Negative	slow	nf	y	8.0	60s	M	W	4.7	20.1	15.3	15.3	NO	68.1	NK
HB3492T	T	T2cN0MX	Negative	slow	nf	y	7.0	50s	M	W	7.4	82.0	22.0	22.0	negative	99.0	None
HB3304T	T	T3bN0MX	Positive	fast	t	y	8.0	50s	M	U	70.0	4.3	0.7	0.7	NEGATIVE	58.7	ADT, CHEMO
HB3526T	T	T3bN0MX	Positive	fast	t	y	6.0	60s	M	W	4.7	1.4	2.7	2.7	POSITIVE FOR BONE METASTASIS	13.9	ADT, CHEMO
HB3568T	T	T3bN0MX	Negative	fast	t	y	7.0	60s	M	W	2.4	22.4	4.2	4.2	NEGATIVE	68.2	ADT, RT
HB3291T	T	T3bN1MX	Negative	fast	t	y	7.0	60s	M	W	17.6	1.3	3.6	3.6	POSITIVE FOR BONE AND HEPATIC METASTASIS	47.0	ADT, CHEMO
HB3603T	T	T3bN1MX	Negative	slow	nf	y	7.0	60s	M	W	8.4	22.1	15.5	15.5	NO	70.7	
HB3650T	T	T2bN0MX	Negative	none	nf	n	7.0	70s	M	W	20.6	N/A	N/A	N/A	not done	97.0	None
HB3700T	T	T2cN0MX	Negative	none	nf	n	7.0	60s	M	W	9.8	N/A	N/A	N/A	not done	97.0	None
HB3991T	T	T3bN1MX	Negative	fast	t	y	7.0	60s	M	W	23.1	15.9	4.0	4.0	POSITIVE FOR BONE AND HEPATIC METASTASIS	47.0	ADT, CHEMO
HB0711T	T		Negative	slow	nf	y	7.0	60s	M	W	2.6	4.3	1.6	1.6	NO	43.6	ADT, RT
HB1107T	T	T2cN0MX	Negative	none	nf	n	8.0	60s	M	W	2.7	N/A	N/A	N/A	not done	94.0	None
HB1111T	T	T2cN0MX	Negative	none	nf	n	7.0	60s	M	W	9.3	N/A	N/A	N/A	not done	94.0	None
HB1112T	T	T3bN0MX	Negative	slow	nf	y	7.0	60s	M	U	4.7	31.8	30.6	30.6	NO	67.2	NK
HB1134T	T	T3bN0MX	Negative	none	nf	n	9.0	70s	M	W	13.7	N/A	N/A	N/A	NO	77.0	None
HB1136T	T	T3bN1MX	Negative	fast	t	y	8.0	50s	M	W	19.6	1.8	2.1	2.1	POSITIVE FOR BONE METASTASIS	69.2	ADT, CHEMO
HB1160T	T	T2cN0MX	Negative	none	nf	n	7.0	60s	M	W	3.0	N/A	N/A	N/A	not done	93.0	None
HB2173T	T	T2bN0MX	Negative	fast	nf	n	7.0	50s	M	W	4.3	10.6	4.0	4.0	NEGATIVE	60.8	RT
HB1897T	T	T2bN0MX	Negative	none	nf	n	7.0	60s	M	W	10.0	N/A	N/A	N/A	not done	91.0	None
HB2983T	T	T3bN0MX	Negative	slow	nf	y	7.0	60s	M	W	5.3	34.3	20.4	20.4	NO	67.0	NK
HB3627T	T	T3bN0MX	Negative	slow	nf	y	7.0	50s	M	W	19.9	4.6	16.0	16.0	NEGATIVE	65.2	RT

ID	T	TNM			nf				M	W		N/A	N/A		90.0	None
JB373T	T	T3bN0Mx	Negative	none	nf	c	7.0	60%	M	W	2.8	1.4	1.7	not done	90.0	None
JB462T	T	T3bN0Mx	Negative	fast	nf	y	7.0	50%	M	W	5.2	3.5	1.7	NO	54.8	ADT, CHEMO
JB154T	T	T3bN0Mx	Negative	fast	nf	y	8.0	50%	M	U	70.0	3.5	0.5	NEGATIVE	58.7	ADT, CHEMO
JR197T	T	T3bN0Mx	Positive	fast	nf	y	7.0	50%	M	W	11.2	1.4	8.85 (death)	SINGLE FOCUS OF INCREASED ACTIVITY	48.4	ADT, CHEMO
JB426T	T	T2bN0Mx	Negative	fast	nf	y	7.0	60%	M	W	3.7	17.1	2.3	NEGATIVE	20.9	ADT, RT
JB770T	T	T3bN0Mx	Negative	fast	nf	y	8.0	60%	M	W	2.4	93.6	3.0	NEGATIVE	33.9	RT
KB170T	T	T3bN1Mx	Negative	fast	nf	y	7.0	70%	M	W	14.1	1.8	4.2	POSITIVE FOR NODAL METASTASIS	37.2	ADT
PR018T	T	T3bN0Mx	Positive	slow	nf	y	7.0	60%	M	W	5.0	78.0	55.0	NO	140.2	
PR033T	T	TURP	Negative	fast	nf	y	TURP	60%	M	W	122.5	1.0	0.1	bone metastasis	15.0	ADT, CHEMO
PR079T	T	T3bN0Mx	Positive	slow	nf	y	7.0	60%	M	W	5.1	93.3	17.3	NO	129.8	
PR227T	T	T2cN0Mx	Negative	none	nf	n	7.0	60%	M	W	4.3	N/A	N/A	not done	135.0	None
PR236T	T	T3bN0Mx	Negative	fast	nf	y	10.0	60%	M	W	5.5	1.3	3.9	POSITIVE FOR ELASTIC METASTASIS	84.7	ADT, CHEMO
PR300T	T	T3bN1Mx	Negative	fast	nf	y	7.0	50%	M	W	20.3	74.3	3.9	NEGATIVE	98.5	NK
PR303T	T	T3bN0Mx	Negative	slow	nf	y	6.0	70%	M	W	10.1	54.5	43.3	NO	79.7	NK
PR306T	T	T3bN0Mx	Positive	slow	nf	y	7.0	60%	M	W	11.2	16.4	22.9	NEGATIVE	109.1	RT
PR310T	T	T3bN0Mx	Negative	fast	nf	y	7.0	60%	M	W	5.1	22.6	1.6	POSITIVE FOR BONE AND ILIAC METASTASIS	47.7	ADT, CHEMO, RT
PR373T	T	T3bN1Mx	Negative	fast	nf	y	7.0	50%	M	W	11.5	1.2	1.1	POSITIVE FOR BONE AND PELVIC METASTASIS	114.5	ADT, CHEMO, RT
PR334T	T	T3bN0Mx	Negative	slow	nf	y	7.0	60%	M	W	6.4	72.8	30.8	NO	137.6	RT
PR321T	T	T2bN0Mx	Negative	slow	nf	y	7.0	50%	M	W	6.4	79.2	15.3	NO	136.1	RT
PR330T	T	T2 N0 Mx	Negative	ND	ND	NO	7.0	60%	M	W	4.4	N/A	N/A	Not Done	25.0	None
PR334T	T	T2b N0 Mx	Negative	none	nf	c	6.0	60%	M	W	8.4	N/A	N/A	not done	13.0	None
PR336T	T	T3b N0 Mx	Negative	none	nf	c	7.0	50%	M	W	5.4	N/A	N/A	not done	136.0	None
R10T	T	T3bN0Mx	Negative	fast	nf	y	8.0	60%	M	W	13.1	11.0	2.3	NO	74.0	ADT, CHEMO
R13T	T	T3bN0Mx	Negative	none	nf	c	7.0	60%	M	W	10.1	N/A	N/A	NO	157.0	None
R16T	T	T3bN0Mx	Negative	none	nf	c	7.0	50%	M	W	5.8	N/A	N/A	NO	159.0	None
R18T	T	T3bN0Mx	Negative	none	nf	c	7.0	50%	M	W	9.1	N/A	N/A	NO	163.5	None
R19T	T	T3bN0Mx	Negative	slow	nf	y	9.0	60%	M	W	13.8	2.0	1.1	NO	60.0	ADT, CHEMO
R26T	T	T3bN0Mx	Negative	none	nf	c	7.0	60%	M	W	7.7	N/A	N/A	NO	146.0	None
R3T	T	T3bN0Mx	Negative	none	nf	c	7.0	60%	M	W	7.1	N/A	N/A	NO	137.0	None
R37T	T	T3bN0Mx	Negative	none	nf	c	7.0	50%	M	W	8.6	N/A	N/A	NO	137.0	None

ID		Stage																
TP12-10765T	T	T3a N0 MX	Negative	ND	ND	ND	NO	7.0	50c	M	W	5.0	ND	ND	ND	Not Done	17.0	None
TP12-10770T	T	T3a N0 MX	Negative	ND	ND	ND	NO	7.0	40c	M	W	9.0	ND	ND	ND	Not Done	19.0	None
TP12-S0770T	T	T3c N1 MX	Negative	fast	.	.	y	7.0	60c	M	W	4.5	1.3	0.6	not done	30.0	ADT
TP12-S0788T	T	T3b N1 MX	Negative	ND	ND	NO	y	7.0	60c	M	W	10.8	NO	NO	Not Done	17.0	None
TP12-S0289T	T	T3a N0 MX	Negative	fast	.	y	y	7.0	60c	M	W	24.2	11.7	3.7	Not Done	28.0	None
TP12-S0290T	T	T2c N0 VX	Negative	NO	ND	NO	y	7.0	50c	M	W	2.4	NO	NO	Not Done	17.0	None
TP13-10793T	T	T3b N0 MX	Negative	NO	ND	NO	y	7.0	50c	M	W	6.4	NO	NO	CT Scan(s) - negative	17.0	None
TP12-10795T	T	T2c NX MX	Negative	NO	ND	NO	y	7.0	60c	M	W	unknown	ND	ND	Not Done	17.0	None
TP12-S0803T	T	T3c N0 MX	Negative	NO	ND	NO	y	7.0	50c	M	W	4.0	NO	NO	Not Done	22.0	None
TP12-S0805T	T	T3a N0 MX	Negative	NO	ND	NO	y	7.0	50c	M	W	6.5	NO	NO	Not Done	17.0	None
TP13-S0816T	T	T3a NX MX	Negative	NO	ND	NO	y	7.0	60c	M	W	7.0	NO	NO	Not Done	16.0	None
TP13-S0915T	T	T3a N0 MX	Negative	fast	.	y	y	7.0	60c	M	W	5.0	N/A	N/A	Not Done	16.0	None
TP12-S0916T	T	T3a N1 MX	Negative	NO	ND	NO	y	8.0	70c	M	W	6.8	0.9	2.2	CT Scan(s) - negative	28.0	ADT
TP12-S0918T	T	T3a N0 MX	Negative	ND	NO	NO	y	7.0	60c	M	W	5.3	ND	ND	Not Done	16.0	None
TP12-S0922T	T	T3a N1 MX	Negative	fast	.	y	y	9.0	50c	M	W	10.5	5.1	3.1	Not Done	28.0	None
TP12-S0543T	T	T3b N0 MX	Negative	fast	.	y	y	7.0	60c	M	W	13.7	1.3	0.4	not done	16.0	None
TP12-S0914T	T	T3b N0 MX	Negative	NO	ND	NO	y	7.0	50c	M	W	12.2	NO	NO	Not Done	16.0	None
TP12-S0966T	T	T2c N0 MY	Negative	NO	ND	NO	y	7.0	60c	M	W	6.0	N/A	N/A	Not Done	14.0	None
TP12-S0967T	T	T2c N0 MX	Negative	NO	ND	NO	y	7.0	60c	M	W	56.4	NO	NO	Not Done	16.0	None
TP12-S0981T	T	T3a N0 MX	Negative	NO	ND	NO	y	8.0	60c	M	W	16.6	NO	NO	Not Done	13.0	None
TP12-S0988T	T	T3a NC MX	Negative	NO	ND	NO	y	8.0	60c	M	W	9.2	NO	NO	Not Done	14.0	None
TP12-S1032T	T	T3a N0 MX	Negative	fast	.	y	y	8.0	60c	M	W	10.6	1.3	0.4	not done	15.0	None
TP12-S1059T	T	T3a N0 MX	Negative	NO	ND	NO	y	7.0	60c	M	W	18.5	NO	NO	Not Done	15.0	None
TP12-S1189T	T	T2c N0 MY	Negative	NO	ND	NO	y	7.0	70c	M	W	5.0	ND	ND	Not Done	14.0	None
TP12-S1197T	T	T2c N0 MX	Negative	fast	.	y	y	7.0	60c	M	W	4.9	7.8	2.0	Not Done	16.0	None
TP12-S1224T	T	T3a N0 MX	Negative	fast	.	y	y	8.0	60c	M	W	22.0	1.3	0.2	NO	12.0	None
TP13-S0043T	T	T3a N1 MX	Negative	fast	.	y	y	8.0	70c	M	W	24.3	1.6	1.1	NO	12.0	None
TP13-S0109T	T	T3a N1 MX	Negative	fast	.	y	y	8.0	60c	M	W	6.8	2.1	0.3	NO	11.0	ADT
TP13-S0345T	T	T3a N0 MX	Negative	fast	.	y	y	7.0	60c	M	W	3.6	7.8	2.0	NO	9.0	None
TP13-S0426T	T	T3a N0 MX	Negative	fast	.	y	y	9.0	50c	M	W	29.9	1.9	1.9	NO	7.0	None

TP13-3046-T	T	T30 N1 MX	Negative	rapt	1	Y	5.0	50c	M	W	10.0	1.1	0.3	ND	7.2	None

nPSADTs4 month; nPSADTs13 months; rYes; n=no; ADT=androgen deprivation therapy; RT=radiation therapy; chemo=chemotherapy; ND=not determined

Table 8. Clinical and pathological characteristics of 30 cases of prostate cancer from Stanford cohort.

Sample	Age	Ethnicity	Preop Rx	Pre PSA	T	N	M	Path Grade	Angio	Margins	Months followup	Recurrence	Months to recurrent	PSADT	Relapse	Relapse fast	Relapse simple
PC 19T	50s	Caucasian	None	4.42	T3a	N1	M0	4+5	Yes	Negative	116.2	Biochemical	19.13333333	4.11	fast	f	y
PC 252T	60s	Caucasian	None	4.2	T4	N0	M0	3+4	Unknown	Positive	22.86666667	Biochemical	10.2	3.85	fast	f	y
PC 265T	50s	African American	None	4.53	T2b	N0	M0	4+4	Unknown	Negative	20.76666667	Biochemical	2.77	3.89	fast	f	y
PC 452T	60s	Caucasian	None	5.12	T2b	N0	M0	4+3	Unknown	Negative	89.3	Biochemical	19.17	4.32	fast	f	y
PC 366T	50s	African American	Horm	4.01	T3b	N0	M0	4+3	Unknown	Negative	82.7	Biochemical	12.33	9.04	intermediate	nf	y
PC 538T	60s	Caucasian	None	10.7	T2b	N0	M0	3+4	No	Negative	73	Biochemical	24.86666667	8.55	intermediate	nf	y
PC 47T	50s	Caucasian	None	9.92	T2b	N0	M0	3+4	Unknown	Negative	63.66666667	Biochemical	37.6	98.58	slow	nf	y
PC 97T	50s	Caucasian	None	4.1	T2b	N0	M0	4+3	Unknown	Negative	117	Biochemical	61.13333333	>20	slow	nf	y
PC 370T	50s	Caucasian	None	10.76	T3b	N1	M0	4+4	Yes	Negative	68.8	Biochemical	15.83	21.89	slow	nf	y
PC 405T	60s	Caucasian	None	15.44	T2b	N1	M0	5+4	Unknown	Negative	40.06666667	Biochemical	2.5	>20	slow	nf	y
PC 446T	60s	Caucasian	None	7.1	T3b	N0	M0	3+4	Unknown	Negative	72	Biochemical	35.63	>20	slow	nf	y
PC 485T	60s	Caucasian	None	5.91	T2b	N0	M0	3+4	Yes	Negative	71.6	Biochemical	49.7	20.69	slow	nf	y
PC 498T	50s	Caucasian	None	4.68	T2b	N0	M0	3+3	Unknown	Negative	50.66666667	None	ND	n/a	ND	ND	ND
PC 551T	40s	Caucasian	None	4.8	T2b	N0	M0	3+3	Unknown	Negative	47.6	None	ND	n/a	ND	ND	ND
PC 494T	60s	Caucasian	None	2.38	T2b	N0	M0	3+4	Unknown	Negative	41.43333333	None	ND	n/a	ND	ND	ND
PC 629T	70s	African American	None	3.2	T2b	N0	M0	3+3	Unknown	Negative	48.3	None	ND	n/a	ND	ND	ND
PC 643T	60s	Caucasian	None	7.16	T2b	N0	M0	3+4	No	Negative	43.8	None	ND	n/a	ND	ND	ND
PC 646T	60s	Caucasian	None	4.9	T2b	N0	M0	3+4	Unknown	Negative	49	None	ND	n/a	ND	ND	ND
PC 473T	60s	Asian	None	4.64	T2b	N0	M0	3+4	Unknown	Negative	52.83333333	None	ND	n/a	ND	ND	ND
PC 470T	70s	Caucasian	None	6.8	T2b	N0	M0	3+4	Unknown	Negative	47.86666667	None	ND	n/a	ND	ND	ND
PC 482T	70s	Caucasian	None	2.84	T2b	N0	M0	3+3	Unknown	Negative	45.9	None	ND	n/a	ND	ND	ND
PC 1ST	40s	Caucasian	None	5.12	T2b	N0	M0	3+3	Unknown	Negative	118	None	>60	n/a	none	nf	n
PC 501T	60s	Caucasian	None	3.93	T2b	N0	M0	4+3	Unknown	Negative	74.6	None	>60	n/a	none	nf	n
PC 274T	60s	Caucasian	None	3.9	T2b	N0	M0	3+4	Unknown	Positive	105.5	None	>60	n/a	none	nf	n
PC 343T	60s	Caucasian	None	10.77	T2b	N0	M0	3+3	Unknown	Negative	61.96666667	None	>60	n/a	none	nf	n
PC 599T	40s	Caucasian	None	8.9	T2b	N0	M0	3+4	Unknown	Negative	61.3	None	>60	n/a	none	nf	n
PC 45T	50s	Caucasian	None	6.58	T2b	N0	M0	3+4	No	Negative	118.1	None	>60	n/a	none	nf	n
PC 86T	60s	Caucasian	None	2.1	T2b	N0	M0	3+4	Unknown	Negative	105.6	None	>60	n/a	none	nf	n
PC 99T	70s	Hispanic	None	6.26	T2b	N0	M0	3+4	Unknown	Negative	120.6	None	>60	n/a	none	nf	n
PC 85T	40s	Caucasian	None	4.8	T2a	N0	M0	3+4	Unknown	Positive	98	None	>60	n/a	none	nf	n

+PSADT ≤ 4 months; nf=PSADT ≥ 3 months; tr=t: mo; tr: mo; ADT=androgen deprivation therapy; RT=radiation therapy; Chemo=chemotherapy; ND=not determined.

Table 9. Clinical and pathological characteristics of 36 cases of prostate cancer from Wisconsin cohort.

Sample ID	Age	Stage	Margin	Pre-operational PSA	Grade	PSA recurrence
W1	60s	T1C	+, and lymph node	12	3+3	yes
W2	50s	T1C	-	4.5	3+4	no
W3	50s	T3a	+	2.9	3+4	yes
W4	70s	T3a	+	5	3+4	no
W5	50s	T2A	+	5.1	3+4	yes
W6	60s	T2A	+, and lymph node	4.13	4+5	yes
W7	60s	T1C	-	5.2	3+3	yes
W8	40s	T1C	-	7	4+4	no
W9	60s	T1C	-	4.95	3+4	yes
W10	40s	T1C	+, and lymph node	42	3+4	yes
W11	40s	unknown	+	5	4+3	yes
W12	60s	D0	-	6.3	4+5	yes
W13	60s	unknown	-	4.3	3+4	yes
W14	50s	T2B	-	2.5	3+3	no
W15	70s	T2B	-	7.9	4+3	yes
W16	60s	T3A	+	4.2	3+4	no
W17	60s	T2C	+	5	3+4	no
W18	60s	T2C	+	5.6	3+4	yes
W19	60s	T2C	-	unknown	4+3	no
W20	60s	T2C	+	4.47	3+4	no
W21	60s	T2A	-	4	3+3	no
W22	60s	T3B	+	6.7	3+4	yes
W23	50s	T2C	-	5.7	3+4	no
W24	50s	T3A	-	5	3+4	no
W25	50s	T2C	-	5.4	3+4	no
W26	60s	T2C	-	4.6	3+4	no
W27	50s	T2C	-	4.1	3+3	no
W28	unknown	unknown	unknown	unknown	4+4	ND
W29	60s	T2C	+	4.6	3+4	no
W30	60s	unknown	unknown	unknown	5+5	no
W31	60s	T2c	-	4	4+5	Yes

5

Table 9 (continued).

W32	40s	T3b	+		27	4+5	Yes
W33	50s	unknown	unknown		unknown	4+4	Yes
W34	50s	T3b	+		3.7	4+5	Yes
W35	unknown	unknown	unknown		unknown	4+5	ND
W36	50s	unknown	unknown		unknown	4+4	ND

Table 10: The status of 8 fusion genes predicting prostate cancer recurrence on 90 training
cohort from UPMC*.

Number of fusion	accuracy	sensitivity	specificity	Youden Inex
Panel of 8 fusion transcripts				
1	0.567	0.19	1	0.19
2	0.644	0.33	1	0.33
3	0.622	0.33	0.95	0.29
4	0.622	0.33	0.95	0.29
5	0.644	0.38	0.95	0.33
6	0.711	0.5	0.95	0.45
7	0.689	0.5	0.91	0.40
8	0.711	0.58	0.89	0.47
Panel of 8 fusion transcripts plus *TMPRSS2-ERG*				
1	0.589	0.42	0.79	0.20
2	0.622	0.48	0.79	0.27
3	0.6	0.48	0.74	0.22
4	0.6	0.48	0.74	0.22
5	0.611	0.5	0.74	0.24
6	0.656	0.58	0.74	0.32
7	0.633	0.58	0.69	0.27
8	0.656	0.63	0.69	0.32

*-Using any fusion transcript as cutoff.

Table 11: The status of 8 fusion genes with or without TMPRSS2-ERG predicting prostate cancer recurrence*.

Cohort	accuracy	sensitivity	specificity
8 fusion transcript			
UPMC training	0.711	0.58	0.89
UPMC testing	0.705	0.51	0.95
Wisconsin	0.8	0.63	1
Stanford	0.762	0.67	0.89
Combined testing**	0.734	0.56	0.951
8 fusion transcript plus *TMPRSS2-ERG*			
UPMC training	0.656	0.63	0.69
UPMC testing	0.681	0.67	0.69
Wisconsin	0.767	0.69	0.86
Stanford	0.762	0.83	0.67
Combined testing**	0.712	0.70	0.73

*-Using any fusion transcript as cutoff; **- Combining UPMC testing, Stanford and Wisconsin data set.

5   Table 12: Association of fusion transcript with clinical/pathological parameters.

Fusion gene	P value				
	Gleason	PSA (pre-operation)	Tumor stage	Lymph node	Nomogram
TMEM135-CCDC67	0.59	0.98	0.432	0.082	0.21
KDM4B-AC011523.2	0.64	0.726	0.688	0.588	0.588
MAN2A1-FER	0.781	0.721	0.679	0.140	1.07E-03
CCNH-C5orf30	0.14	0.313	0.254	0.059	0.156
TRMT11-GRIK2	0.012	0.227	5.38E-04	0.013	8.56E-03
SLC45A2-AMACR	0.566	0.441	0.022	0.181	0.015
MTOR-TP53BP1	0.993	0.57	0.731	1	0.775
LRRC59-FLJ60017	0.877	0.034	0.226	0.206	0.188
At least one	0.064	0.138	3.852e-3	4.77e-3	2.86E-04
TMPRSS2-ERG	0.869	0.306	0.642	0.042	0.325

Table 13: Gleason score prediction of recurrent status of 90 samples of UPMC training Cohort.

Score	accuracy	sensitivity	specificity	Youden Index
6	0.5333333	1	0	0
7	0.6111111	0.95833333	0.2142857	0.17261905
8	0.6111111	0.39583333	0.8571429	0.25297619
9	0.5111111	0.16666667	0.9047619	0.07142857
10	0.4666667	0.02083333	0.9761905	-0.00297619

10

Table 14: Gleason score prediction of recurrent status of 229[1] samples of training and testing cohorts from UPMC, Stanford and Wisconsin*.

Cohort	accuracy	sensitivity	specificity
Gleason alone			
UPMC training	0.611	0.40	0.86
UPMC testing	0.602	0.41	0.85
Wisconsin	0.6	0.31	0.93
Stanford	0.571	0.25	1
Combined testing**	0.597	0.37	0.89
Gleason plus 8 fusion transcripts[+]			
UPMC training	0.722	0.65	0.81
UPMC testing	0.739	0.59	0.92
Wisconsin	0.9	0.81	1
Stanford	0.762	0.67	0.89
Combined testing**	0.777	0.65	0.94
Gleason plus 8 fusion transcripts plus *TMPRSS2-ERG*[+]			
UPMC training	0.644	0.73	0.55
UPMC testing	0.705	0.80	0.59
Wisconsin	0.833	0.88	0.79
Stanford	0.762	0.83	0.67
Combined testing**	0.741	0.82	0.65

*- Using Gleason >=8 as cutoff; +- Using Gleason >=8 or presence of any fusion transcript as cutoff; +-Using <88 or presence of any fusion transcript or *TMPRSS2-ERG* as cutoff; **- Combining UPMC testing, Stanford and Wisconsin data set; |-Gleason score is not graded in one sample and not included in the analysis.

5

10

15

Table 15: Nomogram prediction of recurrent status of 90 samples of UPMC training
Cohort.

Probability*	accuracy	sensitivity	specificity	Youden Index
0	0.4666667	0	1	0
1	0.4666667	0	1	0
2	0.4666667	0	1	0
3	0.4666667	0	1	0
4	0.4666667	0	1	0
5	0.4666667	0	1	0
6	0.4666667	0	1	0
7	0.4666667	0	1	0
8	0.4666667	0	1	0
9	0.4666667	0	1	0
10	0.4666667	0	1	0
11	0.4666667	0	1	0
12	0.4666667	0	1	0
13	0.4777778	0.02083333	1	0.02083333
14	0.4777778	0.02083333	1	0.02083333
15	0.4777778	0.02083333	1	0.02083333
16	0.4777778	0.02083333	1	0.02083333
17	0.4777778	0.02083333	1	0.02083333
18	0.4777778	0.02083333	1	0.02083333
19	0.4888889	0.04166667	1	0.04166667
20	0.4888889	0.04166667	1	0.04166667
21	0.4888889	0.04166667	1	0.04166667
22	0.4888889	0.04166667	1	0.04166667
23	0.4888889	0.04166667	1	0.04166667
24	0.4888889	0.04166667	1	0.04166667
25	0.5	0.0625	1	0.0625
26	0.5	0.0625	1	0.0625
27	0.5111111	0.08333333	1	0.08333333
28	0.5111111	0.08333333	1	0.08333333
29	0.5333333	0.125	1	0.125
30	0.5222222	0.125	0.97619048	0.10119048
31	0.5222222	0.125	0.97619048	0.10119048
32	0.5222222	0.125	0.97619048	0.10119048
33	0.5333333	0.14583333	0.97619048	0.12202381
34	0.5444444	0.16666667	0.97619048	0.14285714
35	0.5444444	0.16666667	0.97619048	0.14285714
36	0.5444444	0.16666667	0.97619048	0.14285714
37	0.5444444	0.16666667	0.97619048	0.14285714
38	0.5555556	0.1875	0.97619048	0.16369048
39	0.5555556	0.1875	0.97619048	0.16369048
40	0.5555556	0.1875	0.97619048	0.16369048
41	0.5555556	0.1875	0.97619048	0.16369048
42	0.5555556	0.1875	0.97619048	0.16369048
43	0.5777778	0.22916667	0.97619048	0.20535714

5

Table 15 (continued).

44	0.5888889	0.25	0.97619048	0.22619048
45	0.5888889	0.25	0.97619048	0.22619048
46	0.5888889	0.25	0.97619048	0.22619048
47	0.6	0.27083333	0.97619048	0.24702381
48	0.6	0.27083333	0.97619048	0.24702381
49	0.6	0.27083333	0.97619048	0.24702381
50	0.6111111	0.29166667	0.97619048	0.26785714
51	0.6111111	0.29166667	0.97619048	0.26785714
52	0.6111111	0.29166667	0.97619048	0.26785714
53	0.6222222	0.3125	0.97619048	0.28869048
54	0.6222222	0.3125	0.97619048	0.28869048
55	0.6222222	0.3125	0.97619048	0.28869048
56	0.6222222	0.3125	0.97619048	0.28869048
57	0.6333333	0.33333333	0.97619048	0.30952381
58	0.6444444	0.35416667	0.97619048	0.33035714
59	0.6444444	0.35416667	0.97619048	0.33035714
60	0.6555556	0.375	0.97619048	0.35119048
61	0.6555556	0.375	0.97619048	0.35119048
62	0.6555556	0.375	0.97619048	0.35119048
63	0.6444444	0.375	0.95238095	0.32738095
64	0.6333333	0.375	0.92857143	0.30357143
65	0.6333333	0.375	0.92857143	0.30357143
66	0.6444444	0.39583333	0.92857143	0.32440476
67	0.6555556	0.41666667	0.92857143	0.3452381
68	0.6555556	0.41666667	0.92857143	0.3452381
69	0.6555556	0.41666667	0.92857143	0.3452381
70	0.6777778	0.45833333	0.92857143	0.38690476
71	0.6777778	0.47916667	0.9047619	0.38392857
72	0.6777778	0.5	0.88095238	0.38095238
73	0.6888889	0.52083333	0.88095238	0.40178571
74	0.6888889	0.52083333	0.88095238	0.40178571
75	0.6888889	0.52083333	0.88095238	0.40178571
76	0.6888889	0.52083333	0.88095238	0.40178571
77	0.7	0.54166667	0.88095238	0.42261905
78	0.7	0.54166667	0.88095238	0.42261905
79	0.7	0.54166667	0.88095238	0.42261905
80	0.7111111	0.5625	0.88095238	0.44345238
81	0.7111111	0.5625	0.88095238	0.44345238
82	0.7111111	0.58333333	0.85714286	0.44047619
83	0.7	0.58333333	0.83333333	0.41666667
84	0.7	0.58333333	0.83333333	0.41666667
85	0.7111111	0.60416667	0.83333333	0.4375
86	0.7333333	0.64583333	0.83333333	0.47916667
87	0.7444444	0.66666667	0.83333333	0.5
88	0.7555556	0.6875	0.83333333	0.52083333
89	0.7333333	0.70833333	0.76190476	0.4702381
90	0.7222222	0.70833333	0.73809524	0.44642857
91	0.7111111	0.72916667	0.69047619	0.41964286

5

Table 15 (continued).

92	0.7	0.75	0.64285714	0.39285714
93	0.7111111	0.83333333	0.57142857	0.4047619
94	0.6777778	0.85416667	0.47619048	0.33035714
95	0.6888889	0.875	0.47619048	0.35119048
96	0.6777778	0.875	0.45238095	0.32738095
97	0.6222222	0.95833333	0.23809524	0.19642857
98	0.5444444	1	0.02380952	0.02380952
99	0.5333333	1	0	0
100	0.5333333	1	0	0

*-Probability of PSA free survival for 5 years

Table 16: Nomogram prediction of recurrent status of 229[|] samples of training and testing cohorts from UPMC, Stanford and Wisconsin.

Cohort	accuracy	sensitivity	specificity
Nomogram alone*			
UPMC training	0.756	0.69	0.83
UPMC testing	0.75	0.80	0.69
Wisconsin	0.6	0.31	0.93
Stanford	0.619	0.33	1
Combined testing**	0.691	0.57	0.84
Nomogram plus 8 fusion transcripts+			
UPMC training	0.778	0.69	0.88
UPMC testing	0.807	0.76	0.87
Wisconsin	0.833	0.69	1
Stanford	0.81	0.75	0.89
Combined testing**	0.813	0.74	0.90
Nomogram plus 8 fusion transcripts plus *TMPRSS2-ERG*†			
UPMC training	0.656	0.63	0.69
UPMC testing	0.681	0.67	0.69
Wisconsin	0.767	0.69	0.86
Stanford	0.762	0.83	0.67
Combined testing**	0.719	0.62	0.84

*-Using <88 as cutoff. +- Using <88 or any fusion transcript as cutoff; †- Using <88 or any fusion transcript or *TMPRSS2-ERG* as cutoff; **- Combining UPMC testing, Stanford and Wisconsin data set; [|] -Gleason score is not graded in one sample and not included in the analysis.

Table 17. Putative fusion transcripts from benign prostate of healthy organ donors.

Fusion gene 1	Fusion_gene2	read pairs	Validation Status
SORBS1	RP11-476E15.3	25	
AHCY	RP11-292F22.3	25	
DCUN1D3	ERI2	12	
MACF1	KIAA0754	11	
C10orf68	CCDC7	11	RT-PCR and sequencing
RP11-166D19.1	BLID	7	
ASS1	ASS1P9	6	
BACH1	BACH1-IT1	6	RT-PCR
MPDZ	RP11-272P10.2	5	
LIG3	RP5-837J1.2	4	
ACAD8	GLB1L3	4	RT-PCR
IGSF9B	RP11-259P6.1	3	
EYA1	RP11-1102P16.1	3	
TTC33	PRKAA1	3	RT-PCR
DNAH1	GLYCTK	3	
PSPC1	ZMYM5	3	
HSP90AB3P	RP11-759L5.2	3	
LSAMP	RP11-384F7.2	3	
RNF4	FAM193A	81	RT-PCR
AHCY	RP11-292F22.3	9	
LSAMP	RP11-384F7.2	8	
CBLL1	AC002467.7	4	
FNBP4	Y_RNA	4	
TBCE	RP11-293G6__A.2	4	
TRIM58	RP11-634B7.4	4	
DCUN1D3	ERI2	4	
PHPT1	MAMDC4	3	

5

10

15

Table 17 (continued).

TRIP6	SLC12A9	3	
NAT14	ZNF628	3	
TLL2	RP11-35J23.5	3	
UFSP2	Y_RNA	3	
TSPAN33	Y_RNA	3	
CADM3	DARC	3	
KIF27	RP11-213G2.3	3	
RABL6	KIAA1984	3	
ZNF615	ZNF350	3	
ZYG11A	RP4-631H13.2	3	
RP11-522L3.6	MTND4P32	3	
MTND3P10	AC012363.10	3	
RP11-464F9.1	BMS1P4	3	
RNF4	FAM193A	14	RT-PCR
GBP3	Y_RNA	3	
NACA	PRIM1	1	
AHCY	RP11-292F22.3	3	
GBP3	Y_RNA	3	
HARS2	ZMAT2	2	RT-PCR and sequencing
EED	C11orf73	1	RT-PCR
CNPY3	RP3-475N16.1	1	RT-PCR
RN7SL2	Metazoa_SRP	1	
SLC16A8	BAIAP2L2	2	RT-PCR
KLK4	KLKP1	2	RT-PCR and sequencing
ZNF137P	ZNF701	1	RT-PCR
AZGP1	GJC3	1	RT-PCR
USP7	RP11-252I13.1	1	
TRRAP	AC004893.11	1	
C6orf47	BAG6	1	RT-PCR
TTTY15	USP9Y	9	

AC005077.12	LINC00174	2	
ADCK4	NUMBL	2	
ZNF606	C19orf18	2	
SLC45A3	ELK4	3	RT-PCR and sequencing

6.6.   REFERENCES

1.   Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin.* Feb 4 2012.

2.   Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin.* Jan-Feb 2012;62(1):10-29.

3.   Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics.* Jul 15 2009;25(14):1754-1760.

4.   Trapnell C, Roberts A, Goff L, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc.* Mar 2012;7(3):562-578.

5.   Trapnell C, Williams BA, Pertea G, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat Biotechnol.* May 2010;28(5):511-515.

6.   Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics.* May 1 2009;25(9):1105-1111.

7.   Edgren H, Murumagi A, Kangaspeska S, et al. Identification of fusion genes in breast cancer by paired-end RNA-sequencing. *Genome Biol.* 12(1):R6.

8.   Wei Zeng C-WF, Stefan Muller Arisona, Huamin Qu. Visualizing Interchange Patterns in Massive Movement Data. *Computer Graphics Forum.* 2013(32):271-280.

9.   Luo JH, Yu YP, Cieply K, et al. Gene expression analysis of prostate cancers. *Mol Carcinog.* Jan 2002;33(1):25-35.

10.   Yu YP, Landsittel D, Jing L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. *J Clin Oncol.* Jul 15 2004;22(14):2790-2799.

11.   Ren B, Yu G, Tseng GC, et al. MCM7 amplification and overexpression are associated with prostate cancer progression. *Oncogene.* Feb 16 2006;25(7):1090-1098.

12.   Yu YP, Yu G, Tseng G, et al. Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. *Cancer Res.* Sep 1 2007;67(17):8043-8050.

13.   Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science.* Oct 28 2005;310(5748):644-648.

14.   Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. *Nature.* Feb 10;470(7333):214-220.

15.   Baca SC, Prandi D, Lawrence MS, et al. Punctuated evolution of prostate cancer genomes. *Cell.* Apr 25;153(3):666-677.

16.   Freedland SJ, Humphreys EB, Mangold LA, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. *J Clin Oncol.* May 1 2007;25(13):1765-1771.

17.   Antonarakis ES, Zahurak ML, Lin J, Keizman D, Carducci MA, Eisenberger MA. Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials. *Cancer.* Mar 15;118(6):1533-1542.

18.   Sinclair PB, Sorour A, Martineau M, et al. A fluorescence in situ hybridization map of 6q deletions in acute lymphocytic leukemia: identification and analysis of a candidate tumor suppressor gene. *Cancer Res.* Jun 15 2004;64(12):4089-4098.

19.   Misago M, Liao YF, Kudo S, et al. Molecular cloning and expression of cDNAs encoding human alpha-mannosidase II and a previously unrecognized alpha-mannosidase IIx isozyme. *Proc Natl Acad Sci U S A.* Dec 5 1995;92(25):11766-11770.

20.   Krolewski JJ, Lee R, Eddy R, Shows TB, Dalla-Favera R. Identification and chromosomal mapping of new human tyrosine kinase genes. *Oncogene.* Mar 1990;5(3):277-282.

21.   Prakash T, Sharma VK, Adati N, Ozawa R, Kumar N, Nishida Y, Fujikake T, Takeda T, Taylor TD: Expression of conjoined genes: another mechanism for gene regulation in eukaryotes, PLoS One 2010, 5:e13284.

22.   Youden WJ: Index for rating diagnostic tests, Cancer 1950, 3:32-35.

23.   Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M: pROC: an open-source package for R and S+ to analyze and compare ROC curves, BMC Bioinformatics 12:77.

24.   Towns WL, Begley TJ: Transfer RNA methytransferases and their corresponding modifications in budding yeast and humans: activities, predications, and potential roles in human health, DNA Cell Biol 2012, 31:434-454.

25.   Misago M, Liao YF, Kudo S, Eto S, Mattei MG, Moremen KW, Fukuda MN: Molecular cloning and expression of cDNAs encoding human alpha-mannosidase II and a previously unrecognized alphamannosidase IIx isozyme, Proc Natl Acad Sci U S A 1995, 92:11766-11770.

26.   Fisher RP, Morgan DO: A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase, Cell 1994, 78:713-724.

27.   Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang IIJ, Pavletich NP: mTOR kinase structure, mechanism and regulation, Nature 2013, 497:217-223.

28.   Wang H, Luo K, Tan LZ, Ren BG, Gu LQ, Michalopoulos G, Luo JH, Yu YP: p53-induced gene 3 mediates cell death induced by glutathione peroxidase 3, J Biol Chem 2012, 287:16890-16902.

29.   Zhen Y, Sorensen V, Skjerpen CS, Haugsten EM, Jin Y, Walchli S, Olsnes S, Wiedlocha A: Nuclear import of exogenous FGF1 requires the ER-protein LRRC59 and the importins Kpnalpha1 and Kpnbeta1, Traffic 2012, 13:650-664.

30.   Yang J, Jubb AM, Pike L, Buffa FM, Turley H, Baban D, Leek R, Gatter KC, Ragoussis J, Harris AL: The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth, Cancer Res 70:6456-6466.

31.   Savolainen K, Kotti TJ, Schmitz W, Savolainen TI, Sormunen RT, Ilves M, Vainio SJ, Conzelmann E, Hiltunen JK: A mouse model for alpha-methylacyl-CoA racemase deficiency: adjustment of bile acid synthesis and intolerance to dietary methyl-branched lipids, Hum Mol Genet 2004, 13:955-965.

7.   **EXAMPLE 2: PTEN-NOLC1 FUSION GENES**

Transcriptome sequencing was performed on 15 samples of prostate cancer from patients who experienced prostate cancer recurrence after radical prostatectomy. One of the candidate gene fusion transcripts is PTEN-NOLC1. To validate the fusion transcript, RT-PCRs using primers specific for PTEN-NOLC1 were performed on the prostate cancer sample that was positive for the fusion transcript, using the following primers: 5'-GCATTTGCAGTATAGAGCGTGC3' (SEQ ID NO: 28)/ 5'GTCTAAGAGGGAAGAGGCATTG3' (SEQ ID NO: 29), under the following conditions: 94°C for 5', then 30 cycles of 94°C for 10 seconds, 61°C for 1 min and 72°C for 3 min, followed by 10 min at 72°C for extension. A 158 bp PCR product was generated. The PCR product was subsequently sequenced. PTEN-NOLC1 fusion transcript was confirmed (Figure 13A). To investigate the mechanism of PTEN-NOLC1 fusion transcript, Fluorescence In Situ Hybridizations (FISH) were performed using probes corresponding to 5'-end of PTEN genome (RP11-124B18) and 3'-end of NOLC1 genome (CTD-3082D22), respectively. In normal prostate epithelial cells, these 2 probes were hybridized to distinct separate locations in the genome due to more than 14 megabase separation of these 2 genes (Figure 13B). In contrast, these two signals appeared to merge to generate an overlapped signal in prostate cancer genome from a

sample that is positive for PTEN-NOLC1 fusion transcript. Interestingly, non-fusion PTEN was virtually undetectable in this prostate cancer sample, suggesting that PTEN-NOLC1 fusion was accompanied with PTEN deletion in another allele. These results suggest that genome rearrangement is the underlying mechanism for PTEN-NOLC1

5   transcription. To investigate the clinical significance of PTEN-NOLC1 fusion, 215 prostate cancer samples were analyzed for PTEN-NOLC1 expression. Over 14% (31/215) prostate cancer samples were found to express PTEN-NOLC1 (Figure 13C). Among the positive samples, 77% (24/31, p=0.03) patients experienced prostate cancer recurrence. This indicates that PTEN-NOLC1 fusion is associated with poor clinical outcome.

10   Interestingly, our analysis of lung adenocarcinoma, Glioblastoma multiforme, and hepatocellular carcinoma indicates that significant number of these cancers are also positive for PTEN-NOLC1 fusion: 35/38 glioblastoma multiformis, 3/20 hepatocellular carcinoma and 29/40 lung adenocarcinoma. These results suggest that PTEN-NOLC1 fusion may have broad implication for cancer development.

15   ***Expression of Pten-NOLC1 in NIH3T3 and PC3 cells increased cell growth.*** To investigate whether PTEN-NOLC1 has pro-growth activity, we ligated PTEN-NOLC1 cDNA into pCDNA-FLAG vector to create pCDNA4-PTEN-NOLC1-FLAG. Subsequently, we transfected NIH3T3 and PC3 cells (a human prostate cancer cell line) with pCDNA4-PTEN-NOLC1-FLAG/pCDNA6. As shown in Figure 27B, induction of

20   NIH3T3 and PC3 cells produces 10.3 (p<0.01) and 3.1 fold (p<0.01) increase of cell growth, respectively. These were accompanied with 2.3 fold (p<0.01) and 2.7 fold (p<0.001) increase of cell entry into S-phase in NIH3T3 and PC3 cells in cell cycle analysis (Figure 27C). Colony formation analyses indicate that expression of PTEN-NOLC1 produced 2.2 fold (p<0.001) higher numbers of colonies from single cell

25   suspension for NIH3T3 cells than the un-induced controls and 2.7 fold (p<0.01) more colonies for PC3 cells when they were induced to express PTEN-NOLC1-FLAG (Figure 27D).

To investigate the subcellular localization of PTEN-NOLC1, NIH3T3 cells were transformed with pCDNA4-PTEN-NOLC1-FLAG/pCDNA6 were induced with

30   tetracycline to express PTEN- NOLC1-FLAG. As shown in Figure 27A, most PTEN-NOLC1-FLAG was localized in the nucleus of the cells. This is contrary to cytoplasmic localization of PTEN. PTEN-NOLC1-FLAG was also detected in purified nucleus fraction. Without being bound to a particular theory, these results indicate that fusion

formation with NOLC1 alters the subcellular localization of PTEN-NOLC1 from cytoplasm to nucleus.

8.   EXAMPLE 3: THERAPEUTIC TARGETING AT FUSION TRANSCRIPT CONTAINING CHIMERA PROTEIN MAN2A1-FER

8.1.   RESULTS

MAN2A1-FER likely produces activated FER kinase.   MAN2A1-FER was present in prostate cancer, hepatocellular carcinoma and Glioblastoma multiforme. MAN2A1 is a Golgi enzyme required for conversion of high mannose to complex type structure of N-glycan for mature glycosylation of a membrane protein[1, 2]. Little is known about its relation with human malignancies. On the other hand, FER, a tyrosine kinase, is a well-documented oncogene[3, 4]. Several studies showed that FER activate androgen receptor (AR) by phosphorylating Tyr223 in AR[5], and is essential for NFκB activation of EGFR[6]. Some studies indicate that FER is an essential component of stem cell tyrosine kinase 1 (STK1)[6] and mast cell growth factor receptor (kit)[7, 8] signaling. Over-expression of FER is associated with poor clinical outcomes of breast cancer[9], renal cell carcinoma[10, 11], non-small cell lung cancer[12, 13] and hepatocellular carcinoma[14]. The N-termini of many tyrosine protein kinases serve to constrain the kinase activity and are regulated by other molecules. Domains of some N-termini bind and select specific targets for the kinases. Removal of the N-terminus from a protein kinase may produce constitutively activated kinase activity that may alter the signaling pathways and generates uninhibited cell growth. The best analogy to MAN2A1-FER is BCR-Abl. When c-Abl is intact, its kinase activity is constrained. Removal of SH3 domain in c-Abl in the BCR-Abl fusion protein converts the mutant Abl tyrosine kinase into an oncogene that plays key role in developing acute lymphoblastic leukemia and chronic myelogenous leukemia. Wild type FER with intact SH2 domain is inactive in kinase activity when assayed in cell free system. In the fusion gene MAN2A1-FER, the N-terminus of FER suffers a loss of SH2 and FHC domain (Figure 14). These domains were replaced with glycoside hydrolase and α-mannosidase middle domain from MAN2A1. As a result, the kinase activity may be activated and substrate targets of FER tyrosine kinase may be altered.

MAN2A1-FER expression accelerates cell cycle entry into S phase and increased tyrosine phosphorylation of EGFR in the absence of EGFR ligand. To investigate whether MAN2A1-FER chimera protein is expressed in prostate cancer samples that contain MAN2A1-FER transcript, protein extracts from 5 prostate cancer

samples positive for MAN2A1-FER RNA were analyzed using antibodies specific for MAN2A1 or FER. These results showed that the samples expressed a 115 Kd protein recognized by both MAN2A1 and FER antibodies (Figure 22). This protein is not detected in prostate cancer samples that are negative for MAN2A1-FER transcript.

5   When MAN2A1-FER was forced to express in RWPE1 cells, a non-transformed prostate epithelial cell line, it increase the proportion of cells in S phase by 4.6-5 fold (p<0.001). MAN2A1-FER was determined to be co-localized with Golgi protein in both immunofluorescence and sucrose gradient analysis, supporting the notion that MAN2A1-FER is primarily located in Golgi apparatus. Interestingly, expression of MAN2A1-FER

10   increased tyrosine phosphorylation of EGFR in RWPE1 cells in the absence of EGFR ligand, suggesting that MAN2A1-FER may ectopically phosphorylate the EGFR extracellular domain. Thus, MAN2A1-FER may function as a transforming oncogene and possess intrinsic tyrosine kinase activity derived from its FER kinase domain. Not to be limited to any particular theory, the kinase domain of MAN2A1-FER may be the driver of

15   its oncogenic activity through ectopic phosphorylation of transmembrane proteins such as EGFR.

        Therapeutic targeting at MAN2A1-FER results in specific cell death prostate cancer cells expressing MAN2A1-FER. Based on the analyses above, we reason that the altered subcellular location and substrate specificity of FER kinase will create oncogenic

20   activity of MAN2A1-FER. A large part of this oncogenic activity results from ectopic phosphorylation and activation of EGFR and its down-stream signaling pathways. Thus, we can intervene and disrupt the oncogenic pathways of MAN2A1-FER using 2 different approaches. The first approach is inhibiting the kinase activity of MAN2A1-FER by targeting MAN2A1-FER proteins using small molecules that can inhibit tyrosine kinase.

25   Several small molecules specific for FER such as diaminopyrimidine TAE684, and pyrazologyrididines WZ-4-49-8 and WZ-4-49-10, generic ALK/FER inhibitor crisotinib are available. Among these compound inhibitors, Crisotinib has been approved by FDA to treat advanced and metastatic non-small cell lung cancer positive for EML4-ALK, another tyrosine kinase fusion protein. The drug has been shown to be able to shrink

30   tumor mass by at least 30% in most patients.

        To investigate whether Crisotinib is also effective against MAN2A1-FER positive cancer cells, we transformed human prostate cancer cell line PC3 with pCDNA4-MAN2A1-FER-FLAG/pCDNA6 to express MAN2A1-FER fusion protein. These cells were treated with low dosage of Crisotinib for 24 hours. As shown in Figure 22, the

treatment resulted in 31% cell death in MAN2A1-FER expressing cells, while it hardly killed the same type of cancer cells that do not express this fusion protein. A dosage effect analysis showed that expression of MAN2A1-FER lowers the cancer killing EC_{50} by at least 2 magnitudes (~100 fold). Thus, it is reasonable to treat MAN2A1-FER positive prostate cancer with Crisotinib at a dosage that is not harmful to normal human cells.

The second approach is to target EGFR activation by EGFR inhibitors. These include erlotinib, cetuximab, bevacizumab, canertinib and bortezomib. Many of these drugs were FDA approved and is widely used in a variety of human solid tumors. To interrogate the effectiveness of EGFR activation interruption in treating prostate cancer, we treated MAN2A1-FER transformed PC3 cells with canertinib. As shown in Figure 23, the treatment also produced 34% cell death of cells expressing MAN2A1-FER. In contrast, the effect on cells not expressing MAN2A1-FER (Tet-) was minimal: The cell death level is similar to those untreated controls. These results suggest EGFR activation is one of the critical pathways for MAN2A1-FER oncogenic activity. Interesting, when we tried to intercept the down-streaming signaling molecule of EGFR, MEK, using an experimental drug AZD6244, the differential killing effect was largely moderated and vanished (data not shown). It suggests that other signaling pathways for EGFR may bypass MEK signaling.

8.2.   REFERENCES

1.   Moremen KW, Robbins PW: Isolation, characterization, and expression of cDNAs encoding murine alpha-mannosidase II, a Golgi enzyme that controls conversion of high mannose to complex N-glycans, J Cell Biol 1991, 115:1521-1534

2.   Misago M, Liao YF, Kudo S, Eto S, Mattei MG, Moremen KW, Fukuda MN: Molecular cloning and expression of cDNAs encoding human alpha-mannosidase II and a previously unrecognized alpha-mannosidase IIx isozyme, Proc Natl Acad Sci U S A 1995, 92:11766-11770

3.   Hao QL, Heisterkamp N, Groffen J: Isolation and sequence analysis of a novel human tyrosine kinase gene, Mol Cell Biol 1989, 9:1587-1593

4.   Krolewski JJ, Lee R, Eddy R, Shows TB, Dalla-Favera R: Identification and chromosomal mapping of new human tyrosine kinase genes, Oncogene 1990, 5:277-282

5.   Rocha J, Zouanat FZ, Zoubeidi A, Hamel L, Benidir T, Scarlata E, Brimo F, Aprikian A, Chevalier S: The Fer tyrosine kinase acts as a downstream interleukin-6

effector of androgen receptor activation in prostate cancer, Mol Cell Endocrinol 381:140-149

6.   Guo C, Stark GR: FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-kappaB, Proc Natl Acad Sci U S A 108:7968-7973

7.   Kwok E, Everingham S, Zhang S, Greer PA, Allingham JS, Craig AW: FES kinase promotes mast cell recruitment to mammary tumors via the stem cell factor/KIT receptor signaling axis, Mol Cancer Res 10:881-891

8.   Voisset E, Lopez S, Dubreuil P, De Sepulveda P: The tyrosine kinase FES is an essential effector of KITD816V proliferation signal, Blood 2007, 110:2593-2599

9.   Ivanova IA, Vermeulen JF, Ercan C, Houthuijzen JM, Saig FA, Vlug EJ, van der Wall E, van Diest PJ, Vooijs M, Derksen PW: FER kinase promotes breast cancer metastasis by regulating alpha6- and beta1-integrin-dependent cell adhesion and anoikis resistance, Oncogene 32:5582-5592

10.   Miyata Y, Kanda S, Sakai H, Greer PA: Feline sarcoma-related protein expression correlates with malignant aggressiveness and poor prognosis in renal cell carcinoma, Cancer Sci 104:681-686

11.   Wei C, Wu S, Li X, Wang Y, Ren R, Lai Y, Ye J: High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma, Oncol Lett 5:473-478

12.   Ahn J, Truesdell P, Meens J, Kadish C, Yang X, Boag AH, Craig AW: Fer protein-tyrosine kinase promotes lung adenocarcinoma cell invasion and tumor metastasis, Mol Cancer Res 11:952-963

13.   Kawakami M, Morita S, Sunohara M, Amano Y, Ishikawa R, Watanabe K, Hamano E, Ohishi N, Nakajima J, Yatomi Y, Nagase T, Fukayama M, Takai D: FER overexpression is associated with poor postoperative prognosis and cancer-cell survival in non-small cell lung cancer, Int J Clin Exp Pathol 6:598-612

14.   Li H, Ren Z, Kang X, Zhang L, Li X, Wang Y, Xue T, Shen Y, Liu Y: Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells, BMC Cancer 2009, 9:366

15.   Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, De Marzo AM, Isaacs WB: Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer, Cancer Res 2003, 63:7365-7376

16.   Krastev DB, Slabicki M, Paszkowski-Rogacz M, Hubner NC, Junqueira
M, Shevchenko A, Mann M, Neugebauer KM, Buchholz F: A systematic RNAi synthetic
interaction screen reveals a link between p53 and snoRNP assembly, Nature cell biology
2011, 13:809-818

5

9.   **EXAMPLE 4. ELIMINATION OF CANCER CELLS POSITIVE
FOR FUSION TRANSCRIPTS THROUGH GENOME EDITING**

Recent advances in genome editing using ZFN and CAS9 has made it possible to
target a specific cancer genome sequence that is not present in normal cells. The

10   mechanism of formation of fusion transcript is chromosome rearrangement. As a result,
breakpoints in the chromosome are readily identified in a cancer genome. Normal cells
do not have similar chromosome rearrangements, and are thus negative for the breakpoint.
Targeting a specific breakpoint in the prostate cancer genome will likely generate an
effective treatment for prostate cancer. Since the genomic breakpoint of CCNH-

15   C5ORF30 and TMEM135-CCDC67 has been identified, genome editing technology
targeting at the breakpoint of CCNH-C5orf30 or TMEM135-CCDC67 can be used to kill
cancer cells.

As shown in Figure 15, genome recombination in prostate cancer case 3T
produced a breakpoint in chromosome 5 that connect intron 6 of CCNH with intron 1 of

20   C5orf30. The resulting breaking point is unique in prostate cancer case 3T. The
breakpoint is positive in most prostate cancer tissues but negative for normal tissues from
this patient. A guide RNA (gRNA) of 23 bp including protospacer adjacent motif (PAM)
sequence is designed specific for the breakpoint region. The DNA sequence
corresponding to this target sequence is artificially ligated into vector containing the

25   remainder of gRNA and CAS9. This sequence is recombined and packaged into
recombinant virus (Adenovirus or lenti-virus). A promoterless Herpes Simplex Virus
Type 1 (HSV-1) thymidine kinase is constructed into a shuttle vector for adenovirus along
with splice tag sequence from intron/exon juncture of CCNH exon 7. A 500 bp sequence
surrounding the CCNH-C5orf30 breakpoint from each side is also ligated into the shuttle

30   vector in order to produce efficient homologous recombination to complete the donor
DNA construction. The vector is recombined and packaged into AdEasy to generate
recombinant viruses. These viruses are administered to patients or animals that have
cancer positive for CCNH-C5orf30 fusion transcript. This leads to insertion of donor
DNA into the target site (fusion breakpoint). Since HSV-1 TK in recombinant virus is

promoterless, no transcription will occur if HSV-1 TK cDNA does not integrate into a transcription active genome. However, transcription of HSV-1 TK is active if HSV-1 TK is integrated into the target site of CCNH-C5orf30, since this transcript is readily detectable in the prostate cancer sample of this patient. When patient 3T takes

5   ganciclovir or its oral homologue valganciclovir, the homologue is readily converted to triphosphate guanine analogue by HSV-1 TK and incorporated into the genomes of cancer cells. This leads to stoppage of DNA elongation in cells that are positive for CCNH-C5orf30. Since mammalian TK does not phosphorylate ganciclovir, ganciclovir is not converted to active (triphosphate) form in cells that are negative for HSV-1 TK protein.

10   Thus, the impact of ganciclovir on normal cells is minimized.

The technique described above was applied to cells having the TMEM135-CCDC67 breakpoint. Since none of the fusion genes we identified so far was present in prostate cancer cell lines, we created a TMEM135-CCDC67 genome breakpoint that is identical to the prostate cancer sample we analyzed. The expression of the TMEM135-

15   CCDC67 breakpoint was driven by a CMV promoter. Subsequently, we constructed a donor DNA that encompassed HSV-1 TK and the splicing sites of TMEM135 exon 14. When we co-transfected this donor DNA with a vector that expresses gRNA targeting at the TMEM135-CCDC67 breakpoint into PC3 cells containing this genome breakpoint, integration of TK into the genome was identified (Figure 28A). In contrast, when we

20   transfected the same pairs of DNA into cells that do not contain the breakpoint, no integration of TK was found (data not shown). Treatment of PC3 cells without TMEM135-CCDC67 breakpoint has minimal cell death, while the same treatment of PC3 cells containing the breakpoint with ganciclovir resulted in 8 fold increase of cell death (Figure 28B). This is remarkable in considering only 5-10% transfection efficiency using

25   conventional liposome method. Without being limited to a particular theory, these data suggest that almost all the cells receiving the DNA died when treated with ganciclovir, if they contain the breakpoint. In light of this promising result, both TMEM135-CCDC67-TK cassette and NicKase-gRNATMEM135-CCDC67-BrkPt DNA are now in the process of packaging into Adenovirus. We will infect the recombinant virus into these cells in the

30   future experiments. This will dramatically improve the delivery efficiency in the subsequent animal study and probably human.

10.   **EXAMPLE 5: NOVEL FUSION TRANSCRIPTS ASSOCIATE WITH PROGRESSIVE PROSTATE CANCER**

The analysis of an additional 68 prostate cancer samples by transcriptome
sequencing leads to the discovery of 5 additional novel fusion transcripts present in
prostate cancer. It is noted that significant number of prostate cancers contained no fusion
transcripts in RNA sequencing. Even though extensive transcriptome sequencings were

5   performed on 30 prostate cancer samples that prove non-recurrent for extended period of
time, no viable fusion transcripts were identified in these samples using fusion catcher
software. These 5 fusion transcripts were validated through Sanger sequencing of the RT-
PCR products (Figure 16). The following primers were used: ACPP-SEC13: 5'-
TCCCATTGACACCTTTCCCAC (SEQ ID NO: 30)/5'-

10   TGAGGCTTCCAGGTACAACAG (SEQ ID NO: 31);
CLTC-ETV1: 5'- GCCCAGTTGCAGAAAGGAATG(SEQ ID NO: 32)/5'-
CTTGATTTTCAGTGGCAGGCC (SEQ ID NO: 33);
DOCK7-OLR1: 5'- GACTACGTCTCATGCCTTTCC (SEQ ID NO: 34)/5'-
TTCTCATCAGGCTGGTCCTTC (SEQ ID NO: 35);

15   PCMTD1-SNTG: 5'- GATGTGGTGGAATATGCCAAGG (SEQ ID NO: 36)/ 5'-
AAATCCATGTGCTGTGGCACC (SEQ ID NO: 37); and
ZMPSTE24-ZMYM4: 5'- CGCAATGAGGAAGAAGGGAAC (SEQ ID NO: 38)/5'-
CATAAATCTGGAATAGGGCTCAG (SEQ ID NO: 39).

       10.1.   RESULTS

20   ***ZMPSTE24-ZMYM4 fusion genes.*** This fusion transcript was discovered in a
prostate cancer sample from a patient who experienced prostate cancer recurrence 1.8
month after radical prostatectomy. The patient's pelvic lymph nodes were positive for
metastatic prostate cancer, while his primary cancer sample was graded with Gleason 7.
In addition to ZMPSTE24-ZMYM4, his prostate cancer sample was also positive for

25   CCNH-c5orf30. ZMPSTE24 is a zinc-metalloproteinase involved in post-translational
proteolytic cleavage that coverts farnesylated prelamin A to form mature lamin A.
Mutation of this protein is associated with mandibuloacral dysplasia[1]. It was suggested
that ZMPSTE24 may be a mediator promoting invasive prostate cancer[2]. ZMYM4 is an
anti-apoptotic gene whose function domain is located in the 3' untranslated region.

30   Expression of ZMYM4 3' UTR has been shown to resist cell death induced by interferon
γ through inhibition of AUF1 activity[3]. The fusion formation between ZMPSTE24 and
ZMYM4 produces a truncation of 159 amino acids from the C-terminus of ZMPSTE24
and 1315 amino acids from the N-terminus of ZMYM4. Motif analysis suggests that

ZMPSTE24-ZMYM4 fusion will delete about 50% of the peptidase domain from ZMPSTE24 and remove all zinc fingers from ZMYM4, but leave ZUF3504 (domain of unknown function) and apoptosis inhibitor domain intact (Figure 17). Thus, ZMPSTE24-ZMYM4 fusion may provide cancer cells an important tool to resist program cell death.

5   *CLTC-ETV1 fusion genes.* CLTC-ETV1 was discovered in a prostate cancer sample that has Gleason's grade of 7. The patient experienced prostate cancer recurrence 22 months after radical prostatectomy, and had been rapidly progressing. In addition to CLTC-ETV1, the prostate cancer sample was also positive for TRMT11-GRIK2 fusion. CLTC is a major protein component of coated vesicles and coated pits, and is universally
10   expressed. Its presence is essential for cell shape formation and cell motility. ETV1 is a transcription factor that was shown to over-express in prostate cancer. ETV1 had been shown to partner at least 12 different head genes in prostate cancer and Ewing's sarcoma[4,5]. However, most of these fusions do not produce a functional transcription factor from ETV1 due to frameshift in the fusion or few amino acids left after the fusion.
15   In contrary, CLTC-ETV1 fusion preserves a largely intact transcription domain in ETV1, and probably represents the first example of potential functional ETV1 fusion in prostate cancer. CLTC-ETV1 fusion deletes 3 clathrin domains from CLTC (Figure 18). This may impair the function of CLTC for coated pit formation. ETV1 has been shown to be oncogenic in several organ systems[6-8]. The regulatory domain is located in the N-
20   terminus. The regulatory domain contains MAPK phosphorylation site as well as ubiquitination site by COP1[9,10]. Truncation in the N-terminus of ETV1 eliminates all these regulatory elements from ETV1. Thus, the protein level CLTC-ETV1 may be increased due to less degradation and activity of ETV1 may become constitutive due to the lack of regulatory constraint in the fusion protein. Since ETV1 has been shown to
25   overexpress in many prostate cancers, CLTC-ETV1 fusion might be the underlying mechanism.

         ACPP-SEC13 fusion genes. The ACPP-SEC13 fusion transcript was discovered in a prostate cancer sample from patients who experienced recurrence but also had a slow rise of PSA with doubling time more than 20 months. The Gleason's grade is 7. The
30   pathological examination reveals invasion into seminal vesicle by prostate cancer cells. ACPP is prostate specific acid phosphatase and is abundantly expressed in prostate acinar cells, while SEC13 belongs to the family of WD-repeat proteins, and is required for vesicle biogenesis from endoplasmic reticulum[11]. Recent studies suggest that SEC13 is a

subunit of GATOR2, an octomeric GTPase activating protein. Inhibition of SEC13 suppresses mTOR activation[12]. In ACPP-SEC13 fusion, only the N-terminus 72 amino acids of ACPP is preserved, and over 2/3 of the phosphatase domain is truncated, while SEC13 loses 196 amino acids from its N-terminus and has 3 WD-repeat domains deleted

5   (Figure 19). Due to the large truncation of critical domains in both proteins, it is expected that ACPP-SEC13 contains neither phosphatase nor GTPase-activation activity. Such loss of function may lead to hyperactivity of mTOR and may make it insensitive to amino acid deprivation. A potential targeted treatment for patients positive for ACPP-SEC13 might be using mTOR inhibitor since cancer cells may become hypersensitive to mTOR

10   inhibitors when SEC13 is not functional.

        DOCK7-OLR1 fusion genes. DOCK7-OLR1 fusion transcript was discovered in a prostate cancer sample from a patient who experienced recurrent prostate cancer 30.5 months after the radical prostatectomy. However, the rise of PSA appeared rapid with PSADT less than 3 months. The prostate cancer Gleason's grade was 7, and there was no

15   invasion into seminal vesicle or other adjacent organs at the time of surgery. The surgical margin was negative. It clearly suggests that some prostate cancer cells had escaped the primary location before the surgery. DOCK7 is a guanine nucleotide exchange factor involving in migration and cell polarization[13,14], while OLR1 is a low density lipoprotein receptor that belongs to the C-type lectin superfamily. OLR1 binds, internalizes and

20   degrades oxidized low-density lipoprotein[15]. Unlike the above 3 fusion transcripts, DOCK7-OLR1 does not produce a chimera protein. Instead, separate translation of DOCK7 and OLR1 occurs from the fusion transcript. The fusion deleted a significant portion of cytokinesis domain of DOCK7 such that motility regulation by DOCK7 might be compromised. However, the fusion transcript will produce an intact OLR1 protein

25   (Figure 20). OLR1 was implicated in Fas-mediated apoptosis. The functional significance of its expression under the control of DOCK7 promoter is to be investigated.

        PCMTD1-SNTG1 fusion genes. PCMTD1-SNTG1 fusion transcript was discovered in a prostate cancer sample from a patient who experienced recurrent prostate cancer 5.5 months after the radical prostatectomy. The rise of PSA was rapid with

30   PSADT less than 3 months. The Gleason's grade is 9. Seminal vesicle invasion was identified in the prostatectomy sample. The prostate cancer sample is also positive for SLC45A2-AMACR and LRRC59-FLJ60017. PCMTD1 is Daspartate methyltransferase domain containing protein. The function of PCMTD1 has not been studied. SNTG1 is a

member of the syntrophin family. SNTG1 belongs to peripheral membrane protein. Recent study suggests that SNTG1 may regulate diacylglycerol kinase zeta subcellular localization and regulates the termination of diacylglycerol signaling. Similar to DOCK7-OLR1 fusion, PCMTD1-SNTG1 fusion does not produce a chimera protein. PCMTD1-

5　SNTG1 fusion produces a truncated PCMTD1. The truncation removes half of the methyl-transferase domain of PCMTD1. However, SNTG1 is intact (Figure 21). Since diacylglycerol kinase weakens protein kinase C activity by depleting the availability of diacylglycerol, higher level of SNTG1 might enhance PKC signaling If PCMDT1-SNTG1 fusion drives up the expression of SNTG1. Alternatively, impairing the function

10　of PCMTD1 may have impact on cell metabolism and cell growth that are yet to be delineated.

10.2.　REFERENCES

1.　　Agarwal, A. K., Fryns, J. P., Auchus, R. J., and Garg, A. (2003) Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. *Human*

15　*molecular genetics* 12(16), 1995-2001.

2.　　Parr-Sturgess, C. A., Tinker, C. L., Hart, C. A., Brown, M. D., Clarke, N. W., and Parkin, E. T. Copper modulates zinc metalloproteinase-dependent ectodomain shedding of key signaling and adhesion proteins and promotes the invasion of prostate cancer epithelial cells. *Mol Cancer Res* 10(10), 1282-1293.

20　3.　　Shchors, K., Yehiely, F., Kular, R. K., Kotlo, K. U., Brewer, G., and Deiss, L. P. (2002) Cell death inhibiting RNA (CDIR) derived from a 3'-untranslated region binds AUF1 and heat shock protein. 27. *The Journal of biological chemistry* 277(49), 47061-47072.

4.　　Clark, J. P., and Cooper, C. S. (2009) ETS gene fusions in prostate cancer.

25　*Nat Rev Urol* 6(8), 429-439.

5.　　Jeon, I. S., Davis, J. N., Braun, B. S., Sublett, J. E., Roussel, M. F., Denny, C. T., and Shapiro, D. N. (1995) A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. *Oncogene* 10(6), 1229-1234.

6.　　Carver, B. S., Tran, J., Chen, Z., Carracedo-Perez, A., Alimonti, A.,

30　Nardella, C., Gopalan, A.,Scardino, P. T., Cordon-Cardo, C., Gerald, W., and Pandolfi, P. P. (2009) ETS rearrangements and prostate cancer initiation. *Nature* 457(7231), E1; discussion E2-3.

7.   Chi, P., Chen, Y., Zhang, L., Guo, X., Wongvipat, J., Sha*mu, T.,* Fletcher, J. A., Dewell, S., Maki, R. G., Zheng, D., Antonescu, C. R., Allis, C. D., and Sawyers, C. L. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. *Nature* 467(7317), 849-853.

8.   Jane-Valbuena, J., Widlund, H. R., Perner, S., Johnson, L. A., Dibner, A. C., Lin, W. M., Baker, A. C., Nazarian, R. M., Vijayendran, K. G., Sellers, W. R., Hahn, W. C., Duncan, L. M., Rubin, M. A., Fisher, D. E., and Garraway, L. A. An oncogenic role for ETV1 in melanoma. *Cancer research* 70(5), 2075-2084.

9.   Vitari, A. C., Leong, K. G., Newton, K., Yee, C., O'Rourke, K., Liu, J., Phu, L., Vij, R., Ferrando, R., Couto, S. S., Mohan, S., Pandita, A., Hongo, J. A., Arnott, D., Wertz, I. E., Gao, W. Q., French, D. M., and Dixit, V. M. COP1 is a tumour suppressor that causes degradation of ETS transcription factors. *Nature* 474(7351), 403-406.

10.   Willardsen, M., Hutcheson, D. A., Moore, K. B., and Vetter, M. L. The ETS transcription factor Etv1 mediates FGF signaling to initiate proneural gene expression during Xenopus laevis retinal development. *Mechanisms of development* 131, 57-67.

11.   Enninga, J., Levay, A., and Fontoura, B. M. (2003) Sec13 shuttles between the nucleus and the cytoplasm and stably interacts with Nup96 at the nuclear pore complex. *Molecular and cellular biology* 23(20), 7271-7284.

12.   Bar-Peled, L., Chantranupong, L., Cherniack, A. D., Chen, W. W., Ottina, K. A., Grabiner, B. C., Spear, E. D., Carter, S. L., Meyerson, M., and Sabatini, D. M. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. *Science (New York, N.Y* 340(6136), 1100-1106.

13.   Watabe-Uchida, M., John, K. A., Janas, J. A., Newey, S. E., and Van Aelst, L. (2006) The Rac activator DOCK7 regulates neuronal polarity through local phosphorylation of stathmin/Op18.*Neuron* 51(6), 727-739.

14.   Nellist, M., Burgers, P. C., van den Ouweland, A. M., Halley, D. *J., and* Luider, T. M. (2005) Phosphorylation and binding partner analysis of the TSC1-TSC2 complex. *Biochemical andbiophysical research communications* 333(3), 818-826.

11.   **EXAMPLE 6: SLC45A2-AMACR FUSION GENES.**

11.1   RESULTS

The fusion transcript of Solute carrier family 45, member 2-alpha-methylacyl-
CoA racemase (SLC45A2-AMACR) produces a chimera protein with Nterminus 187
amino acids of SLC45A2 and the C-terminus 311 amino acids of AMACR. SLC45A2 is
a transporter protein known to be overexpressed in melanoma[1], while AMACR is an

5   enzyme involved in metabolism of branch fatty acid, and is known for its overexpression
in several human malignancies. SLC45A2-AMACR replaces 5 transmembrane and
cytosolic domains of SLC45A2 with an intact racemase domain from AMACR[2], while
leaves the extracellular and the N-terminal transmembrane domains intact (Figure 24).
Most of prostate cancer patients who were positive for SLC45A2-AMACR experienced

10   prostate cancer recurrence within 5 years of surgical treatment. Previous studies suggest
that AMACR is essential for optimal growth of prostate cancer cells in vivo. Knocking
down of AMACR or treatment of prostate cancer with AMACR inhibitors resulted in
death of cancer cells both *in vitro* and *in vivo*[3]. Formation of SLC45A2-AMACR
generates ectopic racemase for fatty acid metabolism to support the growth of prostate

15   cancer cells.

Transformation of prostate epithelial cells with SLC45A2-AMACR results in
dramatic cell growth and transformation, possibly through activation of SHIP2-Akt
pathway. To investigate whether SLC45A2-AMACR chimera protein is expressed in
prostate cancer samples that contain SLC45A2-AMACR transcript, protein extracts from

20   4 prostate cancer samples positive for SLC45A2-AMACR RNA were analyzed using
antibodies specific for MAN2A1 or FER. The results showed that these samples
expressed a 50 Kd protein recognized by both MAN2A1 and FER antibodies (Figure
25A). This protein was not detected in prostate cancer samples that were negative for
SLC45A2-AMACR transcript. When SLC45A2-AMACR was forced to express in

25   RWPE1 cells, a non-transformed prostate epithelial cell line, it increased the proportion of
cells in S phase by an average of 8.7 fold (p<0.001). MTT assays showed a 7.5 fold
increase of cell proliferation (p<0.001)(Figure 25 E-F). SLC45A2-AMACR was
determined to be localized in the plasma membrane by immunofluorescence staining and
membranous fractionation analyses. This is in contrast to native AMACR, which is

30   located primarily in the mitochondria/cytoplasm. To investigate what are the potential
signaling molecules mediating SLC45A2-AMACR induced cell growth and DNA
synthesis. Yeast-two hybrid screening of prostate Yeast two-Hybrid library using pBD-
SLC45A2-AMACR was performed. After 3 rounds of metabolic screening, 15 unique
clones that contain SLC45A2-AMACR binding proteins were identified. One of these

clones encodes inositol polyphosphate phosphatase-like 1 (INPPL1, also called SHIP2). SHIP2 is a SH2 domain containing inositol phosphatase that converts $PIP_3(3,4,5)$ to $PIP_2(3,4)$. In contrast to Pten, which converts $PIP_3(3,4,5)$ to an inactive $PIP_2(4,5)$, $PIP_2(3,4)$ generated by SHIP2 has higher affinity binding with AKT than $PIP_3(3,4,5)$, and

5   thus hyper-activate AKT pathway. The interaction between SLC45A2 and SHIP2 was validated by both yeast Two-hybrid co-transfection analysis and co-immunoprecipitation assays in SLC45A2-AMACR expressing cells (Figure 25G-H). Induction of SLC45A2-AMACR expression in 2 different clones of RWPE1 cells generated 2.1- and 2.3-fold higher level of PIP2(3,4), respectively. These results indicate that binding of SLC45A2-

10   AMACR and SHIP2 leads to activation of SHIP2 phosphatase activity and probably AKT signaling pathway.

Therapeutic targeting at SLC45A2-AMACR using racemase inhibitor. To investigate whether targeting SLC45A2-AMACR is a viable approach to treat prostate cancer, we chose 2 approaches: 1) To intercept SLC45A2-AMACR/SHIP2-Akt pathway

15   with small molecules; and 2) to block the ectopic racemase activity of SLC45A2-AMACR with ebselen or trifluoro-ibuprofen. Surprisingly, both SHIP2 and MTOR inhibitors killed PC3 cells effectively, regardless whether they were transformed with SLC45A2-AMACR. Expression of SLC45A2-AMACR only moderately sensitized PC3 cells to Rapamycin. This is probably due to Pten negative status of PC3 cells such that

20   Akt pathway is fully activated regardless the presence of SLC45A2-AMACR. On the other hand, when we applied ebselen, the potent inhibitor of racemase of AMACR, to SLC45A2-AMACR expressing PC3 cells, 5 fold higher sensitivity of cell growth inhibition was found for PC3 cells transformed with pCDNA4-SLC45A2-AMACR-FLAG/pCDNA6 over the controls. In contrast, non-transformed RWPE1 cells and

25   NIH3T3 cells that expressed little AMACR was largely insensitive to ebselen killing (Figure 26). The differential sensitivity of normal cells versus cancer cells to AMACR inhibitors may prove very useful in treating prostate cancer positive for this fusion gene.

11.2.   REFERENCES

1.   Misago, M., Liao, Y. F., Kudo, S., Eto, S., Mattei, M. G., Moremen, K.

30   W., and Fukuda, M. N. (1995) Molecular cloning and expression of cDNAs encoding human alpha-mannosidase II and a previously unrecognized alpha-mannosidase IIx isozyme. Proceedings of the National Academy of Sciences of the United States of America 92(25), 11766-11770.

2.   Krolewski, J. J., Lee, R., Eddy, R., Shows, T. B., and Dalla-Favera, R. (1990) Identification and chromosomal mapping of new human tyrosine kinase genes. Oncogene 5(3), 277-282.

3.   Zha, S., Ferdinandusse, S., Denis, S., Wanders, R. J., Ewing, C. M., Luo, J., De Marzo, A. M., and Isaacs, W. B. (2003) Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer research 63(21), 7365-7376.

87

CLAIMS:

1.   A method of determining whether a subject is at increased risk of manifesting progressive prostate cancer comprising determining whether a prostate cancer cell of the subject contains a MAN2A1-FER fusion gene, where the presence of the fusion gene indicates that the subject is at increased risk of manifesting progressive prostate cancer.

2.   The method of claim 1, wherein the gene fusion is detected by FISH analysis.

3.   The method of claim 1, wherein the gene fusion is detected by reverse transcription polymerase chain reaction.

4.   The method of claim 1, wherein the progressive prostate cancer is in the form of relapse.

5.   The method of claim 1, wherein the progressive prostate cancer is in the form of rapid relapse.

6.   The method of claim 1, further comprising determining a nomogram score of the subject.

7.   An inhibitor specific for a MAN2A1-FER fusion gene or a downstream target of the MAN2A1-FER fusion gene for use in the treatment of prostate cancer in a subject determined to be at increased risk of manifesting progressive prostate cancer, as determined by the presence of the fusion gene in a prostate cancer cell obtained from the subject, wherein the inhibitor is selected from the group consisting of canertinib, crizotinib and a combination thereof.

8.   An agent that inhibits the expression or activity of a MAN2A1-FER protein encoded by a fusion gene or the expression or activity of one or more downstream targets of the MAN2A1-FER fusion gene for use in the treatment of prostate cancer in a subject determined to be at increased risk of manifesting progressive prostate cancer, as determined by the presence of the fusion gene in a prostate cancer cell obtained from the subject, wherein the agent is selected from the group consisting of canertinib, crizotinib, erlotinib, cetuximab, gefitinib, bevacizumab, panitumumab, bortezomib, RAF265, binimetinib, vemurafenib, PD-325901, selumetinib, trametinib, TAK-733, Honokiol, AZD8330, PD3 18088, BIX 02188, pimasertib, SL-327, BIX 021 89, PD98059, MEK162, PD184352 and U0126-EtOH.

9.   An anti-cancer agent for use in treating prostate cancer in a subject determined to be at increased risk of manifesting progressive prostate cancer, as determined by the presence of a MAN2A1-FER fusion gene in a prostate cancer cell obtained from the subject, wherein the anti-cancer agent is selected from the group consisting of chemotherapeutic agents, radiotherapeutic agents, cytokines, anti-angiogenic agents, apoptosis-inducing agents or anti-cancer immunotoxins and a combination thereof.

10.   A FER inhibitor for use in treating prostate cancer in a subject at an increased risk of manifesting progressive prostate cancer, as determined by the presence of MAN2A1-FER in a prostate cancer cell obtained from the subject, wherein the FER inhibitor is crizotinib.

11.   An EGFR inhibitor for use in treating prostate cancer in a subject at increased risk of manifesting progressive prostate cancer as determined by the presence of MAN2A1-FER in a prostate cancer cell obtained from the subject, wherein the EGFR inhibitor is canertinib.

12.   The anti-cancer agent of claim 9, wherein the anti-cancer agent is selected from the group consisting of Abiraterone Acetate, Bicalutamide, Cabazitaxel, Casodex® (Bicalutamide), Degarelix, Docetaxel, Enzalutamide, Goserelin Acetate, Jevtana® (Cabazitaxel), Leuprolide Acetate, Lupron® (Leuprolide Acetate), Lupron Depot (Leuprolide Acetate), Lupron Depot-3 Month (Leuprolide Acetate), Lupron Depot-4 Month (Leuprolide Acetate), Lupron Depot-Ped (Leuprolide Acetate), Mitoxantrone Hydrochloride, Prednisone, Provenge® (Sipuleucel-T), Radium 223 Dichloride, Sipuleucel-T, Taxotere® (Docetaxel), Viadur® (Leuprolide Acetate), Xofigo® (Radium 223 Dichloride), Xtandi® (Enzalutamide), Zoladex® (Goserelin Acetate), Zytiga® (Abiraterone Acetate) and a combination thereof.

13.   A kit for performing any of the determination steps of claims 1-6, comprising one or more probes that specifically hybridize to the MAN2A1-FER fusion gene to perform a FISH analysis.

14.   A kit for performing any of the determination steps of claims 1-6, comprising one or more pairs of primers that specifically hybridize to the MAN2A1-FER fusion gene to perform a PCR analysis.

15.   A kit for performing any of the determination steps of claims 1-6, comprising one or more antibodies that specifically bind to the product of the MAN2A1-FER fusion gene.

16.   Use of an inhibitor specific for a MAN2A1-FER fusion gene or a downstream target of the MAN2A1-FER fusion gene in the treatment of prostate cancer in a subject

89

determined to be at increased risk of manifesting progressive prostate cancer, as determined by the presence of the fusion gene in a prostate cancer cell from the subject, wherein the inhibitor is selected from the group consisting of canertinib, crizotinib and a combination thereof.

17.   Use of an agent that inhibits the expression or activity of a MAN2A1-FER protein encoded by a fusion gene or the expression or activity of one or more downstream targets of the MAN2A1-FER fusion gene in the treatment of prostate cancer in a subject determined to be at increased risk of manifesting progressive prostate cancer, as determined by the presence of the fusion gene in a prostate cancer cell from the subject, wherein the agent is selected from the group consisting of canertinib, crizotinib, erlotinib, cetuximab, gefitinib, bevacizumab, panitumumab, bortezomib, RAF265, binimetinib, vemurafenib, PD-325901, selumetinib, trametinib, TAK-733, Honokiol, AZD8330, PD3 18088, BIX 02188, pimasertib, SL-327, BIX 021 89, PD98059, MEK162, PD184352 and U0126-EtOH.

18.   Use of an anti-cancer agent in treating prostate cancer in a subject determined to be at increased risk of manifesting progressive prostate cancer, as determined by the presence of a MAN2A1-FER fusion gene in a prostate cancer cell from the subject, wherein the anti-cancer agent is selected from the group consisting of chemotherapeutic agents, radiotherapeutic agents, cytokines, anti-angiogenic agents, apoptosis-inducing agents or anti-cancer immunotoxins and a combination thereof.

19.   Use of a FER inhibitor in treating prostate cancer in a subject at an increased risk of manifesting progressive prostate cancer, as determined by the presence of a MAN2A1-FER fusion gene in a prostate cancer cell from the subject, wherein the FER inhibitor is crizotinib.

20.   Use of an EGFR inhibitor in treating prostate cancer in a subject at increased risk of manifesting progressive prostate cancer as determined by the presence of a MAN2A1-FER fusion gene in a prostate cancer cell from the subject, wherein the EGFR inhibitor is canertinib.

21.   Use of the anti-cancer agent of claim18, wherein the anti-cancer agent is selected from the group consisting of Abiraterone Acetate, Bicalutamide, Cabazitaxel, Casodex® (Bicalutamide), Degarelix, Docetaxel, Enzalutamide, Goserelin Acetate, Jevtana® (Cabazitaxel), Leuprolide Acetate, Lupron® (Leuprolide Acetate), Lupron Depot (Leuprolide Acetate), Lupron Depot-3 Month (Leuprolide Acetate), Lupron Depot-4 Month (Leuprolide Acetate), Lupron Depot-Ped (Leuprolide Acetate), Mitoxantrone Hydrochloride, Prednisone, Provenge® (Sipuleucel-T), Radium 223 Dichloride, Sipuleucel-T, Taxotere® (Docetaxel), Viadur®

90

(Leuprolide Acetate), Xofigo® (Radium 223 Dichloride), Xtandi® (Enzalutamide), Zoladex® (Goserelin Acetate), Zytiga® (Abiraterone Acetate) and a combination thereof.

FIG. 1

FIG. 1 (Continued)

FIG. 1 (Continued)

FIG. 2A

FIG. 2B

Normal   Prostate cancer

FIG. 2C

Normal   Prostate cancer

FIG. 2D

Normal   Prostate cancer

FIG. 2E

Normal   Prostate cancer

FIG. 2F

Normal   Prostate cancer

FIG. 2G

Normal   Prostate cancer

FIG. 2H

8/60

FIG. 3A

FIG. 3A (Continued)

10/60

FIG. 3A (Continued)

11/60

FIG. 3A (Continued)

FIG. 3A (Continued)

FIG. 3A (Continued)

14/60

FIG. 3A (Continued)

FIG. 3B

FIG. 3D

FIG. 3C

FIG. 4C

FIG. 4B

FIG. 4A

FIG. 5A

FIG. 5B

FIG. 6

FIG. 6 (Continued)

FIG. 6 (Continued)

FIG. 6 (Continued)

FIG. 6 (Continued)

FIG. 7A

KDM4B—AC011523.2

FIG. 7A (Continued)

FIG. 7A (Continued)

FIG. 7A (Continued)

CCNH–C5orf30

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72

73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103

104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135

136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154

155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181

182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197

198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213

FIG. 7A (Continued)

FIG. 7A (Continued)

CA 02935216 2016-06-27

FIG. 7A (Continued)

FIG. 7A (Continued)

TMPRSS2—ERG

FIG. 7A (Continued)

FIG. 7A (Continued)

FIG. 7B

FIG. 8

FIG. 9

FIG. 10

38/60

FIG. 11

Recurrence

FIG. 12A

Short PSADT

FIG. 12B

PTEN   NOLC1

10q23.3   10q24.32

14.2 MB

Fusion direction

PTEN   NOLC1

T T T T C T C C A A A T T T T A A G A C A C A G C A G G A T G C C A A (SEQ ID NO: 56)

PTEN (aa1−342)   NOLC1 (aa41−699)

FIG. 13A

FIG. 13B

FIG. 13C

FIG. 14

FIG. 15

FIG. 16

FIG. 16 (Continued)

FIG. 17

FIG. 18

FIG. 19

DOCK7

DUF3398   DOCK-C2   Ded Cyto

OLR1

Lectin C

ΔDOCK7   OLR1

FIG. 20

PCMTD1

PCMT

SNTG1

PDZ

ΔPCMTD1   SNTG1

FIG. 21

FIG. 22A

FIG. 22B

FIG. 22C

FIG. 22D

FIG. 22E

FIG. 22F

FIG. 23

CA 02935216 2016-06-27

FIG. 24

FIG. 25A

FIG. 25B

FIG. 25C

FIG. 25D

FIG. 25E

FIG. 25F

FIG. 25G

pBD-T-antigen/
pAD-p53

pBD/
pAD

pBD-T-antigen/
pAD-LAMIN C

pBD-SLC45A2-AMACR/
pAD-SHIP2

pBD-SLC45A2-AMACR/
pAD

pBD/
pAD-SHIP2

FIG. 25H

1   2   3

SLC45A2-AMACR-FLAG-

IP: Input   α-SHIP2   IgG
WB: α-FLAG

4   5   6

SHIP2-

IP: Input   IgG   α-FLAG
WB: α-SHIP2

FIG. 25I

FIG. 26

FIG. 27A

FIG. 27B

FIG. 27C

FIG. 27D

FIG. 28A

FIG. 28B